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significantly between crosslinking treatment groups. D) IOP levels 
increased after induction of ocular hypertension at Day 0 in microbead-
injected eyes compared to normotensive control eyes. Statistical 
significance is indicated using the following convention: “*” for p < 
0.05, “**” for p <0.01, “***” for p < 0.001, and “****” for p < 0.0001. 
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thickness in hypertensive GP eyes was not different than in GP 
normotensive controls, while thickness in hypertensive HBSS eyes 
was significantly less than in HBSS normotensive controls. Thickness 
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Figure 15 Functional outcome measurements across crosslinking treatment 
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frequency and B) contrast sensitivity; and ERG outcomes, namely C) 
pSTR amplitude, D) nSTR amplitude, E) b-wave amplitude, and F) 
oscillatory potential 3 amplitude. In all cases, a significant deficit was 
observed for hypertensive experimental eyes compared to 
normotensive control eyes. No significant differences were found 
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categories for each crosslinking treatment. Stronger correlations were 
found for HBSS than for GP-treated rats, and for GP-treated rats 
compared to MB-treated rats, particularly in the relationship between 
morphological/functional with biomechanical parameters. Mechanical 
parameters included IOP burden, scleral strain, and eye dimensions. 
Morphological parameters include optic nerve size, axon 
count/density, and retinal thickness. Functional parameters include 
OMR and ERG data. A) HBSS hypertensive experimental eye matrix. 
B) GP hypertensive experimental eye matrix. C) MB hypertensive 
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experimental eye matrix. Statistical significance was calculated for 
null hypothesis of zero correlation (significance indicated with “*” for 
the Bonferroni-corrected p<0.05 level). 
Figure 17 Schematic representation of Franz Cell apparatus used to determine 
MB diffusion constant through 3.14 mm surface area of Brown 
Norway rat sclerae. A 3 mM solution of MB was placed in the donor 
chamber for diffusion across the sclera and into the receiving chamber. 
The scleral samples were mounted between two glass microscope 
slides sealed with O-rings. 
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Figure 18 Schematic representation of the model spatial domain including (left 
to right): choroid, sclera, Tenon capsule, injection reservoir. Light 
enters through the anterior surface of the choroid from a transpupillary 
illuminating source. Oxygen diffuses from the choroid (and to a lesser 
extent, from the retrobulbar tissue). The photosensitizer diffuses from 
the injection reservoir to the Tenon capsule, sclera and choroid (where 
vascular clearance can occur) as well as to the retrobulbar tissue (not 
shown) which is assumed to be a sink due to systemic clearance. The 
model uses the method of lines to discretize a system of partial 
differential equations in space, thus creating a system of ordinary 
differential equations in time. Node thickness (Δx) was uniform in the 
choroid and in the sclera, and non-uniform in the injection reservoir. 
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Figure 19 Schematic representation of the 1-dimensional tissue discretization 
scheme showing three adjacent tissue slices of finite thickness, Δx. The 
ith node with (i-1)th and (i+1)th nodes are shown at left and right, 
respectively. Nodes were defined at the center of each tissue slice. 
Node spacings represented by h1 and h2 were allowed to vary as a 
function of tissue slice thickness in the model. Unequal node spacing 
was used to reduce computation time and provide increased spatial 
resolution in tissues of interest (sclera, choroid). 
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Figure 20 Reaction network for MB photocrosslinking computational model 
showing modeled species and reaction rates. 
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Figure 21 Experimental data from Kamaev et al. 2012 (filled circles) showing 
oxygen concentration under a 130 𝜇m corneal flap in ex vivo porcine 
eyes during riboflavin crosslinking procedure. Computational model 
prediction for oxygen concentration (solid line) showing good 
agreement with the experimental data. No parameters were fitted in the 
model to produce this result. 
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Figure 22 Correspondence of computational model predicted crosslinking with 
experimental crosslinking. A) Computational model prediction for 
riboflavin crosslinking with constant fluence (5.4 J/cm2) at different 
intensities. Open circles represent the computational model output at 
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light intensities corresponding with those experimentally tested in 
Hammer et al. and Aldahlawi et al. B) Percentage stiffness increase in 
porcine corneas treated with riboflavin crosslinking procedure 
calculated from Hammer et al. 2014. C) Porcine cornea dry weight at 
12 days after riboflavin crosslinking and enzymatic digestion 
reproduced from Aldahlawi et al. 2015. D) Computational model data 
plotted against Hammer et al. data with linear regression showing 
reasonable agreement. E) Computational model predicted fraction of 
crosslinks utilized as a function of cornea dry weight after enzymatic 
degradation showing reasonable correspondence. 
Figure 23 Determination of MB diffusion constant in Brown Norway rat sclerae 
ex vivo. Diffusion constant was determined by A) measuring 
cumulative mass of MB transported across a fixed surface area of 
tissue over time. The slope was set equal to MB flux. B) The value of 
the MB diffusion constant was computed from flux in the steady-state 
region of transport. Data points represent A) mean ± standard deviation 
(n=9 replicates) or B) independently calculated values, with mean and 
standard deviations shown. 
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Figure 24 MB concentration in ocular tissues measured 30 min after retrobulbar 
injection in vivo. A) Diagram of scleral sections dissected from rat 
eyes. Injections were performed under anesthesia with Brown Norway 
rats euthanized 30 min after injection to replicate the experimental 
conditions used in scleral crosslinking. B) Average MB concentration 
measured in ocular tissues 30 min post injection. Mean concentration 
for the control eyes was calculated based on the threshold for 
fluorescence detection in cases where fluorescence was below this 
threshold. Data represent mean + standard deviation from 5 replicates 
in all cases except for the ON fat which had only 3 replicates due to 
error in sample collection for two rats. *** p < 0.001, **** p < 0.0001 
by two-way ANOVA. 
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Figure 25 Computational model prediction of average sensitizer concentration in 
sclera 30 minutes after retrobulbar injection represented as a 
percentage of the injected concentration. The experimental value for 
MB concentration (Figure 24) and the corresponding experimental 
value for MB diffusion constant (Figure 23B) are shown (red 
datapoint). Error bars represent ± standard deviation. Simulations were 
performed with light source intensity at 0 mW/cm2 to isolate the 
diffusion/clearance kinetics from possible effects of photodegradation. 
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Figure 26 Computational model prediction of MB photocrosslinking efficiency 
as a function of MB concentration, light intensity, and inspired oxygen. 
Crosslinking as a function of light intensity and MB concentration was 
modeled at A) 100% and B) 21% inspired oxygen concentrations 
corresponding to isoflurane anesthesia with 100% oxygen and 
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anesthesia with subject breathing atmospheric oxygen, respectively. 
Crosslinking is also shown as a function of MB concentration when 
light intensity was held constant (424 mW/cm2) for both C) 100% and 
D) 21% inspired oxygen. 
Figure 27  Injection volume and concentration affect MB distribution and 
crosslinking. A) Normalized MB concentration in the sclera at 30 
minutes post injection increases with injection volume but is not 
affected by concentration. B) At all concentrations studied except for 
30 mM MB, increasing injection reservoir volume improved 
crosslinking efficiency. At 30 mM MB concentration, crosslinking 
efficiency had a local maximum at approximately 1 mm reservoir 
volume. 
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Figure 28 A) Monomeric and B) dimeric MB concentrations over time and 
distance through the choroid and sclera reach a quasi-steady state 
equilibrium after approximately 3 minutes from which time they 
decline due to choroidal and retrobulbar clearance. Note concentration 
is plotted with a family of curves describing logarithmically spaced 
time points. 
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Figure 29 Light intensity profile over space/time in the choroid and sclera during 
MB photocrosslinking. 
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Figure 30 Triplet oxygen concentration over space and time during MB 
photocrosslinking. Note, concentration is plotted with logarithmically 
spaced time from 0 to 30 minutes. 
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Figure 31 Amino acid concentrations during MB photocrosslinking procedure 
for A) histidine, B) methionine, C) tryptophan, and D) tyrosine. 
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Figure 32 Melanin concentration as a function of space and time during MB 
photocrosslinking. 
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Figure 33 A) Singlet oxygen, B) MB triplet, and C) cumulative degraded MB 
concentrations modeled as a function of space and time. 
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Figure 34 A) Cumulative average crosslink concentration over time in the 
choroid and sclera with individual contributions from His, Trp, and 
Tyr, and B) crosslink concentration over time and space during MB 
photocrosslinking procedure. 
142 
Figure 35 Ranked sensitivities of model parameters categorized by property type 
for the default MB photocrosslinking procedure considered in this 
study. Only parameters having a 0.1% or greater magnitude sensitivity 
were included in this figure. Choroid thickness, irradiation duration, 
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and scleral thickness are among the properties most sensitive to a 1% 
increase in parameter values. 
Figure 36 Representative OCT images from rat eyes treated with a targeted light 
beam without methylene blue. A) Control (untreated eye receiving no 
light exposure) and B) Contralateral eye exposed to 424 mW/cm2 660 
nm light treatment for 30 min without methylene blue using the same 
apparatus and protocol as used for selective photocrosslinking. 
182 
Figure 37 Chemical crosslinker genipin (left inset) or photocrosslinker 
methylene blue (right inset) were injected by retrobulbar injection to 
induce scleral crosslinking. Genipin induced non-targeted 
crosslinking. Methylene blue was activated with a transpupillary light 
beam to selectively crosslink peripapillary sclera. 
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Figure 38 A) Image of BN rat fundus viewed through refraction-negating corneal 
contact lens showing optic nerve head and retinal vasculature. The lens 
created a clear optical path facilitating B) projection of an annular 
beam (measuring 2 mm outer diameter, 1 mm inner diameter) of 660 
nm incoherent light from a custom-designed microscope to the 
peripapillary sclera following retrobulbar injection of MB. The inset 
shows an image of the beam projected onto a BN rat fundus as viewed 
using the microscope’s camera (inset scale bar = 1 mm). 
187 
Figure 39 Resolved A) spatial frequency and B) contrast sensitivity of 
normotensive control eyes at Days -7, 0, 7, and 14 with respect to 
induction of hypertension at Day 0. Significant differences were found 
at Day 7 and Day 14 compared to Day -7 (baseline) for spatial 
frequency and for contrast sensitivity in all crosslinking treatment 
groups. These findings suggest the presence of a hyperacuity effect in 
the normotensive eye after induction of hypertension in the 
contralateral eye C) Spatial frequency differed between Day -7 
(baseline) and Day 0 (after stiffening treatment) for GP (p < 0.01) and 
MB (p < 0.0001). D) Contrast Sensitivity differed between Day -7 
(baseline) and Day 0 (after stiffening treatment) for GP (p < 0.05) and 
MB (p < 0.05). 
189 
Figure 40 A) Axon density and B) optic nerve cross-sectional area were 
measured from sectioned optic nerves. Axon density was calculated as 
the measured axon count divided by measured area (B). 
190 
Figure 41 Correlations of baseline control and experimental eye values prior to 
treatments. “Control” indicates eyes designated to be normotensive. 
“Experimental” indicates eyes designated to be normotensive 
(microbead injection). A) pSTR amplitude, B) nSTR amplitude, C) b-
wave amplitude, D) oscillatory potential 3 amplitude, E) retinal 
thickness at 0.5 mm from the ON, F) retinal thickness at 1.2 mm from 
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the ON, G) spatial frequency, and H) contrast sensitivity, showed no 
significant correlation at baseline between eyes of the same rat. 
Figure 42 No qualitative differences were found in optic nerve cross-sections of 
hypertensive eyes between crosslinking treatment groups. 
Representative images from each treatment in specified range of IOP 
burden are shown. Images were taken from the central region of each 
nerve. Scale bar = 10 µm. Damage qualitatively increases with 
increasing IOP burden. 
191 
Figure 43 Representative experimental eye optic nerve/retina OCT images from 
each treatment in specified range of IOP burden. Damage qualitatively 
increases with increasing IOP burden. Vertical yellow lines on each 
image indicate (from left to right), -1.2 mm, -0.5 mm, 0 mm, 0.5 mm, 
1.2 mm distances from center of optic nerve head at which retinal 
thickness measurements were taken. Scale bar = 0.5 mm. Specifically, 
cupping at the optic nerve head increases in all groups. 
191 
Figure 44 A) Peripapillary and B) peripheral strain as a function of IOP burden. 192 
Figure 45 OCT retinal thickness measurements as a function of IOP burden at A) 
0.5 mm from the ONH and B) 1.2 mm from the ONH. 
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Figure 46 ERG outcomes vs IOP burden for A) pSTR amplitude, B) nSTR 
amplitude, C) b-wave amplitude, and D) oscillatory potential 3 
amplitude. 
193 
Figure 47 Eye size parameters vs IOP burden including A) anterior chamber 
depth, B) equatorial width, and C) axial length. 
194 
Figure 48 A) Axon count, B) axon density, and C) optic nerve cross-sectional 
area as functions of IOP burden. 
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Figure 49 Spatiotemporal profiles of A) crosslink concentration, and B) light 
intensity model predictions over the choroid and sclera during 30-min 
MB photocrosslinking procedure. The dashed line demarcates the 
boundary of choroid (left) and sclera (right). A) The model predicts 
that crosslinking increases over time with the highest number of 
crosslinks in the choroid. In both the choroid and sclera, the anterior 
surfaces experience more crosslinking than the posterior surfaces. B) 
Light intensity maintains a relatively steady profile throughout the 
procedure due to relatively fast diffusion of MB which reaches a steady 
state profile within the first few minutes. 
202 
Figure 50 Spatiotemporal profiles of A) MB monomers, B) MB dimers, C) MB 
triplets, and D) degraded MB. The dashed line demarcates the 
boundary of choroid (left) and sclera (right). Note, degraded MB is a 
cumulative sum over time and does not account for diffusion dynamics 
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in order to simply visualize the locations at which degradation was 
most prevalent. MB monomers, dimers, and triplets, on the other hand 
are represented as absolute values subject to all model diffusion and 
reaction dynamics. 
Figure 51 A) Triplet oxygen and B) singlet oxygen concentrations over space and 
time during MB photocrosslinking treatment in rat sclera/choroid. The 
dashed line demarcates the boundary of choroid (left) and sclera 
(right). A) Triplet oxygen is rapidly depleted in the sclera at early 
stages in the treatment, reaching a relatively steady state profile as 
diffusion equilibrates with photochemical consumption. B) Singlet 
oxygen generated throughout the course of the treatment reaches 
increased concentration late in the treatment duration due to the 
depletion of quenching species (amino acids and melanin). 
204 
Figure 52 Spatiotemporal profiles of amino acid concentrations in the choroid 
and sclera during MB photocrosslinking. The dashed line demarcates 
the boundary of choroid (left) and sclera (right). A) Histidine, B) 
tryptophan, C) methionine, and D) tryptophan concentrations were 
modeled as they are believed to be the predominate species involved 
in crosslinking and quenching reactions. 
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Figure 53 Spatiotemporal profiles of melanin concentration over space and time 
during MB photocrosslinking shows a gradual depletion in the choroid. 
The dashed line demarcates the boundary of choroid (left) and sclera 
(right). Initial concentration is higher in the choroid than in the sclera. 
Almost complete depletion of melanin occurs in the anterior choroid 
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Glaucoma is the leading cause of irreversible blindness worldwide and has a complex 
etiology associated with elevated intraocular pressure. Biomechanical forces induce vision 
loss through strain-induced damage to the retinal ganglion cells conducting visual 
information from the retina to the brain. This work tests the hypothesis that stiffening the 
peripapillary scleral (collagenous tissue adjacent to the optic nerve) protects against 
glaucomatous vision loss. A photocrosslinking approach was 1) developed to selectively 
stiffen the peripapillary sclera in vivo, 2) tested for efficacy in a rat animal model of 
glaucoma, and 3) simulated using a computational model to predict optimal 
photocrosslinking parameters. 
Scleral photocrosslinking was successfully targeted to the peripapillary sclera in vivo and 
found to have moderate treatment toxicity. In vivo studies in glaucomatous rats revealed 
that our treatment did not worsen glaucomatous damage contrary to a previous study. 
Computational modeling predicted key treatment parameter values and showed that 
crosslinking is most sensitive to tissue rather than sensitizer properties. Together, this body 
of work demonstrates the feasibility of using targeted scleral photocrosslinking as a 





CHAPTER 1. INTRODUCTION 
Glaucoma is a leading cause of blindness worldwide and has been the subject of 
pharmacological and biomechanical research[1–3]. This work consists of a novel method 
for treatment for glaucoma described in three parts: 1) in vivo proof of concept in healthy 
rats, 2) in vivo safety and efficacy studies in glaucomatous rats, and 3) a theoretical 
computational model for treatment optimization.  
1.1 Scleral Stiffening as a Therapeutic Strategy in Glaucoma 
It has been hypothesized that reducing the pressure-induced strain on the optic nerve head 
will reduce glaucomatous vision loss. Previously, Coudrillier et al. showed that 
mechanically stiffening the peripapillary sclera (sclera adjacent to the optic nerve head) 
will reduce the pressure-induced strain experienced by the optic nerve head[4]. This finding 
suggested that scleral stiffening is a promising therapeutic strategy for preventing pressure-
induced glaucomatous damage. However, it was recently shown that whole globe scleral 
stiffening increased glaucomatous axon loss in mice contrary to the anticipated effect of 
preserving axon health[5]. We believe whole globe stiffening may exacerbate 
glaucomatous damage due to the inability for the sclera to attenuate cyclical fluctuations 
in intraocular pressure. Therefore, we propose to selectively stiffen the peripapillary sclera 
as a method for preventing pressure-induced damage in glaucoma.  
1.2 Targeted Peripapillary Stiffening Approach 
In the investigated approach, targeted peripapillary scleral stiffening is enabled by directing 
a transpupillary light beam at the peripapillary region to excite a photosensitive 
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crosslinking agent. In comparison to non-photoactivated crosslinking agents, 
photosensitive crosslinking agents allow for selective stiffening with millimeter resolution 
only where both light and crosslinking agents are present. We designed a microscope which 
allows for controlled illumination of the peripapillary sclera by means of a transpupillary 
approach. The transpupillary approach is advantageous because it is non-invasive (unlike 
catheterized delivery) and provides a clear optical path for targeting the peripapillary 
region. A photosensitive crosslinking agent was administered using a retrobulbar injection 
whereby the agent is injected into the retrobulbar muscle cone adjacent to the posterior 
scleral surface. This injection approach, while already in common clinical practice, also 
delivers the crosslinker near the target peripapillary scleral tissue achieving local 
concentration sufficient for crosslinking.  
1.3 Theoretical Computational Modeling 
In addition to experimental evidence for targeted photocrosslinking at the peripapillary 
sclera, a theoretical model for predicting degree of crosslinking was created to optimize 
treatment parameters. The model incorporates elements of molecular photodynamics, 
diffusion, and chemical kinetics to predict the final distribution of crosslinks in the sclera 
over time and 1-dimensional space. A combination of temporal and spatial information is 
useful for analyzing trends in the distribution of crosslinking and for assessing optimal 
treatment time scales, especially if reaction mechanisms change over time. Key treatment 
parameters of interest (inputs) include crosslinker concentration, light intensity, and 
irradiation duration. Additionally, the model may be used to simulate the efficiencies of 
various crosslinking agents, thus informing research decisions to pursue future crosslinking 
experiments.  
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CHAPTER 2. BACKGROUND 
2.1 Glaucoma  
Glaucoma is the second leading cause of blindness in the world affecting an estimated 70 
million individuals globally[1]. It is a pressure-sensitive optic neuropathy which damages 
retinal ganglion cells responsible for transmitting visual information from the retina to the 
brain[6,7]. The only known effective therapy is IOP pressure management.  Glaucoma is 
closely associated with aging and is the leading cause of blindness in African Americans[8–
10]. Retinal ganglion cell death may remain undetected until there is significant visual loss, 
leading to late diagnoses at which point loss is permanent[11]. When diagnosed early, 
treatment strategies aiming to reduce elevated IOP are employed[12]. Unfortunately, 
certain patients experiencing little or no IOP elevation may still progress towards 
glaucomatous vision loss[13]. Therefore, a preventative treatment which can reduce or 
entirely inhibit loss of vision from glaucomatous RGC damage is of vital interest and would 
change the treatment paradigm for glaucoma management. 
2.2 Intraocular Pressure Elevation 
Elevated intraocular pressure associated with hypertension glaucoma is caused by impaired 
outflow of aqueous humor from the anterior chamber of the eye combined with unimpaired 
production. In healthy eyes, aqueous humor is generated by the ciliary body and is cleared 
through the trabecular meshwork, a network of extracellular lamellae and cells located at 
the iridocorneal angle[14]. In addition to clearance through the trabecular meshwork to 
episcleral veins (conventional outflow), there exists a second, less prevalent route of 
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clearance, the uveoscleral pathway, whereby aqueous humor ultimately exits through a 
number of structures including the sclera, suprachoroidal space, or uveal blood vessels[15]. 
Increased resistance for aqueous outflow in the trabecular meshwork has been associated 
with changes in tissue mechanical properties, gene expression, and induced 
decellularization[16–18].  
2.3 Retinal Ganglion Cell Loss 
Hypertensive IOPs result in biomechanical insult to posterior ocular tissues, leading to 
RGC death. Specifically, RGC death is caused by increased IOP-induced mechanical 
strains at the lamina cribrosa which trigger cellular apoptosis[19]. This apoptotic pathway 
is believed to be mediated by mechanical strain-induced dysfunction of axonal transport 
mechanisms leading to deficits in neurotrophic factors[20]. While the biological pathway 
of strain-mediated apoptosis is not well defined, effects of elevated IOP on RGC loss have 
been well characterized. For example, it is known that retinal ganglion cell death occurs in 
a spatially inhomogeneous manner with superior/inferior quadrant axon loss preceding that  
of the nasal/temporal quadrants[21]. 
2.3.1 Current Treatment Strategies 
Glaucoma treatment research focuses on two main strategies for protecting against vision 
loss: 1) reduction of IOP, and 2) neuroprotection[22][23]. Pressure reduction strategies aim 
to lower IOP in order to prevent pressure-induced damage to RGCs. Neuroprotection aims 
to confer resistance to apoptosis to retinal ganglion cells by modulating cellular 
biochemistry[24].  
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2.3.2 Pressure Reduction 
Pressure reduction strategies are the only clinically-utilized glaucoma treatments[25]. 
These include 1) pressure-lowering pharmaceutical eye drops, 2) trabeculoplasty (laser 
treatment), 3) shunts (surgery), 4) trabeculectomy (surgery), and 5) cyclophotocoagulation 
(laser ablation)[26][27]. Medication is preferred for ease of use and generally positive 
outcomes. In cases where pressure management is difficult with medication, 
trabeculoplasties, shunting procedures, and trabeculectomies (incisional pressure relief) are 
used[28].  
2.3.3 Neuroprotectants 
Neuroprotectants are a relatively new class of drug recently entering clinical trials which 
aims to protect retinal ganglion cells against oxidative stress, immune dysregulation, and 
apoptotic pathway initiation[24]. Memantine, a glutamate receptor antagonist shown to be 
promising in Alzheimer’s clinical trials, was recently tested for neuroprotection in 
glaucoma but failed to show benefit compared to placebo[29]. Despite great research 
interest in the area of neuroprotection for treatment of glaucoma, few agents have 
succeeded in early clinical trials[30].  
2.4 Eye Structure 
2.4.1 Optic Nerve 
Elevated IOP is directly associated with optic nerve deformation and retinal ganglion cell 
loss[31]. Retinal ganglion cells form the retina nerve fiber layer. RGC axons travel from 
the retina nerve fiber layer through the optic nerve head to the optic nerve. The optic nerve 
 6 
head in humans is supported structurally by a thin connective tissue, the lamina cribrosa, 
through which retinal ganglion  cell axons pass[32]. It is hypothesized that glaucomatous 
damage will be more severe in individuals with weaker material structure of the lamina 
cribrosa[33]. The lamina cribrosa itself is structurally weaker than the surrounding 
collagenous scleral tissue and is observed to become “cupped” in glaucomatous 
individuals[34]. Cupping is the indentation of the lamina cribrosa posteriorly and is 
identified by the loss of axons of the retinal nerve fiber layer from the space normally 
occupied by healthy axons flush with the surrounding sclera. In glaucomatous individuals, 
cupping depth increases with disease severity ranging from approximately 344 μm in 
healthy individuals to 448 μm in moderate/late stage glaucoma[35]. For visual 
representation of these changes in optic nerve head morphology, see Wollstein et al. [36].  
2.4.2 Sclera & Peripapillary Collagen 
The sclera is the collagen-rich outer layer of the eye which provides the primary structural 
support for the retina and other ocular tissues and has a distinctive white color in human 
eyes[37]. It separates the choroid, a vascularized layer of tissue posterior to the retina, from 
the tenon capsule, a fibrous fascia posterior to the sclera. The sclera begins anteriorly at the 
limbal interface with the cornea and contiguously encompasses the posterior globe with 
the exception of the scleral canal, a small circular opening through which the optic nerve 
passes[38]. The peripapillary sclera is defined as the scleral region immediately proximate 
to the scleral canal and is suspected to play a role in the biomechanics of the optic nerve 
head[4]. Type I collagen constitutes the major structural protein of the sclera which has a 
collagen composition of approximately 22.5% - 50% in humans [39,40].  
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2.4.3 Collagen Structure 
Type I collagen is one of the most abundant proteins in animals and is organized into a 
triple helix comprised of three separate fibrils[41]. The primary structure of collagen is rich 
with glycine and proline residues, comprising approximately 34% and 25% respectively of 
the helical chain[42]. Natural crosslinks formed between lysine and arginine residues 
provide structural connectivity between fibers[43]. 
2.5 Glaucoma Biomechanics and Scleral Stiffening 
2.5.1 Peripapillary Scleral Stiffening 
Optic nerve head biomechanical properties have long been hypothesized to play a key role 
in glaucoma progression[44]. Furthermore, properties of the surrounding sclera including 
stiffness and thickness are predicted to strongly impact optic nerve head 
biomechanics[45][46].  Peripapillary scleral stiffening has been shown by Coudrillier et al. 
to reduce strain applied to the optic nerve in porcine whole globe inflation tests with a 47% 
reduction in lamina cribrosa strain corresponding with a 34% increase in peripapillary 
scleral stiffening [4]. This finding reveals the potential for a glaucoma treatment utilizing 
peripapillary scleral stiffening for reduction of lamina cribrosa strains and therefore for 
preservation of RGC health in glaucoma.  
2.5.2 Whole Scleral Stiffening 
It has been shown by Kimball et al. that mice treated with the scleral stiffening agent 
glyceraldehyde throughout the posterior segment experience greater axonal loss than those 
without treatment[5]. These findings were unexpected in light of the Coudrillier study as 
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they contradict the expectation that axon loss would be mitigated due to reduction of 
peripapillary scleral strain, and thus lamina cribrosa strain. However, we believe the 
findings of Kimball et al. could not be used to rule out the possibility for axon protection 
by peripapillary scleral stiffening for a few reasons. First, the injection osmolarity used in 
the Kimball study (900 mOsm) was higher than physiological conditions (285-295 
mOsm)[47]. Second, we believe whole sclera stiffening may worsen glaucomatous damage 
by reducing the eye’s natural compliance capable of attenuating fluctuations in the 
intraocular pulse. Targeted peripapillary stiffening, on the other hand, may preserve the 
eye’s natural compliance while mitigating damaging strain at the optic nerve head. It has 
been shown that increasing IOP in hypertension glaucoma increases amplitude of the 
ocular pulse, leading to our suspicion that the ocular pulse is a potential driver of 
biomechanical insult[48,49].  
2.6 Chemical Crosslinking 
2.6.1 Chemical Crosslinkers 
Chemical collagen crosslinkers include glutaraldehyde, glyceraldehyde, and genipin. 
Glutaraldehyde is perhaps the strongest of these, but it suffers from high toxicity[50]. 
Chemical crosslinkers readily react with collagen without the need for additional reactants 
and have been shown to induce stiffening in both ex vivo and in vivo rat sclera[51][52]. 





2.6.2 Mechanisms of Chemical Crosslinking 
Both glyceraldehyde and glutaraldehyde contain reactive aldehyde groups. Glutaraldehyde 
reacts with free amine groups, particularly with those of the side chains of lysine[53]. 
Likewise, glyceraldehyde reacts with amines of lysine or arginine[54]. Though not 
containing aldehydes in its chemical structure, genipin reacts with primary amines through 
an aldehyde intermediate[55]. 
2.7 Photosensitizers & Photocrosslinking 
Photosensitizers have been used both to kill unwanted cells and to strengthen collagenous 
tissues throughout the body, though they have only recently found use in the eye. Previous 
non-ophthalmic experimental studies have used photosensitizers for oncological treatment, 
pericardial tissue stabilization, tendon repair and dentin crosslinking[56][57][58–60]. 
2.7.1 Photodynamic Therapy (PDT) 
Photodynamic therapy is the use of a photosensitizer and incident photons to target and 
destroy select tissues in vivo. As a cancer treatment, PDT has been in use clinically since 
the 1970s  with an established body of accompanying research from which numerous 
photosensitizers (Table 1) have emerged[61–64]. The primary disadvantage of PDT is the 
limited depth of light penetration through biological tissues resulting in use for superficial 
rather than deep tissue applications. Therefore, PDT treatments have been developed for 




2.7.2 Desirable Photosensitizer Properties 
Desirable properties for photodynamic therapeutic agents include efficient localization to 
cancer sites, low off-target localization, efficient absorbance of incident photons, 
absorbance in the phototherapeutic window, efficient triplet state energy transfer to triplet 
oxygen, and low dark toxicity[66]. Generally, strong absorbance at longer wavelengths is 
desirable since biological absorber efficiency declines in the 650-800 nm regime 
encompassing most current sensitizers[67]. Novel photosensitizer development has 
evolved continuously to meet these standards with an emphasis on improving energy 
transfer efficiency by preventing aggregation of molecules as well as improved absorbance 
at longer wavelengths[68,69].  
2.7.3 Photosensitization Mechanism 
Photosensitization reactions begin with the absorbance of a photon by a photosensitizer in 
the ground state, the condition in which all electrons are in the lowest energy state[70]. 
Upon absorption of the photon, an electron enters an elevated singlet excited state (excited 
electron has opposite spin state compared to paired ground state electron), from which it 
may lose its energy through three processes: 1) vibrational relaxation (heat dissipation), 2) 
fluorescence emission of a lower energy photon, or 3) intersystem crossing where the 
excited singlet state electron converts to a triplet excited state thus resulting in two unpaired 
electrons with identical spin state[70]. Triplet states are long-lived in most sensitizers, for 
example, on the order of 29 𝜇s for riboflavin in water and 77𝜇s for methylene blue in 
water[71,72]. The efficiency at which an absorbed photon will result in a triplet excited 
state sensitizer molecule is the triplet quantum yield (𝟇T). Photosensitizers with high triplet 
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quantum yield and long triplet lifetimes are the most efficient since the triplet excited state 
subsequently reacts with ground-state oxygen to produce reactive oxygen species. 
2.7.4 Photophysical Properties of Photosensitizers 
Two important quantifiable properties of photosensitizers are 1) molar absorptivity (ε), and 
2) singlet oxygen quantum yield (𝟇Δ.) Molar absorptivity describes the absorbance of a 
photoactive molecule and is useful as a component of the Beer-Lambert Law, with higher 
molar absorptivity values indicating more proficient absorbance. Singlet oxygen quantum 
yield is defined as the fraction of absorbed photons which result in the generation of a 
molecule of singlet oxygen. Mathematically, this value is represented as the product of the 
triplet quantum yield, fraction of triplets quenched by oxygen, and the fraction of oxygen 
molecules which have quenched the triplet state and convert to singlet oxygen[73].  High 
singlet oxygen quantum yields indicate greater photophysical efficiency of sensitization, 
with a value of 1 indicating highly efficient conversion and 0 indicating no conversion. 
Singlet oxygen quantum yields greater than 1 are theoretically possible, though small 
molecule sensitizers generally have yields in the range of 0.3-0.8. The photophysical 












Porfimer Sodium 632 nm 3,000 M-1cm-1 0.89 [62,67] 
Temoporfin 652 nm 30,000 M-1cm-1 0.87 [62,67] 
Mono Aspartyl 
Chlorin e6 
654 nm 40,000 M-1cm-1 0.56-0.77 [74,75] 








675 nm 105,000 M-1cm-1 0.38 [81,82] 
Verteporfin 689 nm 33,000 M-1cm-1 0.78 [83] 
Motexafin 
Lutetium 
732 nm 40,000 M-1cm-1 0.38 [84] 
Redaporfin 743 nm 140,000 M-1cm-1 0.17 [67] 
Padeliporfin 762 nm 110,000 M-1cm-1 0.15-0.21† [67,85] 
Indocyanine 
Green 
800 nm 115,000 M-1cm-1 0.012-0.12 [86,87] 
† Oxygen consumption quantum yield – padeliporfin does not generate singlet oxygen 
 
2.7.5 Molecular Classifications of Photosensitizers 
Photosensitizers are a class of light-absorbing molecules which mediate cell death by direct 
interaction of the excited dye molecule with cellular constituents or by energy transfer to 
form toxic reactive oxygen species[63]. They can be classified into groupings based on 
chemical structure with those absorbing in the phototherapeutic window including 
porphyrins, chlorins, pheophorbides, bacteriopheophorbides, texaphyrins, 
phthalocyanines, naphthalocyanines, and phenothiazines[62]. Photosensitizers in FDA-
approved products include Levulan (5-amniolevulinic acid) indicated for actinic keratosis, 
 13 
Visudyne (verteporfin) indicated for AMD, and Photofrin (porfimer sodium) indicated for 
endobronchial cancer[62]. 
2.7.6 Methylene Blue 
Methylene blue (Figure 1) is a small molecule phenothiazinium dye photosensitizer with 
marked blue color due to its strong absorbance at approximately 665nm[88]. It is primarily 
a type II sensitizer[89]. Historically used as a cyanide antidote, methylene blue is presently 
FDA-approved for intravenous injection as a treatment for the blood disorder, 
methemoglobinemia[90,91]. Methylene blue has been shown to be well-tolerated by the 
rat retina after intravitreal injection, indicating reasonable biocompatibility in the eye[92]. 
Interestingly, it has also recently shown promise as a neuroprotectant for Alzheimer’s[93].  
 
Figure 1: Molecular structure of methylene blue. Methylene blue is a synthetic cationic 
dye with molecular weight of 318.95 g/mole containing a centralized sulfur atom. Source: 
https://commons.wikimedia.org/wiki/File:Methylene_blue.svg  
 
Methylene blue is an attractive photosensitizer because it is relatively inexpensive, absorbs 
light in the phototherapeutic window, has high solubility in water (approximately 16 mM 
in water), has a high molar absorptivity (79,800 M-1cm-1) and has a strong singlet oxygen 
quantum yield (0.52)[76,77,94]. With an octanol-water partition coefficient of -0.1, 
methylene blue’s partitioning into hydrophilic environments makes it suitable for delivery 
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to the relatively acellular sclera, though Prausnitz and Noonan found no evidence for a 
relationship between partition coefficient and scleral permeability[95,96]. Furthermore, its 
cationic nature should slightly decrease its permeability in the sclera compared to neutral 
or negatively charged species, though this may be advantageous for slowing clearance from 
the sclera[97].  
2.7.7 Collagen Photocrosslinking Mechanism 
The mechanisms of collagen crosslinking by photocrosslinkers are categorized into two 
types: type I reactions and type II reactions[62]. Type I reactions require the direct reaction 
of an excited state sensitizer with substrate. Type II reactions require that the excited state 
energy of a sensitizer be transferred to oxygen, thus generating singlet oxygen, which then 
reacts with collagen to form crosslinks[70]. Amino acids selectively participate in 
crosslinking reactions depending upon type I or type II mechanism. Histidine has been 
found to be a strong target for singlet oxygen and has been shown to readily dimerize in 
the presence of rose bengal, an exclusively type II sensitizer[98][99]. Histidine crosslinking 
is believed to occur through initial reaction of singlet oxygen with the histidine imidazole 
ring to form a hydroperoxide, the decomposition of which is amenable to nucleophilic 
attack by another histidine side chain[100].  Tryptophan, tyrosine, and cysteine are known 
to be involved in sensitized crosslinking reactions as well[101]. However, the reaction of 
these residues with methylene blue-generated singlet oxygen was shown to be less 
significant than that with histidine[102].  
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2.7.8 Clinical Applications of Photosensitizers in Ophthalmology 
2.7.8.1 Age-Related Macular Degeneration (AMD) Treatment (Verteporfin) 
Verteporfin is a notable FDA-approved photosensitizer (formulated as Visudyne) for its 
use in the eye to treat AMD by facilitating laser ablation of aberrant retinal 
vasculature[103]. It is injected intravenously and facilitates selective ablation of vessels 
targeted with a transpupillary laser beam due to its localization in the vascular lumen[103]. 
Structurally, verteporfin belongs to the class of sensitizers derived from the chlorophyll 
ring (chlorins) and is an efficient absorber at 689nm[66]. 
2.7.8.2 Keratoconus Treatment (Riboflavin 5’-Phosphate) 
Riboflavin 5’-phosphate (FMN), a derivative of riboflavin (vitamin B2), is another notable 
FDA-approved photosensitizer indicated for use in the eye. Unlike verteporfin treatment 
for AMD, riboflavin collagen crosslinking (CXL) was developed to treat keratoconus, a 
disease of the cornea characterized by weakened corneal collagen, by introducing collagen 
crosslinks[104]. Riboflavin crosslinking utilizes a topical application of riboflavin to the 
corneal stroma after removal of the corneal epithelium followed by irradiation with 365nm 
UV light for 30 minutes and prevents further corneal deformation due to the mechanical 
stiffening conferred on the stroma from crosslinking[105].  
2.8 Scleral Photocrosslinking Challenges 
Studies to date on scleral photocrosslinking have focused on the equatorial/anterior regions 
where topical application of photosensitizer and direct external illumination are most 
feasible[106,107]. Drug delivery to the posterior globe is difficult due to limited access but 
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important for treating diseases of the retina/optic nerve[108]. While drug delivery to the 
posterior hemisphere of the eye is difficult, injection techniques exist both for localization 
to the suprachoroidal space and to the retrobulbar space[109]. 
2.8.1 Drug Delivery Considerations 
The first challenge of scleral photocrosslinking is physical delivery of a photosensitizer to 
the sclera. Delivery of photosensitizers to the sclera may be achieved in one of three 
primary routes: 1) through the posterior scleral surface, 2) through the anterior scleral 
surface, and 3) intrasclerally. The epithelialized conjunctiva and Tenon capsule layers 
present barriers to posterior surface scleral sensitizer delivery. However, these barriers may 
be overcome using targeted injections such as sub-conjunctival and sub-Tenon injections 
which place the injected volume directly against the posterior scleral surface[110]. Anterior 
scleral surface delivery is made difficult by the anterior structures of the eye, namely the 
retina. Recent advances in targeted suprachoroidal injections capable of reaching the 
posterior pole have made a suprachoroidal route feasible[111]. The disadvantage of a 
suprachoroidal delivery route is perhaps the rapid clearance of the adjacent choroid 
combined with limited potential space[112,113]. Finally, an intrastromal delivery, while 
most direct, is currently not feasible due to the difficulty of precisely positioning a needle 
within the sclera at the posterior globe. 
2.8.2 Light Delivery Considerations 
Light absorbance in biological tissues is well characterized with melanin, hemoglobin, and 
water being the primary absorbing species in the visible/NIR spectrum[67]. The 
phototherapeutic window is a region of the visible spectrum where absorbance of these 
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species in biological tissues is minimal. This region ranges from approximately 650nm to 
850nm and is bounded by the decreasing absorbance of melanin on the higher frequency 
wavelengths and by the increasing absorbance of water on the lower frequency 
wavelengths[67]. Photosensitizer research has focused heavily on photosensitizers with 
strong peak absorbance in the phototherapeutic window[78,114,115].  
2.8.3 Light Absorbance in the Eye 
The eye’s structure presents a unique opportunity for use of photodynamic agents due to 
the highly transparent cornea, lens, and vitreous. Furthermore, the opaque sclera and 
choroid are thin tissues (<1mm in humans) amenable to light penetration despite their 
propensity for absorbing visible light[116]. Notably, the retinal pigmented epithelium  
presents a formidable barrier to light penetration due its highly pigmented (melanin) 
nature[117][118][119]. With melanin and hemoglobin ranked as leading absorbing 
biological species in the visible spectrum, the choroid represents a unique challenge for 
light delivery. The sclera, on the other hand, is only moderately absorbing compared to the 
choroid[120,121]. Light absorbance by a bulk medium (rather than concentration-varying 
species) is described using the linear attenuation coefficient (μ). The linear attenuation 
coefficient is defined for a given wavelength and is useful for mathematically modeling 
light attenuation in a medium such as the sclera or cornea using the Beer-Lambert Law, 
especially when modeling sensitizer activity in that tissue. For the choroid/RPE, it is 
perhaps more practical to consider percent light transmission at a given wavelength since 
these tissues merely represent a barrier to light penetration before light can reach the 
posterior sclera. For example, 660nm light used for excitation of methylene blue has an 
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approximate transmission of 20% in the human retina/choroid, while 808nm light used to 
excite indocyanine green has an approximate transmission of 50%[118].  
2.8.4 Light Toxicity in the Eye 
The wavelengths of the phototherapeutic window, visible to near infrared, require different 
toxicity considerations as far as transpupillary illumination approaches are concerned. The 
visible spectrum has a stricter range of maximum permissible exposure limits compared to 
near infrared due to the potential not only for photothermal impacts but also photochemical 
damage[122]. The maximum permissible retinal exposure limit for 660nm light with 
exposure duration of 30 minutes and beam size proportional to the size of the (rat) 
peripapillary sclera is approximately 160 mW/cm2 based on calculations from Delori et al 
[123]. Wollensak et al found that transscleral illumination of riboflavin with blue light 
results in retinal toxicity[124]. In addition to phototoxicity of light, photosensitizer-
mediated singlet oxygen generation is expected to have toxicity as is the case for cancer 
treatment and antibacterial applications[125,126]. 
2.9 Theoretical Photocrosslinking Computational Modeling 
A predictive model of scleral photocrosslinking should account for 1) diffusion, 2) light 
propagation/absorbance, and 3) chemical reaction kinetics. An abundance of modeling has 
been performed for riboflavin crosslinking simulation including both analytical and 




2.9.1.1 Retrobulbar Injection Distribution & Diffusion 
While the film thickness of riboflavin on the corneal surface during riboflavin crosslinking 
is small, it is deemed significant enough to include in mathematical models (though also 
neglected in others)[130][131]. However, in these models it is considered constant rather 
than dynamic as would need to be the case for a retrobulbar injection where replenishment 
of the reservoir does not occur. Furthermore, clearance of photosensitizer through 
retrobulbar vasculature complicates transport dynamics and requires experimental 







where 𝐶 represents concentration of the diffusing species, 𝐷 represents the diffusion 
constant, and 𝑥 and 𝑡 represent position and time, respectively. While Fick’s Second Law 
may be solved analytically easily using a steady state assumption, a model accounting for 
dynamic changes in boundary conditions and accounting for reaction conditions will make 
solving an analytical solution impractical.  
2.9.1.2 Oxygen Supply and Consumption 
Considering the role of reactive oxygen species in collagen photocrosslinking, the 
concentration and interaction of oxygen with sensitizer are both important for accurate 
modeling[132][133]. Oxygen diffusion dynamics were previously measured and modeled 
for riboflavin crosslinking representing an important milestone providing an experimental 
reference against which computational models may be tested[129]. Unlike riboflavin 
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crosslinking models, a posterior scleral photocrosslinking model would need to account for 
oxygen supply from the choroid rather than atmospheric oxygen. 
2.9.1.3 Light Absorbance  
Light attenuation by molecular and bulk absorbers is popularly modeled using the Beer-
Lambert Law (Beer’s Law) [134]. According to Beer’s Law, the change of light intensity 
as it travels through a medium is proportional to the intensity times the absorbance of the 
medium on an infinitesimal length: 
 𝑑𝐼
𝑑𝑥
= −𝐼𝐶𝜀 (2) 
where I is light intensity, x is the distance in the direction of photon travel, and C and 𝜀 are 
the concentration and molar absorptivity of light-absorbing species, respectively.  The 
analytical solution to the Beer-Lambert Law yields a light intensity function with 
exponential decay over distance. Unlike riboflavin crosslinking models where light 
attenuation in the cornea is the only tissue-dependent photophysical property, modeling 
transpupillary penetration of light through the fundus requires that light attenuation by the 
choroid/RPE be accounted for as well as attenuation of light by the sclera. Furthermore, 
pigmentation of the choroid/RPE may vary by species or individual, and thus a melanin 
concentration-dependent parameter for light attenuation would be advantageous[118]. 
2.9.1.4 Sensitizer Degradation and Aggregation 
Sensitizer degradation and aggregation are significant detractors from photocrosslinking 
efficiency which are often well-characterized[135,136]. Riboflavin suffers from facile 
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degradation under UV light[137]. Methylene blue on the other hand is less photolabile, but 
aggregates far more readily than does riboflavin, leading to quenching of the triplet 
state[138][76,139]. It is also notable that methylene blue is believed to form higher order 
aggregates beyond simple dimerization[140,141]. Simple dimerization is described 






where M is the concentration of monomeric photosensitizer and D is the concentration of 
aggregated (dimeric) photosensitizer[76]. Thus, concentration of aggregated species 
changes nonlinearly with total concentration, complicating the estimation of 
photosensitizer efficiency in an environment with dynamic concentration changes. 
2.9.1.5 Chemical Kinetics 
Kinetic rate laws have been applied in many riboflavin crosslinking models and provide 
important temporal information dependent upon dynamic reactant 
concentrations[129,130]. Fortunately, photochemical studies of photosensitizers and 
reactions involving target amino acid residues are abundant for riboflavin and for 
methylene blue and involve first order assumptions for reaction kinetics[142–144]. For a 
simple bimolecular reaction as would be the case for singlet oxygen generation from triplet 
oxygen and triplet state photosensitizer, the reaction can be modeled as: 
 𝑑[𝐶]
𝑑𝑡
= 𝑘[𝐴][𝐵] (4) 
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where A and B are the concentrations of reactants, C is the concentration of product, t is 
time, and k is the reaction rate constant. Solving the differential equation results in an 
analytical solution with product concentration increasing exponentially over time. 
2.9.2 Experimental Studies as Test Cases for Computational Model 
Riboflavin crosslinking experiments provide a wealth of test cases against which 
computational models may be validated. Particularly, studies have investigated oxygen 
concentration over time, crosslinking magnitude as a function of illumination intensity and 
duration, riboflavin concentration as a function of stromal depth, and fluorescent crosslink 
concentration as a function of stromal depth[129,145–147]. Since these studies track a 
single parameter over space or time (usually not both), they may be used in combination 
to provide multiple points of reference against which a model can be tested.  
2.9.3 Quantification of Crosslinking and Stiffening 
Crosslinking has been estimated variously by either assuming singlet oxygen reacts with 
histidine or by using broad polymer reaction rate kinetics simplifications[130][128,148]. 
One notable limitation to these methods is the inability to relate crosslinking to tissue 
stiffening. While studies exist which attempt to relate the two, it is difficult to find studies 
with material properties matching those of the cornea/sclera[149,150]. Therefore, 
comparison of theoretical crosslink densities achieved during transpupillary illumination 
of scleral photosensitizers with those of riboflavin crosslinking would provide a useful 
benchmark for stiffening as stiffness increase has been quantified experimentally for 
riboflavin crosslinking[104,107,124,151,152]. 
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2.10 Scleral Stiffening as a Therapeutic Strategy in Glaucoma 
It has been hypothesized that reducing the pressure-induced strain on the optic nerve head 
will reduce glaucomatous vision loss. Previously, Coudrillier et al. showed that 
mechanically stiffening the peripapillary sclera (sclera adjacent to the optic nerve head) 
will reduce the pressure-induced strain experienced by the optic nerve head[4]. This finding 
suggested that scleral stiffening is a promising therapeutic strategy for preventing pressure-
induced glaucomatous damage. However, it was recently shown that whole globe scleral 
stiffening increased glaucomatous axon loss in mice contrary to the anticipated effect of 
preserving axon health[5]. We believe whole globe stiffening may exacerbate 
glaucomatous damage due to the inability for the sclera to attenuate cyclical fluctuations 
in intraocular pressure. Therefore, we propose to selectively stiffen the peripapillary sclera 
as a method for preventing pressure-induced damage in glaucoma.  
2.11 Targeted Peripapillary Stiffening Approach 
In the investigated approach, targeted peripapillary scleral stiffening is enabled by directing 
a transpupillary light beam at the peripapillary region to excite a photosensitive 
crosslinking agent. In comparison to non-photoactivated crosslinking agents, 
photosensitive crosslinking agents allow for selective stiffening with millimeter resolution 
only where both light and crosslinking agents are present. We designed a microscope which 
allows for controlled illumination of the peripapillary sclera by means of a transpupillary 
approach. The transpupillary approach is advantageous because it is non-invasive (unlike 
catheterized delivery) and provides a clear optical path for targeting the peripapillary 
region. A photosensitive crosslinking agent was administered using a retrobulbar injection 
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whereby the agent is injected into the retrobulbar muscle cone adjacent to the posterior 
scleral surface. This injection approach, while already in common clinical practice, also 
delivers the crosslinker near the target peripapillary scleral tissue achieving local 
concentration sufficient for crosslinking.  
2.12 Theoretical Computational Modeling 
In addition to experimental evidence for targeted photocrosslinking at the peripapillary 
sclera, a theoretical model for predicting degree of crosslinking was created to optimize 
treatment parameters. The model incorporates elements of molecular photodynamics, 
diffusion, and chemical kinetics to predict the final distribution of crosslinks in the sclera 
over time and 1-dimensional space. A combination of temporal and spatial information is 
useful for analyzing trends in the distribution of crosslinking and for assessing optimal 
treatment time scales, especially if reaction mechanisms change over time. Key treatment 
parameters of interest (inputs) include crosslinker concentration, light intensity, and 
irradiation duration. Additionally, the model may be used to simulate the efficiencies of 
various crosslinking agents, thus informing research decisions to pursue future crosslinking 
experiments.   
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CHAPTER 3. SPATIALLY TARGETED SCLERAL 
PHOTOCROSSLINKING WITH METHYLENE BLUE 
Note on Contribution: Data presented in this chapter are the product of contributions from 
a number of individuals I wish to acknowledge. Bailey Hannon contributed the data 
pertaining to ERG studies and axon counts and to analysis of data pertaining to ERG 
studies. Dr. Thomas Read contributed axon sections used in axon count data. Amir Hejri 
contributed histological sectioning/staining of ocular tissues. Dr. Hans Grossniklaus 
contributed to histological sectioning/staining of ocular tissues as well as expertise in 
analysis of these tissues. Elisa Schrader, Lauren Nichols, and Erin Winger contributed to 
DIC data analysis. Hannah Gersch, Erin Winger, Niyati MacLeod, and Elisa Schrader 
contributed to collection of confocal microscopy data for determination of methylene blue 
retrobulbar distribution. Lauren Nichols contributed to data analyses of methylene blue 
confocal microscopy data. 
3.1 Abstract 
To prevent optic nerve head cupping associated with glaucomatous retinal ganglion cell 
damage, this study sought to selectively stiffen the peripapillary sclera, and thereby reduce 
tissue deformation near the optic nerve head. Previously, scleral crosslinking has been used 
to stiffen tissue for treatments of glaucoma or myopia but has either been regionally non-
selective or regionally selective but with limited access to the posterior globe. We present 
a method for selectively stiffening the peripapillary sclera using a transpupillary annular 
light beam to activate methylene blue administered by retrobulbar injection. Unlike prior 
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approaches to photocrosslinking in the eye, this approach avoided the damaging effects of 
ultraviolet light by employing a red visible light crosslinking method. Targeted 
photocrosslinking in this way reduced average strain of the peripapillary region in treated 
eyes by 54% compared to untreated eyes and by 46% compared to the untreated peripheral 
sclera of the treated eye for at least 6 weeks post injection. Post-treatment characterization 
with optic nerve axon counts, electroretinography, and retinal histology revealed evidence 
of moderate toxicity of the procedure. In conclusion, this study shows that a transpupillary 
photocrosslinking approach enables selective scleral stiffening targeted to the peripapillary 
region that may be useful in future treatments of glaucoma and myopia. 
3.2 Introduction 
Glaucoma is the second leading cause of blindness in the industrialized world and affects 
approximately 70 million individuals worldwide [153,154]. Disease progression is strongly 
linked to elevated intraocular pressure (IOP) which has been shown to correlate with 
cupping of the lamina cribrosa and damage to retinal ganglion cell axons in the optic nerve 
head[6]. While IOP management is the primary modality of treatment, direct prevention of 
optic nerve head deformation through modulation of tissue mechanical properties may 
confer protective advantages to retinal ganglion cells[12,155].  
Stiffening of the peripapillary sclera was previously shown to reduce strain on the lamina 
cribrosa of ex vivo porcine eyes[4]. However, an in vivo study in glaucomatous mice found 
that whole-globe scleral stiffening worsened axon loss in glaucomatous mice[5]. This 
result was unexpected considering the prior evidence of peripapillary scleral stiffening 
leading to reduction in lamina cribrosa strain. An explanation for this result may be that 
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whole-globe scleral stiffening reduces the overall compliance of the eye to an extent that 
IOP fluctuations become larger in amplitude may no longer be safely accommodated[156]. 
We believe such an effect may be overcome by targeted crosslinking of the peripapillary 
sclera, rather than whole globe stiffening. 
Collagen crosslinking (CXL) has been employed as a means of scleral stiffening through 
either photomediated (“light”) or non-photomediated (“dark”) crosslinking. Riboflavin 
crosslinking is a well-established procedure in the cornea for treatment of the refractive 
disorder, keratoconus, in which the photosensitizer riboflavin is applied topically to de-
epithelialized corneas and exposed to ultraviolet A (UVA) light for 30 minutes[105,157]. 
The success of this method in keratoconus treatment has led to additional studies testing  
riboflavin’s effects on scleral stiffening for myopia management[106,152]. However, 
riboflavin crosslinking has largely been limited to the anterior sclera due to the toxicity of 
UVA light at high doses and difficulty of reaching posterior ocular tissues[124,151]. 
Recently, UVA light was delivered by optic waveguide/optical fiber to equatorial rabbit 
sclera in vivo for targeted  photocrosslinking, illustrating the recent interest for regionally 
selective scleral stiffening[158].  
In addition to light-activated photocrosslinking strategies, dark crosslinkers have been used 
for corneal and scleral stiffening[159,160]. Recently, we have shown the feasibility of in 
vivo scleral crosslinking with a single injection of the dark crosslinker, genipin, which was 
motivated by the need for scleral stiffening with less cytotoxicity compared to dark 
crosslinkers used in the past[52]. Previously-used dark crosslinkers such as glutaraldehyde 
and glyceraldehyde are known to have toxicity profiles which may limit the effective 
scleral dose due to proximity to the retina[161]. However, small molecule dark crosslinkers 
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typically stiffen the entire globe non-selectively, as they diffuse quickly through tissues 
and react with collagen on contact.  
Despite advances in both dark- and light-mediated crosslinking approaches in the eye, none 
have achieved in vivo spatial selectivity on the millimeter scale, which is fine enough to 
selectively crosslink the peripapillary sclera to test the hypothesis that targeted crosslinking 
of the peripapillary sclera confers protection on retinal ganglion cells in glaucomatous eyes, 
a stiffening approach is needed which selectively crosslinks the peripapillary sclera while 
leaving the remainder of the globe unaffected. The goal of this study was to develop a 
targeted stiffening method capable of selectively stiffening the peripapillary sclera, 
resulting in a >38% reduction in strain (comparable to the strains used in Coudrillier et al.) 
[4]. A photocrosslinking approach was chosen to achieve millimeter-scale targeted 
stiffening, and therefore considerations were made for using a light-activated crosslinking 
agent, delivery of that agent to the peripapillary sclera, and illumination of that agent with 
a transpupillary light beam.  
We have developed a targeted scleral crosslinking approach capable of selectively 
stiffening the peripapillary sclera. With our targeted approach, an annular light beam of 
660nm light with dimensions measuring 2 mm outer diameter and 1 mm inner diameter 
was projected onto the peripapillary sclera through a transpupillary approach.  
Methylene blue is a known type II (singlet oxygen-generating) photosensitizer and has 
found many medical uses since its discovery over a century ago including as an anti-
malarial, antidote for cyanide poisoning, and currently as a treatment for 
methemoglobinemia[90,91,96,126,162]. We chose MB for its efficient absorbance of red 
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light (molar absorptivity, ε = 73,300 M-1cm-1), high triplet quantum yield (𝞍T = 0.52) , 
solubility, and availability [76,163]. Selection of a sensitizer absorbing in the 
phototherapeutic window (650-850 nm), where melanin and hemoglobin absorbances are 
relatively low, was an important criterion[67]. Furthermore, MB has been shown to 
increase collagen stability in rat tail tendon and to induce crosslinking of porcine 
pericardial tissue, suggesting it would perform well as a crosslinker in a collage-rich tissue 
such as the sclera[102,164,165].  
While current glaucoma treatments primarily aim to lower intraocular pressure associated 
with mechanical insult at the optic nerve head, an alternative future strategy may be to 
mechanically reinforce the peripapillary sclera. Therefore, an alternative treatment which 
confers protection on retinal ganglion cells independently of pressure would be 
advantageous. This study aims to establish the method for targeted peripapillary 
photocrosslinking as a step towards testing the viability of such treatment in a future 
glaucomatous animal model.  
3.3 Materials and Methods 
3.3.1 Rats 
Brown Norway retired male breeder rats (age 6-12 months) were obtained from Charles 
River Laboratories (Wilmington, MA). All procedures involving animals were approved 
by the Georgia Institute of Technology Institutional Animal Care and Use Committee 
(IACUC) and complied with the ARVO statement for the Use of Animals in Ophthalmic 
and Vision Research. Rats were housed and maintained by veterinary staff at the institute 
animal facility and were fed standard rodent diet (LabDiet 5001, Lab Supply, Fort Worth, 
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Texas). Prior to any procedure, rats were allowed at least three days to become acclimated 
to the animal facility. 
3.3.2 Anaesthesia and Eye Dilation 
Rats were placed under anesthesia using a mixture of isoflurane gas (5%) and oxygen gas 
(95%) supplied through a stereotaxic head positioner (Kopf Instruments, Tujunga, CA). A 
heating pad was placed under the rats to maintain body temperature throughout the 
procedure. After induction of anesthesia, 0.5% tetracaine eye drops (Tetracaine 
Hydrochloride Ophthalmic Solution, Amici Pharmaceuticals, Melville, New York) were 
applied topically to the eyes bilaterally. Excess fluid was gently wicked away from the 
surface of the eyes, and 1% tropicamide dilating drops (Tropicamide Ophthalmic Solution, 
Henry Schein, Melville, New York) were applied bilaterally and allowed to take effect for 
approximately 10 min. Pupil dilation was confirmed visually prior to each experiment to 
ensure sufficient visual access to the fundus. Anesthesia was maintained throughout the 
remaining duration of the procedure with an isoflurane/oxygen flow rate of approximately 
800 mL/min. At the conclusion of survival procedures, rats were allowed to recover from 
anesthesia, returned to their housing, and were monitored for any adverse effects of the 
procedure. For non-survival procedures, rats were euthanized by exposure to 100% CO2.  
3.3.3 Ocular Imaging and Photocrosslinking by Microscopy 
We constructed an ophthalmic microscope (Figure 2) to enable simultaneous transpupillary 
fundus visualization and annular beam projection from an incoherent diode light source 
(Thorlabs, Newton, NJ). The microscope was constructed from readily available optical 
components and was mounted on a three-axis manual micro-positioner, allowing for fine 
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corrections in beam alignment. The microscope was mounted with the objective and 
projected beam facing downwards toward a platform mounted on laboratory jacks on 
which anesthetized rats were supported. Light intensity was adjusted using a variable 
power source/controller. An annular beam was formed from the diode source using an 
aperture, axicon lens, and microscope objective. A microscope camera connected to a 
computer was used to visualize the projected annular beam as it was projected through a 
beam splitter and the microscope objective. See Supplemental Materials for additional 
information on microscope design.   
 
Figure 2: Ophthalmic microscope designed to enable simultaneous transpupillary fundus 
visualization and annular beam projection in the rat eye in vivo. A) Component diagram, 
and B) photographic image of the microscope set-up. The microscope allows a user to 
simultaneously project an annular beam onto a rat fundus, observe the location of the 
beam on the fundus, and precisely position the beam using a three-axis manual micro-
positioner stage (behind the microscope). 
 
3.3.4 Photocrosslinking Materials 
Methylene blue (Apollo Scientific, Stockport, UK) in powder form was solubilized in 
Hank’s balanced salt solution (HBSS) (Mediatech, Manassas, Virginia) resulting in a 
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buffered solution with final MB concentration of 3 mM. HBSS buffer vehicle solution was 
chosen to neutralize the otherwise acidic nature of dissolved MB. The solution was heated 
to 100°C for 15 min to facilitate MB solubilization and subsequently allowed to cool prior 
to injection. Sterile, disposable syringes (300 µL) with 31 G needles (BD Insulin Syringes 
with BD Ultra-Fine™ needle, Becton, Dickinson and Company, Franklin Lakes, New 
Jersey) were filled with 100 µL of either HBSS or 3 mM MB in HBSS.  
3.3.5 Retrobulbar Injection 
After anesthesia induction and pupil dilation, a single 100 µL retrobulbar injection was 
administered to each eye using forceps to gently proptose the eye. Our stereotaxic head 
mount equipped with a tooth bar (but no ear bars) allowed for rotation and elevation of the 
head as well as unobstructed access to the eyes. Injections were administered at the inferior 
quadrant using tactile feedback to determine position of the needle tip in the muscle cone. 
Syringes/needles were held in place for 10 s after injection to avoid reflux of fluid from the 
retrobulbar space. After injection was complete, hydrating eye lubricant (Puralube Vet 
Ointment, Dechra, Northwich, United Kingdom) was applied topically to the eye not 
receiving light to prevent dehydration during the photocrosslinking procedure.  
3.3.6 Photocrosslinking Procedure 
Following retrobulbar injection, the rat was positioned with the eye receiving light 
treatment facing upward in the optical path of the microscope. A contact lens designed for 
fundus imaging in rat eyes (OFA5.4, Ocular Instruments, Bellevue, Washington) was 
placed on the cornea and optically coupled to the surface with HBSS, allowing clear 
visualization of the fundus (Figure 3A). A low intensity (<0.1 mW) “guide” beam was used 
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to locate the optic nerve head through the microscope’s camera. The beam projection was 
then aligned so that the optic nerve was positioned at the dark center of the annular beam 
using three manual micropositioners to translate the entire microscope in the vertical and 
two horizontal planes. After alignment, light intensity was adjusted to a power of 10 mW 
measured using an optical power meter (ThorLabs) and maintained for 30 min (Figure 3B). 
The diode’s output centered at a frequency of 660 nm (i.e., visible red light). Annular beam 
dimensions were 1 mm inner diameter and 2 mm outer diameter, resulting in an intensity 
of approximately 425 mW/cm2. Right and left eyes received alternating treatments from 
rat to rat to control for any variation due to orientation of the eyes. 
 
Figure 3: Selective illumination of the peripapillary region of the rat eye. A) A contact 
lens placed on the corneal surface creates a clear visual path for viewing the fundus. The 
optic nerve can be seen (red dot) from which blood vessels emanate. The blue color is 
due to the retrobulbar injection of MB, visible in this case, in a non-pigmented Wistar rat. 
B) Image from microscope camera during illumination procedure showing annular beam 
spot relative to the optic nerve head (center). The beam appears yellow due to false color 
imaging used to help visualize the optic nerve head (ONH) and blood vessels during the 





3.3.7 Whole Globe Inflation Testing 
Scleral stiffness was measured post mortem using a digital image correlation (DIC) system 
(Dantec Dynamics, Skovlunde, Denmark) as previously described in Hannon et al. and 
others[4,52,166]. Eyes were enucleated immediately after CO2-induced euthanasia and 
excess orbital tissue was carefully removed with dissection microscissors to expose the 
sclera. After tissue removal, each eye was mounted with the optic nerve positioned upward 
under the downward-facing cameras on a custom pressurization apparatus by applying 
cyanoacrylate-based adhesive (Henkel, Düsseldorf, Germany) to the circumferential 
contact point with the limbus. The cornea was excised, and the lens was removed to prevent 
any hinderance to subsequent pressurization, leaving only the mounted scleral shell, which 
was filled with phosphate-buffered saline (PBS). The optic nerve was trimmed to leave 
approximately 1 mm protruding from the scleral surface.  
Graphite powder was applied to the posterior scleral surface to create a speckled pattern 
used by the digital image correlation system cameras to track displacement of the surface. 
The mount with attached scleral shell was then secured with the anterior scleral surface in 
fluidic communication with a PBS pressure reservoir and in-line flow sensor (SLG64-
0075, Sensirion, Staefa, Switzerland) used to monitor flow of PBS into the eye upon 
pressurization. A walled, open-top chamber surrounding the eye was filled with PBS to 
prevent drying of the eye, and a layer of mineral oil was floated on top of the PBS to prevent 
evaporation of the PBS while maintaining a clear optical path between the sclera and 
cameras.  
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Eyes were mechanically preconditioned prior to testing by cycling the height of the 
pressure reservoir to create IOPs from 3 mmHg to 15 mmHg (10 cycles), thus improving 
consistency of mechanical measurements across tests. Immediately following 
preconditioning, eyes were pressurized at 3, 10, 20, and 30 mmHg in sequential steps. 
Pressure was only increased when the measured PBS flow rate stabilized to a near-constant 
value, ensuring that a steady state had been reached. Digital microscopic images were 
collected throughout the experiment. 
Two-dimensional displacement maps were generated by the DIC system’s software 
(Dantec Dynamics), from which regional strain averages were calculated. For analysis, we 
defined the peripapillary region as the scleral region within a 2 mm diameter circle centered 
at the optic nerve. Care was taken to avoid excess light exposure during inflation testing to 
reduce the possibility of post mortem photocrosslinking. Right and left eyes as well as 
control and experimental eyes were alternated in order of testing to reduce the possibility 
of systematic error due to testing order. 
3.3.8 Confocal Microscopy/Distribution Study 
Injection solutions were prepared using 3 mM MB diluted in HBSS. Rats were randomly 
selected for each experiment and assigned to a diffusion time group (30, 20, or 10 min from 
injection to death). To begin the procedure, rats were anesthetized using isoflurane gas. 
Topical tropicamide (0.5%) followed by topical tetracaine (0.5%) were applied bilaterally. 
Topical administration was used to match the experimental procedure used for 
photocrosslinking (though in this study, light was not applied). A retrobulbar injection of 
50 μl of methylene blue solution was performed using a 3 mL insulin syringe in the OD 
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eye. Immediately after, a retrobulbar injection of 50 μl of HBSS was administered in the 
contralateral OS eye.   
Five minutes prior to the total diffusion time assigned to each rat (10, 20, or 30 min), rats 
were exposed to CO2 for euthanasia. This was done to ensure an accurate diffusion time 
since prior studies have shown that time from first breath of CO2 to cessation of pulsatile 
blood flow (with the endpoint being death) is 5 min[167,168]. Following euthanasia, the 
OD (experimental) eye was immediately enucleated and fat and excess tissue from the 
posterior eye were removed. The eye was then flash frozen in optimal cutting temperature 
compound using liquid nitrogen for sectioning and imaging. While the OD eye was 
freezing, the same enucleation, cleaning, and freezing procedure was started for the OS 
eye. The time from death to complete freeze for both eyes was typically no more than 5 
min. Once frozen, eyes were cryosectioned within 20 min and immediately imaged by 
confocal microscopy, with each OD eye being sectioned and imaged before each OS eye. 
Multiple sagittal sections were taken for each eye, and sections were then evaluated by two 
different researchers to ensure that the section chosen to be imaged was in the center of the 
eye in the sagittal plane. Care was taken to ensure the post-death diffusion time for each 
eye (death to imaging) was less than 30 min. The same pre-determined set of optimal 
settings for MB fluorescence was used to image each eye. All images were taken on a Zeiss 
LSM 780 Confocal microscope (Oberkochen, Germany) using optimal settings for MB 
fluorescence.  
 Data acquisition was performed using the “Profile” tool in the Zeiss imaging software. 
This tool allows distance and intensity data to be collected across a user-defined region 
drawn on the image. Data sampling was performed with average profiles defined across 
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the thickness of the sclera (normal to the scleral surface) at a number of measured distances 
from the optic nerve. Average fluorescence intensity at each point in the sclera was 
tabulated for each eye and values were normalized to the brightest intensity value within 
each respective eye. The normalized intensities were then averaged across rats with similar 
treatment to mitigate the effects of variability caused by injection technique. 
3.3.9 DIC Data Analysis 
Raw displacement values were converted to strain values using a custom script coded in 
MATLAB Software (MathWorks, Natick, Massachusetts). Strain values for the 
peripapillary region and peripheral region were averaged separately and recorded for each 
pressure step. A pressure-strain relationship was established by fitting the measured strain 
average at each inflation pressure step to a Fung-type model, from which strain at any 





 (𝑒𝐵𝜀 − 1) 
 
(5) 
where ε is the calculated strain, and A and B are parameters fitted with MATLAB’s least 
squares non-linear regression function[169]. The non-linear regression was calculated with 
pressure as the independent variable and strain as the dependent variable. As done 
previously, percent strain reduction was calculated using means of the strain in two 
compared regions according to: 
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 % 𝑆𝑡𝑟𝑎𝑖𝑛 𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
𝜀𝑒𝑥𝑝 − 𝜀𝑐𝑡𝑟𝑙
𝜀𝑐𝑡𝑟𝑙
× 100% (6) 
where εexp and εctrl are the strain values of the experimental and control regions of the eye 
being compared, respectively[52].  
3.3.10 Six-Week Crosslinking Study 
To test the safety and duration of photocrosslinking, rats (n=8) were treated unilaterally 
with MB photocrosslinking and monitored for 6 weeks. Electroretinograms were 
conducted prior to euthanizing the rats to assess safety. Digital image correlation was 
performed on the eyes after euthanasia to investigate scleral stiffness. Optic nerves were 
collected immediately after euthanasia, fixed, and sectioned for axon counting. 
3.3.11 Electroretinograms 
Electroretinograms were measured using a full-field ERG in a Ganzfeld dome (UTAS Big 
Shot, LKC Technologies, Gaithersburg, MD). Rats were dark-adapted for 30 min prior to 
testing for measurement of scotopic photoreceptor response. After dark adaptation, rats 
were anesthetized with a subcutaneous injection of ketamine/xylazine. Tetracaine (1%) and 
tropicamide (1%) were applied topically to locally anesthetize and dilate the eyes, 
respectively. Electrodes were placed subcutaneously in the cheek (reference) and tail 
(ground), and a gold loop electrode was placed in contact with the cornea. Scotopic 
measurements were taken at -3.0 to 2.1 log cd s m-2 and photopic measurements were taken 
at 0.4 to 1.4 log cd s m-2. Representative voltage traces were reported for scotopic and 
photopic responses at the brightest flash intensities (2.1 and 1.4 log cd s m-2, respectively). 
 39 
3.3.12 Optic Nerve Axon Counts  
Axon counts were performed on the histological cross sections of optic nerves fixed in 
Sorensen’s buffer containing glutaraldehyde (2.5%) and PFA (2%, EMS, Hatfield, PA) 
after enucleation. The nerves were subsequently embedded in araldite-epon plastic 
(Araldite 502/Embed 812, EMS, Hatfield, PA). Cross sections (0.5 µm thickness) were 
stained with toluidine blue and imaged. Whole images of the optic nerve cross sections 
were then analyzed using a custom designed computer algorithm coded in AxoNet for 
automatic counting of axons deemed healthy using the code’s image recognition 
features[170].  
3.3.13 Retinal Histology 
Two groups of rats (n=3 each) were treated with either methylene blue and light or with 
light alone, allowed to recover, and euthanized 10 days later. Upon euthanasia, eyes were 
enucleated and placed in 2.5% glutaraldehyde solution for embedding, sectioning, and 
hematoxylin and eosin staining. Paraffin embedding was used for the group receiving 
methylene blue and light. Cryosectioning was used for the group receiving light only. 
3.3.14 Optical Coherence Tomography 
Optical coherence tomography images (Bioptigen 4300, Leica Microsystems, Buffalo 
Grove, IL) were taken at 10 days post-injection. Anaesthesia was administered using 
ketamine/xylazine, and topical tetracaine (1%) and tropicamide (1%) were applied for local 
anaesthesia and dilation, respectively. A 3 mm radial scan (1,000 A-scans per B-scan) was 
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collected for each eye centered at the optic nerve head. B-scans were assessed from the 
superior-inferior and nasal-temporal axes for evidence of treatment toxicity. 
3.3.15 Statistical Analysis 
Data are reported as mean ± standard deviation. Statistical analyses were performed using 
GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California). 
In cases where a t-test or ANOVA was used, the t-statistic and F-statistc are reported, 
respectively as well as degrees of freedom (df). For the study of whole globe scleral 
mechanical properties, strain values were compared using a two-way ANOVA (on the 
factors of experiment duration and scleral region) with matched pairs and adjusted for 
multiple comparisons using a Sidak correction. Axon counts were analyzed with a paired 
t-test. Electroretinograms were analyzed using a two-way ANOVA with Sidak correction. 
All data were considered statistically significant at p<0.05. For electroretinograms, where 
multiple flash intensities were employed, a two-way repeated measures ANOVA was used 
to compare effects across flash intensity and treatment and post hoc tests with Sidak 
correction were conducted where the effect of treatment was significant.  
3.4 Results 
3.4.1 In Vivo Targeted Peripapillary Scleral Stiffening 
We used a whole globe inflation test to determine tissue strain under a range of different 
applied stresses as a function of position on the posterior, external scleral surface (Figure 
4). This approach enabled us to measure local strain values across the ocular surface, and 
thereby determine average strain in the peripapillary and non-papillary regions of eyes that 
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were either exposed to the selective photocrosslinking procedure or naïve to treatment. 
This was accomplished by distributing graphite microparticles across the external ocular 
surface (Figure 4A) and imaging to measure the movement of theses particle as a function 
of whole globe inflation pressure. Digital image correlation analysis of these data produced 




Figure 4: Whole globe inflation testing to determine the spatial distribution of strain 
values on the posterior, external scleral surface. (A) The position of graphite 
microparticles was tracked on the scleral surface as a function of applied intraocular 
pressure. (B) Digital image correlation analysis generated spatial strain maps, from which 
average strain was calculated. Strain values were determined across the peripapillary 
scleral region and the peripheral scleral region (labeled in A) separately and reported for 





3.4.2 Scleral Stiffening at Day 0 
Immediately after selective photocrosslinking, there was a statistically significant decrease 
in strain (i.e., indicating an increase in stiffening) in the peripapillary region compared to 
the peripheral region (12.0 ± 4.7 mStrain vs 22.2 ± 7.3 mStrain, p<0.05, respectively), 
corresponding to a 46% strain reduction (Figure 5). Strain in the peripapillary sclera in the 
photocrosslinked eye also decreased compared to the peripapillary region of the untreated 
eye (12.0 ± 4.7 mStrain vs 33.6 ± 8.9 mStrain, p<0.0001), corresponding to a 64% strain 
reduction. Together, these findings show that selective photocrosslinking significantly 
stiffened the peripapillary sclera compared to both the peripheral region of the same eye 
and the peripapillary region of the untreated contralateral eye.  
Additional analysis showed that there was a statistically significant decrease in the 
peripheral region of the treated eye compared to that of the control eye (26.7 ± 7.1 mStrain 
vs 33.2 ± 13.2 mStrain, p<0.05, respectively, Figure 5). This may be due to off-target 
stiffening resulting from methylene blue diffusion beyond the peripapillary region and non-
zero light illumination in the peripheral region due to light scattering along the light beam 
path. 
3.4.3 Scleral Stiffening at 6 Weeks 
To determine if the scleral stiffening observed immediately after photocrosslinking 
persisted, we euthanized and enucleated eyes from rats 6 weeks after treatment. This 
analysis showed that there was again a statistically significant decrease in strain in the 
peripapillary region compared to the peripheral region of photocrosslinked eyes (14.2 ± 
2.9 mStrain vs 26.7 ± 7.1 mStrain, p<0.05, respectively), corresponding to a 47% strain 
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reduction (Figure 5). Peripapillary sclera strain in treated eyes were also still reduced 
compared to the peripapillary region of the untreated contralateral eye (14.2 ± 2.9 mStrain 
vs 32.0 ± 9.5 mStrain, p<0.0001, respectively), corresponding to a 56% strain reduction. 
Moreover, comparison of strain in the peripapillary region of treated eyes at Day 0 and 
Week 6 revealed no significant difference (12.0 ± 4.7 mStrain vs 14.2 ± 2.9 mStrain, 
p>0.05). These data show that selective stiffening of the peripapillary sclera persisted for 
at least 6 weeks after treatment. 
 
 
Figure 5: Effect of selective photocrosslinking treatment and time on scleral strain. 
Whole globe inflation testing at 22 mmHg with digital image correlation analysis 
compared strain in peripapillary regions (PP) to non-peripapillary (i.e., peripheral) 
regions of the sclera in the posterior rat eye. Experimental eyes received selective 
photocrosslinking of the peripapillary region, whereas control eyes were HBSS-injected 
contralateral eyes. Eyes were enucleated from rats either immediately (Day 0) or six 
weeks after (Week 6) photocrosslinking treatment. Data points show mean + standard 
deviation from n = 7 replicates per data point. * p<0.05. **** p<0.0001.   
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3.4.4 Changes in Strain Ratios 
To better understand the comparative changes in strain by region and thereby assess extent 
and selectivity of scleral stiffening, strain data were analyzed as ratios of the crosslinked 
region strain divided by the strain in the non-crosslinked region strain of interest (Figure 
6). These were subsequently compared with the corresponding ratio for the control region 
or eye using two-way ANOVAs followed by post hoc comparisons with Sidak correction 
(Figure 6). Strain ratio between identical regions of different eyes differed significantly on 
the main effects of regions compared (F1,12 = 30.81, p = 0.0010) and by study duration 
(F1,12 = 9.832, p = 0.0086), though there was not a significant interaction (F1,12 = 3.808, p 
= 0.0747). Post hoc analysis showed a significant difference between the peripapillary 
(0.48 +/- 0.20 mStrain) and peripheral (1.18 +/- 0.37 mStrain) regional strain ratios across 
eyes at week 6 (p = 0.0004). Strain ratio between different regions within the same eye 
differed significantly by contralateral regions compared (F1,12 = 30.81, p = 0.0010) and 
study duration (F1,12 = 9.832, p = 0.0086), though there was not a significant interaction 
(F1,12 = 0.9878, p = 0.3399). Post hoc analysis showed a significant difference between the 
strain ratios of the peripapillary to peripheral region in the experimental (0.57 +/- 0.22 
mStrain) and control (1.10 +/- 0.37 mStrain) eyes at day 0 (p = 0.0180). A significant 
difference existed as well at week 6 between the peripapillary to peripheral region strain 




Figure 6:Strain values expressed as ratios between scleral regions on Day 0 and Week 6. 
A) Ratio of strain in experimental eye to control eye, and B) ratio of strain in 
peripapillary region to peripheral region. Ratios were determined from data in Figure 4. 
Data points show mean + standard deviation from n = 7 replicates per data point. * 
p<0.05. ** p<0.01. *** p<0.001. 
 
3.4.5 Confocal Imaging Study 
Photocrosslinking of the peripapillary region requires that methylene blue photosensitizer 
injected into the retrobulbar space reaches that region on the time scale of laser illumination 
(i.e., 30 min). Moreover, localization of the methylene blue just to the peripapillary space 
can facilitate targeted crosslinking, in addition to the targeting enabled by controlling the 
shape and location of the annular light beam.  
Methylene blue fluorescence was observed in the scleras of rats sacrificed at 10, 20, and 
30 minutes after retrobulbar injection. Mean normalized fluorescent intensity shows a 
qualitative trend in MB localization near the optic nerve head (Figure 7). The average 
normalized intensity was greatest at 1-2 mm from the optic nerve head and relatively 
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decreased in the +/- 0.5 mm distance region. Furthermore, the intensity gradually decreased 
at a distance greater than 2 mm distance from the optic nerve head. Little difference was 
seen between 10, 20, and 30 min diffusion times.  
 
Figure 7: Fluorescence intensity of methylene blue in sclera of rats. A) Representative red 
fluorescence distribution of methylene blue can be seen at the posterior globe near the 
optic nerve head (ONH). B) Relative fluorescence intensity of methylene blue in rats 
euthanized 10 (n=5), 20 (n=3), or 30 (n=5) min after injection. Experimental (Exp) 
animals received methylene blue injection. Control (Ctrl) animals receives sham injection 
of HBSS. Average intensity was first calculated at each distance from the optic nerve. 
The average intensity at each distance was then normalized to the greatest average 
intensity value in each animal. Negative and positive values indicate distance in the 
inferior and superior direction from the ONH, respectively. Data points show mean + 
standard deviation.  
 
Toxicity of Scleral PhotocrosslinkingGiven the known toxicity of other sensitizers, we 
sought to characterize the possible toxicity of methylene blue photocrosslinking in the 
peripapillary sclera using optic nerve axon counts, electroretinograms, histology and OCT 
imaging. Retinal OCT imaging of rats treated with light only showed no evidence of retinal 
toxicity (Appendix A, Figure 36). Optic nerves collected from rats 6 weeks post-treatment 
indicated a deficit in retinal ganglion cell count in photocrosslinked rats compared to the 
HBSS injected contralateral control eyes (Figure 8). Control optic nerves had an average 
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axon count of 74,500 ± 6,600 axons while nerves of the crosslinked eyes had an average 
of 56,300 ± 15,200 axons (p = 0.0205, paired t-test). 
 
Figure 8: Axon counts obtained from the optic nerve of rats 6 weeks after treatment with 
MB photocrosslinking (MB+Light). Control eyes were injected with HBSS and did not 
receive MB or light. Data points show mean + standard deviation from n = 6 replicates 
for HBSS Control and n= 7 replicates for MB + Light. * p<0.05. 
 
3.4.6 Electroretinograms  
Full flash electroretinograms provide a measure of retinal function, and identified a 
moderate deficit across various cell types when assessed 6 weeks after the 
photocrosslinking procedure (Figure 9).  
Positive scotopic threshold response (pSTR) amplitude, which is a measure of dark-
adapted retinal ganglion cell function, was significantly decreased in photocrosslinked eyes 
compared to the HBSS contralateral eyes (paired t-test, t = 2.728, df = 7, p = 0.0294).  
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Scotopic A-wave amplitude, which is a measure of dark-adapted photoreceptor function, 
was found to have a significant interaction between flash intensity and treatment (F3,21 = 
7.787, p = 0.0011). A-wave amplitudes were significantly decreased in photocrosslinked 
eyes compared to HBSS contralateral eyes at the 0.7 and 2.1 log(cd s/m2) intensities (p = 
0.0003, p < 0.0001, respectively).  
Scotopic b-wave amplitude, which is a measure of dark-adapted amacrine cell function, 
increased was found to have a significant interaction between flash intensity and treatment  
(F1.353,9.469 = 7.311, p = 0.0177). However, no significant differences were found between 
the photocrosslinked and HBSS groups in post hoc tests (p = 0.2108, p = 0.1314, p = 
0.1434, p = 0.1049, p = 0.0972 at -3.0, -1.9, -0.6, 0.7, and 2.1 log cd s m-2, respectively).  
Photopic b-wave amplitude, which is a measure of light-adapted amacrine cell function, 
was found to have a significant interaction between flash intensity and treatment (F1.166,8.161 
= 5.154, p = 0.0239). Photocrosslinked eyes had significantly lower photopic b-wave 
amplitudes in post hoc tests at all three flash intensities (p = 0.0161, p = 0.0153, p = 0.0139 
at 0.4, 1.0, and 1.4 log cd s m-2, respectively). 
Finally, photopic negative response (PhNR) amplitude, which is a measure of light-adapted 
inner retinal activity, was found to have a significant interaction between flash intensity 
and treatment (F1.291,9.038 = 18.05, p = 0.0025). Photocrosslinked eyes had significantly 
decreased PhNR amplitudes in post hoc testing at the 1.0 and 1.4 log(cd s/m2) intensity 
levels (p = 0.0540, p = 0.0012, p = 0.0011 at 0.4, 1.0, and 1.4 log cd s m-2, respectively). 
Overall, we conclude that the photocrosslinking procedure used here caused moderate 
deficits in retinal function in the treated rats.   
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Figure 9: Electroretinogram (ERG) measurements in rats 6 weeks after 
photocrosslinking.  In all animals, one eye received methylene blue injection followed by 
photocrosslinking, and the contralateral eye received HBSS injection. Retinal function 
was assessed in both eyes under scotopic (dark-adapted) conditions by measuring A) 
positive scotopic threshold response (pSTR) amplitude, B) scotopic A-wave amplitude 
and C) scotopic B-wave amplitude and under photopic (light-adapted) conditions by 
measuring F) flicker B-wave amplitude, G) photopic B-wave amplitude and H) photopic 
negative response (PhNR) amplitude. Representative ERG voltage traces showing A) 
scotopic (at 2.1 cd s m-2 flash intensity) and (E) photopic response (at 1.4 log cd s m-2 
intensity). Data points show mean ± standard deviation from n = 8 replicates per data 
point. * p<0.05. ** p<0.01. *** p<0.001 for comparisons between photocrosslinked and 
non-photocrosslinked eyes.  
 
3.4.7 Histology 
Safety of photocrosslinking was further assessed by examination of histological sections 
from rats euthanized 10 days after unilateral photocrosslinking treatment with methylene 
blue and light to identify possible optic nerve and retinal damage. Sections were imaged at 
the optic nerve head and peripheral retina (>2 mm from the optic nerve head) to assess 
localization of damage. The contralateral control eye was untreated. Among the three rats 
in this study, one did not have any obvious damage to the optic nerve or retina, one had 
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evidence of a foreign body reaction in the optic nerve sheath and retinal degradation 
adjacent to the optic nerve head (Figure 10), and the third rat appeared to have gliosis 
localized near the optic nerve head. Notably, all three rats had no damage in the peripheral 
retinas of the treated eyes, indicating focal damage likely caused by the presence of both 
methylene blue and light near the peripapillary sclera. 
 
Figure 10: Histological sections of optic nerve head and peripheral retina to assess safety 
after photocrosslinking. Paraffin embedded sections with hematoxylin and eosin staining 
of optic nerve head and peripheral retina (< 2 mm from optic nerve head) of rats 
euthanized 10 days after unilateral treatment with targeted methylene blue 
photocrosslinking. Scale bars = 100 𝜇m. Tissues are labeled including the optic nerve 
head (ONH), optic nerve (ON), vitreous (V), retina (R), choroid (C), sclera (S), and 
retrobulbar tissue (B). While local tissue responses varied in eyes after photocrosslinking, 
the most severe damage seen among the three rat eyes examined is exhibited. A) Control 
eye injected with HBSS showing healthy optic nerve and healthy retina both adjacent to 
the optic nerve head, and B)in the periphery. C) Immune foreign body response (lower 
arrow) and retinal damage (upper arrow) near the optic nerve. This damage was localized 
to the region adjacent to the optic nerve as D) retina in the periphery appeared normal. 
Data are representative of histological sections examined in 6 eyes from 3 rats. 
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To assess possible damage from light alone (without methylene blue), another cohort of 
rats was treated according to the photocrosslinking procedure previously described with 
light but HBSS was injected instead of methylene blue. Histological analysis did not reveal 
significant evidence of retinal damage in either the optic nerve region or the peripheral 
retina (Figure 11).  
We also assessed possible effects of light exposure without methylene blue by OCT (Figure 
36, Appendix A). There were no apparent morphological differences between eyes exposed 
to targeted illumination compared to contralateral eyes receiving no treatment, further 
supporting finding from retinal histology indicating that light alone does not damage the 
retina.  
The light intensity used in this study (i.e., 424 mW/cm2) exceeded the maximum 
permissible intensity for human eyes (211 mW/cm2, calculated using ANSI 2000) exposed 
to 660 nm light for the given exposure conditions (see Appendix A)[123]. Considering the 
intensity used in this study exceeded the calculated maximum permissible intensity, it was 
unexpected that treatment with light alone caused no apparent changes in retinal 
morphology. We conclude that damage seen near the optic nerve due to the 
photocrosslinking procedure was not due to light alone and was probably a result of 




Figure 11: Cryosections with hematoxylin and eosin staining of rat optic nerves/retinas 
treated unilaterally with targeted light exposure (no MB). Scale bar = 100 𝜇m. Tissues are 
labeled including the optic nerve head (ONH), optic nerve (ON), blood vessel (BV), 
vitreous (V), retina (R), choroid (C), sclera (S), and retrobulbar tissue (B). A) Control eye 
injected with HBSS showing healthy tissue in both the optic nerve head region and B) 
peripheral retina. C) Treated eye showing healthy optic nerve region and D) healthy 
periphery. Note, the vacant circular region in the center left of the optic nerve head is 
likely a retinal blood vessel.  
 
3.5 Discussion 
We have shown for that selective peripapillary scleral crosslinking at the millimeter scale 
in vivo is possible and reported a new procedure for its implementation. Our approach used 
a photosensitizer, MB, administered by retrobulbar injection followed by transpupillary 
illumination of the peripapillary region with 660nm red light. Importantly, this 
demonstration shows that the drug and light delivery challenges presented by crosslinking 
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the posterior sclera may be overcome in vivo. This method is unique from existing 
photocrosslinking protocols in the eye for its spatially targeted nature at the peripapillary 
sclera. While it appears that laser light illumination itself did not harm the eye, the 
photocrosslinking resulting from light exposure in the presence of methylene blue had 
moderate adverse effects. This finding is consistent with the literature on other singlet-
oxygen generating photosensitizers are known to have toxic effects when irradiated in 
vivo[171–173]. Consistent with our targeted delivery approach, damage was isolated to the 
peripapillary region, as shown by histological analysis. Deficits seen in the 
electroretinography data may be related to damage in the retina and in the optic nerve, since 
unabsorbed light passing through the fundus may excite MB within the optic nerve/sheath. 
Likewise, axon loss may have been caused by damage directly to the optic nerve or 
indirectly by collateral damage to axons in the retina that extend into the optic nerve.  
Electroretinography revealed greater functional deficits at higher flash intensities than at 
lower flash intensities. This observation may indicate selective damage of cone 
photoreceptors compared to rod photoreceptors since cone function corresponds with 
brighter flash intensities[174]. A possible explanation for selective cone damage is 
presence of a cone subpopulation with preferential absorbance for red light (red cones) 
compared to rods which have preferential absorbance in the blue-green wavelength range. 
However, rats generally lack sensitivity in the red wavelengths[175].The damage to retinal 
function may also be non-specific photothermal damage in the in the strongly absorbing 
retinal pigment epithelium. 
Methylene blue alone may play a role in the damage observed to the retina and optic nerve, 
as shown in prior studies that reported retinal ganglion cell toxicity in rats injected 
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intravitreally with 2 𝜇L at 2% (6.25 mM) concentration[92]. Comparatively, our 100 𝜇L 
retrobulbar injection at 3 mM represents a significantly higher dose, but our injection is 
separated from the retina by the choroid which serves as a formidable clearance route and 
barrier to retinal entry, so local methylene blue concentrations in the retina were certainly 
lower. The proximity of the optic nerve to the retrobulbar injection may have caused the 
optic nerve to experience a high concentration of methylene blue.  
Observed off-target stiffening may be caused by light scattering within the posterior fundus 
tissues. Narrowing the beam size and reducing light intensity may help to further localize 
stiffening. For practical reasons in this study, we chose not to reduce the beam size since 
doing so would approach the lower bounds of spatial resolution on our globe inflation 
testing platform. Future studies may make use of atomic force microscopy to overcome 
this limitation. Additional ex vivo testing or tissue mechanics computational modeling is 
warranted to understand the lower limits of beam size which would result in sufficient 
stiffening. 
Toxicity of the photocrosslinking procedure could be reduced by lowering light intensity. 
While reducing light intensity may result in lower crosslink density, strain reductions in 
this study (54%, 64%) exceeded those reported by Coudrillier et al. (38%) to reduce strain 
on the lamina cribrosa. Therefore, it may be possible to reduce light intensity and still 
induce sufficient crosslinking, but at less toxic levels. It has been reported by Wernli et al. 
and that for identical fluences of UVA irradiation during riboflavin collagen crosslinking, 
higher light intensities result in less efficient crosslinking than lower light 
intensities[176,177]. The intensity of light reaching the sclera in our study would in fact be 
at the high end of the intensities used in the Wernli et al. study (~90mW/cm2), though direct 
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comparison is difficult considering the different diffusion direction, sensitizer molecule, 
and tissue studied. 
Slowing methylene blue diffusion to the optic nerve and retina could also reduce 
photocrosslinking toxicity. Formulation strategies may include methylene blue conjugation 
to macromolecules or encapsulation in liposomes/carriers. Diffusion across the Tenon 
capsule at the posterior scleral surface may present a challenge. Its epithelialized surface is 
likely similar to that of the optic nerve sheath, making it difficult to design a delivery 
formulation capable of discriminating between the two. Alternatively, methylene blue 
could be delivered by suprachoroidal injection placing it at the interface of the sclera and 
choroid. This approach is minimally invasive and overcomes any physical barriers to 
diffusion. However, only small volumes may be injected, and the choroid’s adjacency 
would lead to rapid clearance. 
A strategy to improve photocrosslinking efficiency may be to use an alternative sensitizer 
instead of methylene blue. Methylene blue was chosen for its known low dark toxicity in 
vivo, efficient triplet yield, absorbance of red light in the phototherapeutic window, and its 
low cost/high availability. However, there exist many other sensitizers which may 
overcome limitations in this study due to their mechanisms of action, wavelengths of 
absorbance, and transport properties[103,178]. 
Besides potential application as a future glaucoma treatment, another interesting 
application for our targeted crosslinking approach is for treatment of myopia. Recently, the 
possibility of preventing myopic progression through scleral stiffening has attracted 
interest[179,180]. Targeted stiffening may be especially useful for correction of refractive 
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error by differentially modulating scleral stiffness, resulting in controlled shaping of the 
eye. This technique would work similarly to the LASIK procedure or refractive keratotomy 
in the cornea by artificially producing regions of relative weakness in the sclera which 
mechanically deform to produce the desired eye shapes. 
3.6 Conclusion 
In conclusion, this study introduces a method for implementing regionally targeted scleral 
photocrosslinking in the posterior globe using a novel microscope apparatus. We have 
shown methylene blue and 660 nm red light to be efficacious at reducing scleral strain by 
as much as 64% compared to untreated contralateral eyes and peripheral sclera in the 
same eye. In its current form, this treatment generated moderate toxicity localized near 
the optic nerve head that affected retinal function; effects of visual acuity remain to be 
assessed. Future studies should further optimization the procedure to reduce these adverse 
effects. Importantly, this study provides the means for future work to assess the impact of 
targeted peripapillary stiffening on functional and morphological glaucoma disease 
outcomes in a glaucomatous animal model. Such a targeted approach to mechanical 
stabilization of the peripapillary region of the eye could provide a powerful new approach 
to glaucoma therapy that is mechanistically different from other approaches in use or 
under development today.    
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CHAPTER 4. EFFECTS OF SCLERAL PHOTOCROSSLINKING 
IN GLAUCOMATOUS RATS 
Note on Contribution: My colleague, Bailey Hannon, contributed significantly to the 
following chapter in execution of experiments, data analysis, and in its 
writing/composition. She induced ocular hypertension in glaucomatous rats and collected 
IOP, OMR, ERG, OCT, and axon count data. Dr. Thomas Read contributed axon sections 
for axon count data. Matthew Ritch contributed to axon counting software to produce axon 
count data. Elisa Schrader and Lauren Nichols contributed data analysis for DIC and other 
experimental studies. 
4.1 Introduction 
Glaucoma is the leading cause of irreversible blindness and affects an estimated 80 million 
people worldwide[1]. This optic neuropathy is characterized by the loss of retinal ganglion 
cell axons in the optic nerve head, which is the main and early site of damage in the 
disease[32]. Since a major risk factor for glaucoma is elevated intraocular pressure (IOP), 
current treatments aim to lower IOP by increasing aqueous outflow or by decreasing 
aqueous humor production [181,182]. Although these treatments can be successful in 
slowing or preventing progression of glaucomatous damage, they are not always effective; 
further, medication-based treatments have poor patient compliance [183,184]. Therefore, 
treatments that overcome the limitations of current therapies are desirable. 
It is known that elevated IOP leads to increased biomechanical strain in the ONH tissues 
which is thought to promote RGC loss in glaucoma, and thus a promising alternative 
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treatment approach for glaucomatous optic neuropathy is to protect against mechanical 
insult at the ONH due to ocular hypertension. Finite element modeling studies have 
analyzed the main factors that influence ONH mechanical insult, finding that scleral 
stiffness is the main such factor [45,46]. Experimentally, Coudrillier et al. found that 
localized stiffening of the peripapillary sclera reduced strain in the lamina cribrosa in ex 
vivo porcine eyes[4]. Therefore, it is hypothesized that scleral stiffening may confer 
protection against IOP-induced glaucomatous damage [185].  
A previous study (Kimball et al. 2014) assessed the effects of scleral stiffening on 
glaucomatous damage in mice[5]. Specifically, Kimball et al. induced scleral stiffening in 
ocular hypertensive mice using the collagen crosslinking agent glyceraldehyde. Contrary 
to the expected outcome, they found that scleral stiffening increased rather than decreased 
glaucomatous damage. There are several possible explanations for this observed outcome. 
For example, whole globe scleral stiffening is known to increase the magnitude of IOP 
fluctuations [156], which may in turn damage RGC axons [186]. Alternatively, 
glyceraldehyde toxicity may have outweighed the neuroprotection due to scleral stiffening.  
To further investigate the neuroprotective potential of scleral stiffening, we considered two 
different stiffening approaches (Table 13). In the first, we specifically stiffened only the 
peripapillary sclera, hypothesizing that such a localized stiffening would prevent 
glaucomatous damage by reducing ONH strain while maintaining the native compliance 
of the globe and thus minimizing IOP fluctuations. Our second approach was to stiffen the 
entire posterior sclera using a well-tolerated collagen crosslinking agent. For this purpose 
we used genipin, which has recently been shown to provide prolonged scleral stiffening at 
a much lower concentration than glyceraldehyde [52,166] and which has a promising safety 
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profile [187–190]. We here assess the protective effects of these two stiffening paradigms 
in a rodent model of ocular hypertension.  
4.2 Methods 
4.2.1 Rationale for Using the Rat Model of Glaucoma 
We chose to use the widely used rat model of glaucoma because of its many parallels to 
glaucoma in humans. Specifically, rat models of OHT demonstrate several of the clinical 
hallmarks of glaucoma, including: the ONH being a main and early site of damage, RGC 
apoptosis, remodeling of extracellular matrix components in the ONH, and ONH ‘cupping’ 
[191–193]. Rodents are also more cost-effective and ethically defensible than non-human 
primates. Considering only rodents, rat eyes are twice the size of mouse eyes and are 
therefore easier to work with than mice, e.g. for surgical techniques related to our targeted 
crosslinking procedure and for mechanical testing [194]. Additionally, IOP measurements 
in mice are typically performed under anesthesia, which has been shown to underestimate 
the IOP by as much as 50% in OHT mice[195]. Our chosen strain of rat, the Brown Norway 
rat, is notably more docile than other strains and therefore IOP can be measured without 
anesthesia. Further, we can confidently assess visual function in Brown Norway rats 
because they are a pigmented strain, and thus have a strong optomotor response (OMR), 
whereas albino rodents have little to no OMR [196]. Together, these reasons make the 




4.2.2 Decision to Implement an Unpaired Treatment Paradigm 
Our study design (Figure 12) was guided by the desire to prioritize statistical power for 
comparing axon counts between crosslinking treatment groups in microbead-treated eyes. 
In other words, we wished to minimize variance for axon counts in crosslinked microbead-
treated eyes. Thus, an unpaired experimental design (“Design A”) was used in this study 
in which, for each rat, one eye was received both a scleral stiffening treatment and 
microbeads to induce OHT (hypertensive experimental), while the contralateral eye was 
untreated (naïve normotensive control). In addition, three alternative study designs were 
considered (Table 2) involving the hypertensive experimental eye treatment above but with 
different normotensive control eye treatments, including: (1) a paired design in which the 
control eye received a crosslinking treatment only (“Design B”), (2) a paired design in 
which the control eye received an HBSS (vehicle) injection only (“Design C”), and (3) a 
paired design in which the contralateral eye received a microbead injection only (“Design 
D”). Design C was eliminated because preliminary data suggested that HBSS injections do 
not cause significant axon loss and would only risk adding potential damage due to bilateral 






Table 2: Experimental designs considered in this study. Ultimately, an unpaired design 
was chosen with rats receiving a unilateral crosslinking and microbead treatment to 




In addition to the two remaining options (Designs A and B) for control eye conditions 
discussed above, we considered two ways to assess RGC axon count differences between 
crosslinking treatment groups, including: (1) using raw values of axon counts in 
crosslinked hypertensive eyes (“Comparison I”), or (2) computing the difference in axon 
counts between the crosslinked hypertensive eye and control eye for each rat (“Comparison 
II”). The four possible combinations of two study designs and two comparisons are listed 
in Table 2 with our assessment of advantages and disadvantages of each. 
The key advantage of a paired design is the ability to account for (or explain) animal-
specific variance in axon count comparisons between crosslinking groups. However, a 
paired design only increases statistical power if the required control eye treatment does not 
introduce greater variability. Therefore, merits of various design and comparison 
combinations rely on (1) the expected degree of parity between eyes of the same rat and 





A (Unpaired) I (Unpaired) Lowest variance 
Does not account for parity between 
eyes or for treatment toxicity in 
individual rats 
A (Unpaired) II (Paired) 
Moderate variance due to 
computed difference 
Accounts for parity between eyes of 
individual rats 
B (Paired) I (Unpaired) 
Moderate variance due to 
injection variability 
Accounts for treatment toxicity in 
individual rats 
B (Paired) II (Paired) 
High variance due to both 
computed difference and 
injection variability 
Accounts for both parity between eyes 
and for treatment toxicity in individual 
rats 
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to the control eye treatments. While axon count parity between eyes of healthy rats has 
been demonstrated previously, we believe that injection variability and measurement 
variability offset the potential statistical advantage gained by using a paired design[197].    
In further support of an unpaired design, we have previously observed that crosslinking 
treatments increase variance in axon counts. Additionally, preliminary data in our lab 
suggested that bilateral crosslinking treatment leads to greater axon loss than a unilateral 
treatment, possibly due to increased systemic inflammation from two injections instead of 
one. In conclusion, we considered consequences of control eye injections and statistical 
comparisons involving parity between eyes. We concluded an unpaired design would 
maximize statistical power while sacrificing the ability to account for within-rat toxicity 
effects of each treatment.  
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Figure 12: A) Scleral crosslinked eyes received one of three treatments by retrobulbar 
injection: HBSS (vehicle), Genipin (GP), or Methylene blue (MB). Those in the MB 
group also received 30 minutes of localized red light (660nm) to selectively stiffen the 
peripapillary (but not peripheral) sclera. B) Timeline of experiments. Seven days after 
scleral stiffening treatment. the treated (“experimental”) eye received a microbead 
injection to induce ocular hypertension. Ocular hypertension was induced at Day 0. Rats 
were sacrificed at Day 14. C) Timing of experiments. IOP measurements were taken at 
Days -7, 0, 1, 3, 4, 7, 10 , and 14. OMR measurements were taken at Days 0, 7, and 14. 
ERG measurements were taken at Days -7, 7, and 14, and OCT measurements were taken 
at Days -7 and 14. DIC and axon count measurements were necessarily taken post 
mortem after collecting the sclerae and optic nerves on Day 14 immediately after 
euthanasia. 
 
4.2.3 Animals and Study Design 
86 male, retired breeder Brown Norway rats (8 - 10 months old) were purchased from 
Charles River Laboratories (Wilmington, MA). All procedures involving animals were 
approved by the Georgia Institute of Technology Institutional Animal Care and Use 
Committee and the Atlanta VA Medical Center Institutional Animal Care and Use 
Committee (IACUC). All procedures complied with the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research.   
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Our study design followed a “crosslink then OHT” approach. In other words, animals 
received a scleral stiffening treatment (or sham) unilaterally, were allowed to recover for 
one week, and then received a treatment to induce ocular hypertension in the same 
crosslinked eye. We chose to stiffen the sclera prior to inducing OHT to facilitate 
comparison of our results with those of Kimball et al.[5]. We used the well-established 
magnetic microbead model to induce OHT, which was applied to all eyes that received 
scleral crosslinking treatment (or sham). As noted above, all contralateral eyes were naïve, 
i.e. received no scleral crosslinking treatments (or sham) and no microbead injections. 
Animals were followed for 2 weeks after induction of OHT and then sacrificed.  
In more detail, rats were randomly divided into three “treatment groups” (Figure 12A and 
Figure). Hanks balanced salt solution (HBSS) was used as the vehicle for treatments and 
as the sham injectate. One group (HBSS rats, n = 32) received this sham injection. The 
second group (GP Rats, n = 27) received genipin chemical crosslinking. The third group 
(MB Rats, n = 27) received methylene blue photocrosslinking. Treatments were applied 
unilaterally seven days prior to microbead injections using retrobulbar injections for the 
HBSS Rats (“HBSS hypertensive experimental” eyes), GP Rats (“GP hypertensive 
experimental” eyes), and MB Rats (“MB hypertensive experimental” eyes). Contralateral 
eyes received no injections and therefore served as normotensive controls for each animal 
(“HBSS normotensive control” eyes, “GP normotensive control” eyes, and “MB 
normotensive control” eyes). Within each animal, the eye (left (OS) or right (OD)) 
receiving treatment was randomly assigned.  
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4.2.4 Intraocular Pressure Measurements 
IOP measurements for each rat were taken between 7:00am and 10:00am using a Tonolab 
rebound tonometer (Icare Finland Oy, Vantaa, Finland) at baseline and at Day 0, 1, 3, 5, 7, 
10, and 14 after microbead injection. Awake rats were gently restrained by hand while 
eight tonometer readings were acquired from each eye. The lowest and highest IOP values 
were excluded from each set of daily measurements and the remaining six IOP values were 
averaged to obtain a representative IOP measurement. Prior to this study, the rebound 
tonometer was calibrated using a cannulated intact rat eye in which IOP was externally 
imposed using a hydrostatic pressure reservoir set to heights ranging from 5 to 50 mmHg 
(data not shown). Calibration results showed good agreement between set IOP values and 
measured IOP values, and thus no IOP correction was necessary. We then calculated the 
IOP burden, also referred to as cumulative IOP difference, IOP exposure, or positive 
integral IOP, which provides an estimate of the total IOP “insult” to the hypertensive 
eye[198–200]. We defined IOP burden as the area between the OHT and normotensive 
eyes on the IOP versus time plot.  If the measured IOP in the OHT eye was transiently 
lower than IOP in the contralateral (normotensive) eye, the IOP difference was set to zero 
at that time point, i.e. we did not allow negative contributions to the IOP burden. 
4.2.5 Crosslinking Injection Preparation 
Genipin and methylene blue solutions were both freshly prepared the morning of the 
retrobulbar injection. Genipin (Wako Pure Chemical Industries, Ltd., Richmond, VA) and 
methylene blue of USP grade (Apollo Scientific, Stockport, UK) were obtained in powder 
form and dissolved in Hank’s balanced salt solution (HBSS). Genipin was solubilized at a 
 66 
concentration of 15 mM by vortexing the solution for 15 minutes. Methylene blue was 
solubilized at a concentration of 3 mM by vortexing the solution in a microcentrifuge tube 
and heating to a temperature not greater than 100 degrees Celsius for 5 minutes. Care was 
taken to minimize light exposure of the methylene blue solution to prevent possible 
photodegradation.  
4.2.6 HBSS and Genipin Crosslinking Injection Procedures 
For HBSS and genipin retrobulbar injections, rats were anesthetized with a ketamine (60 
mg/kg) and xylazine (7.5 mg/kg) cocktail. Once anesthetized, rats were placed on a heating 
pad and received a drop of topical tetracaine (0.5 %, Tetracaine Steri-Units, Alcon, Geneva, 
Switzerland) as a local anesthetic. Retrobulbar injections were performed on the eye 
designated as hypertensive experimental by gently proptosing the eye with curved forceps 
and inserting a disposable insulin syringe with a 31 G needle (BD 300 µl Insulin Syringe 
Ultra-Fine™ needle, Becton, Dickinson and Company, Franklin Lakes, New Jersey) into 
the muscle cone through the inferior quadrant of the conjunctiva. 150µl of either HBSS or 
genipin (15 mM) was then injected into the muscle cone. After injections, rats were given 
topical antibiotic (Vetropolycin, Dechra Pharmaceuticals, Northwich, United Kingdom) to 
prevent infection and antisedan (1 mg/kg) to reverse anesthesia [201].  
4.2.7 Methylene Blue Photocrosslinking Procedure 
Rats were anesthetized with isoflurane/oxygen (5%/700 mL/min) and placed in a 
stereotaxic head mount (Kopf Instruments, Tujunga, CA) equipped with tooth bar over a 
heating pad, allowing facile manipulation of head position. 0.5% tetracaine (Tetracaine 
Hydrochloride Ophthalmic Solution, Amici Pharmaceuticals, Melville, New York) was 
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applied topically as a local anesthetic to the eye designated as MB hypertensive 
experimental, followed by topical application of a 1% tropicamide eye drop (Tropicamide 
Ophthalmic Solution, Henry Schein, Melville, New York). An additional eye drop of 1% 
tropicamide was applied after 5 minutes and allowed to take effect for another 10 minutes 
to ensure maximal dilation of the iris. A hydrating eye lubricant (Puralube Vet Ointment, 
Dechra Pharmaceuticals, Northwich, United Kingdom) was applied to the contralateral eye 
designated as normotensive control, to prevent dehydration during the procedure. After 
dilation of the eye designated as MB hypertensive experimental, a 100 µL retrobulbar 
injection of 3 mM methylene blue was administered using a sterile 31 G insulin needle and 
syringe.   
Immediately after injection, a contact lens was placed on the corneal surface to eliminate 
refraction from the cornea/lens, allowing for visualization of the fundus (Figure 38). The 
rat’s head was positioned with the eye designated as hypertensive experimental aligned on 
the optical axis of a custom-designed microscope capable of simultaneously imaging the 
fundus and projecting an annular beam of light tuned to excite methylene blue at 660 nm 
wavelength. Upon alignment of a low intensity guide beam (<0.1 mW) with the optic nerve, 
the light intensity was increased to a dose of 10mW for 30 minutes to facilitate scleral 
crosslinking. During this time, beam position relative to the optic nerve head was 
monitored with the microscope and adjusted if necessary, using micropositioners to move 
the microscope position relative to the eye. At the conclusion of the 30-minute illumination 
period, the light source was turned off, the contact lens was removed, and once ambulatory 
on the heating pad, the rat was returned to its cage.  
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4.2.8 Microbead Injection Preparation and Procedure 
The magnetic microbead model of glaucoma was used to induce unilateral ocular 
hypertension in the eyes designated as hypertensive experimental. All microbead injections 
occurred at Day 0, which was seven days after crosslinking procedures.  A mixture (1:1) 
of 2 µm and 6 µm magnetic polystyrene microbeads (micromer®-M, Micromod, Rostock, 
Germany) with PEG-COOH surface chemistry (to promote biocompatibility) was used for 
microbead injections. Beads were autoclaved according to manufacturer’s specifications 
(20 minutes at 121 °C and 3500 mbar pressure) and then rinsed five times with sterile 
HBSS using cell culture sterility practices. Rats were anesthetized with a single dose of 
ketamine (60mg/kg) mixed with xylazine (7.5 mg/kg) and placed on a heating pad. 
Tetracaine (0.5%, Tetracaine Steri-Units, Alcon, Geneva, Switzerland) was then applied to 
the eye. The bead suspension was vortexed for 15 seconds to suspend the beads, and a 
volume of 25µl was pipetted onto a sheet of wax parafilm. Deposited solutions were then 
drawn into sterile, disposable syringes with 31 G needles.   
The eye designated as hypertensive experimental was proptosed with a small section of a 
latex glove so that an annular magnet could be placed within the same plane as the 
iridocorneal angle. A neodymium, grade N40, nickel plated annular magnet (H125D, 
Amazing Magnets, Anaheim, CA) with dimensions of 7.14 mm inner dimeter, 12.70 mm 
outer diameter, and thickness of 3.18 mm was placed around the limbus after proptosing, 
and the eye received a intracameral injection of magnetic microbeads (2.25 x 106 to 4.5 x 
106 beads total per 25 µl injection) into the anterior chamber. The needle was held in the 
anterior chamber for 60 seconds following injection and then slowly removed to minimize 
fluid reflux. After injection, the section of latex glove was removed, and the magnet was 
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placed back on the eye for 10 minutes to ensure that beads had settled into the iridocorneal 
angle. Both eyes (hypertensive experimental and normotensive control) of each rat 
received topical antibiotic (Vetropolycin, Dechra Pharmaceuticals, Northwich, United 
Kingdom) to prevent infection and hydrate the eye. Rats were placed on heating pads until 
ambulatory.   
IOP was measured 1, 3, 5, and 7 days following induction of ocular hypertension via 
microbead injection. If the experimental (injected) eye did not demonstrate at least one day 
of OHT, defined as an IOP elevation of  >5 mmHg compared to contralateral control eye 
within 7 days of injection, the eye was considered to be a non-responder and was then 
reinjected with 15 µl of microbead solution on Day 7 (n = 12 of 74 total rats). Rats for 
which IOP elevation failed 7 days after reinjection were removed from the study (n = 3) 
and therefore no rat was reinjected with microbeads more than once. Additionally, 7 rats 
were removed from the study upon reaching IACUC endpoint criteria for health/safety and 
2 rats died during anesthesia recovery, leaving a total of 74 rats analyzed in the study.   
4.2.9 Assessment of Retinal Function: Electroretinography 
Dark-adapted electroretinograms (ERGs) were used to assess inner and outer retinal 
neuronal function. ERG measurements were taken at baseline, before both the crosslinking 
procedure and microbead injection, and at 7 and 14 days after microbead injection. At each 
timepoint, rats were dark-adapted for 30 minutes under dim red light and anesthetized using 
a cocktail of ketamine (60 mg/kg) and xylazine (7.5 mg/kg). Once asleep, both eyes 
received drops of tetracaine (0.5%) and tropicamide (1%) topically to anesthetize corneas 
and dilate pupils, respectively. A ground electrode was inserted into the tail of the rat and 
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reference needle electrodes were inserted subcutaneously into the cheek by each eye. 
Custom gold-loop electrodes were placed on the cornea of each eye and a layer of 
carboxymethylcellulose (Celluvisc, Allergan, Dublin, Ireland) was applied over the corneal 
electrode to ensure electrical conductivity and prevent drying. Under dark-adapted 
conditions, a 6-step series of increasing flash intensities (-6.0 to 2.1 log cd s/m2) was used. 
Electrical responses to various full-field flash stimuli in a Ganzfeld dome were recorded 
using a signal-averaging ERG system (UTAS BigShot; LKC Technologies, Gaithersburg, 
MD). Oscillatory potentials (OPs) were filtered with a 65-275 Hz bandpass fifth order 
Butterworth filter. Amplitudes and implicit times were measured in the following way: 
baseline to peak (positive scotopic threshold (pSTR)), baseline to trough (negative scotopic 
threshold (nSTR) and a-wave), trough to peak (b-waves and OPs). We elected to analyze 
ERG amplitudes of the positive scotopic threshold (pSTR) and negative scotopic threshold 
(nSTR) at -6.0 log cd s/m2, the b-wave at -3.0 log cd s/m2 (b-wave), and the third OP 
(OP3) at 2.1 log cd s/m2 because these amplitudes have been shown to be associated with 
retinal ganglion cell damage in rodent models of glaucoma [202–205]. 
4.2.10 Ischemic Damage Exclusion Criteria  
Rats with likely ischemic damage to the retina were excluded from analysis. Exclusion was 
based on the b-wave amplitude from the brightest flash (2.1 log cd s/m2) at Day 14, since 
bipolar cell function (which drives b-wave amplitude) is known to be sensitive to ischemic 
damage at bright scotopic flashes [206,207]. The 99.5% confidence interval of the b-wave 
amplitude was computed for all normotensive control eyes (n = 74). If the b-wave 
amplitude of the hypertensive experimental eye lay below this 99.5% confidence interval, 
that rat was excluded from analysis. Of the 74 rats analyzed, 14 rats were excluded by this 
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criterion. The final total number of animals was thus 60, divided into HBSS rats (n = 21), 
GP rats (n = 20), and MB rats (n = 19). 
4.2.11 Assessment of Visual Function: Optomotor Response 
Visual function was assessed via quantitative analysis of optomotor response (OMR) 
thresholds of spatial frequency and contrast sensitivity (OptoMotry®; Cerebral-Mechanics, 
Lethbridge, AB, Canada). OMR was measured at baseline (prior to crosslinking treatment), 
Day 0 (7 days after crosslinking procedure, but prior to microbead injection that day), Day 
7, and Day 14, following a protocol similar to that of Prusky and Douglas [196,208]. In 
brief, rats were placed on a raised platform in the middle of a box consisting of four flat 
screen monitors which displayed black and white vertical gratings that rotated at a speed 
of 12 degrees/second (d/s) to create a virtual drum. A trained observer then monitored the 
rat for a positive or negative reflexive head movement in response to the rotating gratings 
moving in a clockwise or counterclockwise direction, assessing the responses of the OS 
and OD eyes, respectively [196]. To determine an animal’s spatial frequency threshold, the 
vertical bands were held at 100% contrast and spatial frequency was adjusted in a staircase 
paradigm starting at 0.042 cycles/degree (c/d) until the threshold where the rat could no 
longer see the gratings was established. Contrast sensitivity threshold was determined 
using a similar staircase paradigm, but the spatial frequency was held at 0.064 (c/d) while 
the contrast was decreased from 100% until the threshold was determined. Contrast 
sensitivity is reported as the reciprocal of the Michelson contrast from the screen’s 
luminance, as previously described [208]. Prior to OMR measurements, each rat eye was 
carefully inspected for any opacity or speckling of microbeads in the anterior chamber that 
might occlude the rat’s visual axis. If this was the case, that eye’s OMR was not recorded, 
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making the final number of data used in OMR analysis 48, with 16 rats in each treatment 
group.  
4.2.12 Assessment of Retinal Morphology: Optical Coherence Tomography 
A Spectral-Domain Optical coherence tomography (SD-OCT) system (Bioptigen 4300, 
Leica Microsystems, Buffalo Grove, IL) was used to measure total retinal thickness and 
qualitative retinal morphology in the posterior eye at baseline and Day 14. Total retinal 
thickness was measured at locations 0.5 mm and 1.2 mm from the center of the ONH. Rats 
were anesthetized using ketamine/xylazine, and eyes received drops of tetracaine and 
tropicamide as described above. A 3-mm radial scan (1,000 A-scans per B-scan) centered 
at the optic nerve head was acquired in both normotensive control and hypertensive 
experimental eyes. B-scans from the superior-inferior and nasal-temporal axes of all eyes 
were assessed manually by a trained technician blinded to treatment group using a 
customized MATLAB program (MATLAB R2019a, Mathworks, Natick, MA). If fewer 
than two scans were of sufficient quality to measure retinal thickness accurately, the rat 
was eliminated from the OCT retinal thickness dataset. Measurements were taken at 
locations avoiding local vasculature, and these individual values from each quadrant were 
averaged together.  
4.2.13 Optic Nerve Sectioning and Imaging 
 Immediately after euthanasia via CO2 overdose, rat optic nerves were dissected from 
enucleated eyes and fixed in isotonic Sorensen’s buffer containing glutaraldehyde (2.5%) 
and PFA (2%, EMS, Hatfield, PA). Tissue was post-fixed in osmium tetroxide, dehydrated 
in an ethanol series, infiltrated and embedded in araldite-epon plastic (Araldite 502/Embed 
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812, EMS, Hatfield, PA). Semi-thin sections of (0.5 µm thick) were cut on a Leica UC7 
Ultramicrotome (Leica Microsystems, Buffalo Grove, IL) approximately 1.5mm posterior 
to the sclera. Sections were stained with 1% toluidine blue and imaged with a Leica DM6 
B microscope (Leica Microsystems, Buffalo Grove, IL) using a 63x lens and 1.6x 
multiplier for a total magnification of 100x. The entire nerve was imaged with a series of 
z-stack tile scans from which, the optimally focused image within each z-stack tile was 
selected using the “find best focus” feature in the LAS-X software (Leica Microsystems, 
Buffalo Grove, IL). Contrast was then adjusted for each tile by maximizing grey-value 
variance. Finally, normal axons were automatically counted using AxoNet, a fully 
convolutional neural-network previously developed in our lab [170].  
4.2.14 Whole Globe Inflation Testing 
After euthanasia, eyes underwent inflation testing as previously described [52]. A few 
modifications to the previously published method were made to adapt to the altered 
mechanical properties of microbead-injected eyes. In brief, when eyes were pressurized 
during whole globe inflation testing, we observed leakage of PBS through the scleral shell 
via vasculature and the scleral canal. Such leakage was not previously observed in 
untreated eyes. Therefore, to reduce leaking, we substituted previously used PBS or 
mineral oil with a more viscous silicone oil as the pressurization medium. 
After enucleation, eyes were refrigerated on ice in PBS until preparation for inflation 
testing. Orbital muscle, fat, and connective tissues were removed to expose the posterior 
sclera. Eyes were blotted dry and adhered to a custom-designed thin aluminum plate 
incorporating a machined cup in the surface perforated with a hole, as follows. The cornea 
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was positioned in this cup so the posterior sclera faced upward (away from the plate), and 
cyanoacrylate-based adhesive was cured with PBS to adhere the eye to the plate, taking 
care to remove any air bubbles that might have been trapped in the adhesive with the tip of 
a 30-gauge needle. The cornea was then carefully excised through the hole in the bottom 
side of the mounting plate, allowing for removal of the aqueous humor, lens, and vitreous 
humor. Silicone oil was used to replace the contents of the eye to reduce leakage of fluid 
through the sclera upon pressurization as noted above. The eye and aluminum plate were 
then mounted onto a threaded acrylic base with screws such that the interior of the eye was 
in fluidic communication with channels in the acrylic plate. PBS was perfused through 
tubing connecting an adjustable pressure reservoir to the acrylic base. The eye was then 
pressurized to maintain its natural shape and blotted dry atop the aluminum plate. Black 
graphite powder (#970 PG, General Pencil Company, Inc., Redwood City, CA) was applied 
to the scleral surface with a cotton Q-tip to form a speckled pattern on the surface. Residual 
powder was flushed away with water and the eye was covered with PBS solution facilitated 
by placement of a removable reservoir atop the aluminum plate. Silicone oil was added to 
cover the surface of PBS in the reservoir, thus reducing loss of water through evaporation 
during testing as visualized in [52]. 
Mounted scleral shells were subsequently prepared for inflation testing. Sensors were used 
to monitor pressure (142PC01G; Honeywell, Charlotte, NC) and flow rate (SLG64-0075; 
Sensirion, Stafa, Switzerland) of PBS into the eye. After confirming absence of major leaks 
at 15 mmHg, pressure was maintained at 15 mmHg for 5 minutes. Shells were then 
preconditioned for 10 cycles at a rate of 1 cycle per minute with pressure linearly varied 
from 3 mmHg to 15 mmHg and back to 3 mmHg as previously described [52]. At the 
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conclusion of preconditioning, pressure was set to 1 mmHg and allowed to stabilize for 10 
seconds. Pressure was then increased sequentially to 3, 10, 20, and 30 mmHg at time 
intervals dictated by a flow rate stabilization criterion. Specifically, we required the 
magnitude of the measured rate of change in flow rate to be less 2 (nl/min)/s over a 10 
minute window, thus allowing the shells to reach steady state at each pressure level. During 
inflation, images of the scleral surface were captured using a digital image correlation 
system (Dantec Dynamics, Skovlunde, Denmark).   
At the conclusion of testing, Lagrange first principal strain over the scleral shell was 
computed from images using Dantec’s Istra 4D software (v4.4.1, Dantec Dynamics, 
Holtsville, NY). Data were exported to MATLAB for analysis with a customized script 
which identified/removed outliers as previously specified [52]. Steady state strain values 
at each pressure step were averaged over the peripapillary and over the non-peripapillary 
regions, and a Fung model was fit to the data. For each region an average strain value at 22 
mmHg (physiological condition) was calculated and reported. 
4.2.15 Data Analysis 
Data were analyzed using SPSS (IBM Corp. IBM SPSS Statistics for Windows, Version 
25.0. Armonk, NY: IBM Corp) and GraphPad software (GraphPad Software, San Diego, 
California) and graphed using GraphPad. For each outcome measure, a linear regression 
was calculated for each treatment group, and outliers were removed by controlling the false 
discovery rate at 1% in GraphPad. Subsequently, the remaining data were analyzed using 
a two-way ANCOVA in SPSS with cumulative IOP burden at Day 14 as the covariate. IOP 
burden was chosen as the covariate since it is a measurable indicator of the degree of 
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biomechanical insult. All data are reported as mean ± standard deviation, unless otherwise 
stated. 
A two-way ANCOVA was used to analyze mean differences for each measured 
experimental parameter. Simple comparisons were made between hypertensive and 
normotensive eyes in each of the three crosslinking treatment groups (3 comparisons). 
Additionally, simple comparisons were made between mean values of the hypertensive 
eyes of each crosslinking group (3 comparisons).  Bonferroni correction was applied for 
each parameter analyzed. For DIC strain analysis, a two-way ANCOVA was used with 
factors of: (1) “Region” having levels of (a) peripapillary sclera and (b) peripheral sclera; 
and (2) “Crosslinking Treatment” with levels of (a) HBSS, (b) GP, and (c) MB. Unless 
otherwise specified, all other outcome measures were analyzed with two-way ANCOVAs 
having two factors defined as: (1) “Microbead Treatment” having levels of (a) 
normotensive and (b) hypertensive; and (2) “Crosslinking Treatment” with levels of (a) 
HBSS, (b) GP, and (c) MB. Levene’s test was used to assess inequality of variance. 
Homogeneity of regression slopes was assessed using interaction terms of the factors and 
IOP burden covariate. In cases where statistically significant interactions existed for either 
factor and the IOP burden covariate, significance was interpreted only at the mean value 
of IOP burden for comparisons involving that factor.  
We created correlation matrices for ease of visualizing all outcome parameters at once. 
Parameters were grouped into the categories of “biomechanical”, “morphological”, or 
“functional”. Specifically, biomechanical parameters were those related to elevated IOP 
insult, including IOP burden, peripapillary scleral strain, peripheral scleral strain, 
equatorial diameter, axial length, and anterior chamber depth. Morphological parameters 
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were those related to ON and retinal structure, including ON cross-sectional area, ON axon 
count, ON axon density, and retinal thicknesses 0.5 mm and 1.2 mm from the ON. 
Functional parameters were those related to visual acuity and retinal function, including 
contrast sensitivity, spatial frequency, pSTR amplitude, nSTR amplitude, b-wave 
amplitude, and oscillatory potential 3 amplitude.  
4.3 Results 
4.3.1 Microbead Injection Successfully Increased IOP 
Induction of ocular hypertension after microbead treatment at Day 0 produced an IOP 
elevation with an initial rapid rise peaking at Day 3, followed by a gradual decrease until 
Day 14 (Figure 13D). Though not statistically significant, we observed that HBSS-treated 
eyes tended to have higher mean IOP burden compared to both GP- and MB-treated eyes. 
We accounted for any possible differences in IOP burden between individual rats or groups 
of rats by incorporating IOP burden as a covariate in our statistical analyses. Furthermore, 
to eliminate those rats which may have experienced IOP levels corresponding to ischemic 
damage, we introduced an ERG-based exclusion criterion. This functional ERG criterion 
eliminated rats with non-glaucomatous retinal damage. 
At all time points after microbead injection, mean IOP in microbead eyes was significantly 
elevated compared to normotensive controls (two-way RM ANOVA, time x treatment: F 
(30, 684) = 8.716, p < 0.0001, Tukey post-hoc) except for the GP cohort at Day 14. No 
significant differences in IOP were found between experimental treatment groups at any 
time point. Mean IOP burden values did not differ statistically significantly between 
treatment groups (Figure 13C one-way ANOVA, F (2, 57) = 1.629, p = 0.21).  
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Figure 13: A) Representation of the posterior eye showing the peripapillary sclera, here 
defined as the region enclosed by a 2 mm diameter circle centered at the ON. The 
peripheral sclera was defined as the sclera outside this region.  B) Whole globe inflation 
tests indicated whole sclera stiffening with GP and targeted peripapillary sclera stiffening 
with MB. Mean values are plotted. Statistical comparisons were performed using an 
ANCOVA and therefore are comparisons of adjusted means. C) Mean IOP burden 
(pressure x time) did not differ significantly between crosslinking treatment groups. D) 
IOP levels increased after induction of ocular hypertension at Day 0 in microbead-
injected eyes compared to normotensive control eyes. Statistical significance is indicated 
using the following convention: “*” for p < 0.05, “**” for p <0.01, “***” for p < 0.001, 





4.3.2 Mechanical Testing Confirmed that Crosslinking Effectively Increased Scleral 
Stiffness 
It was important to verify that Genipin and MB stiffened the sclera in treated eyes. For this 
purpose, we conducted inflation testing of post-mortem eyes and quantified their 
deformation using DIC analysis. We report adjusted mean strains from the ANCOVA 
analysis over the peripapillary and peripheral scleral regions (Figure 13A), a quantity that 
is inversely proportional to scleral stiffness. Peripapillary strain was greater than peripheral 
strain (p < 0.01, Figure 13B) in HBSS-injected (control) eyes, likely due to presence of the 
scleral canal in the peripapillary region. We found that mean scleral strain was 2- to 3-fold 
lower in both scleral regions in GP eyes  compared to the corresponding regions in HBSS 
eyes (p < 0.0001, Table 3), indicating successful whole-scleral crosslinking by GP. There 
was no significant difference in scleral strains between regions within GP eyes. In MB 
eyes, peripapillary scleral strain was approximately 3-fold lower than in HBSS-treated eyes 
(p < 0.001,Table 3), but strains in the peripheral sclera did not differ significantly between 
HBSS and MB eyes, indicating that targeted peripapillary MB stiffening was successful. 
MB eyes had significantly reduced strain in the PP region compared to the peripheral 
region within the same MB eye (p < 0.0001). Mean scleral strain values in hypertensive 
experimental eyes were analyzed using a two-way ANCOVA with IOP burden as the 
covariate (Figure 13; see Methods: Data Analysis). Strains were significantly correlated 
with IOP burden (p < 0.01, Figure 13 and Figure 44).  
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Table 3: Adjusted means and simple comparisons for each parameter measured from rat 
microbead study. Two-way ANCOVAs were used to analyze each parameter with IOP 
burden as the covariate. 
 
 
4.3.3 Retinal Thickness Measurements Suggest Protective Effects of Scleral Stiffening 
We used OCT imaging to measure total retinal thickness, expected to be decreased in eyes 
experiencing RGC axonal loss. Total retinal thickness at 0.5 mm from the ONH was not 
significantly different between hypertensive GP and HBSS eyes (Figure 14A, Table 3), 
and was less in hypertensive MB eyes compared to HBSS eyes (p < 0.05,Table 3) and GP 
eyes (p < 0.0001,Table 3). Total retinal thickness at 0.5 mm from the ONH was 
significantly decreased in hypertensive experimental eyes for both HBSS and MB cohorts 
compared to respective normotensive controls (p < 0.0001, Figure 14A) but not for GP 
eyes. Total retinal thickness at 0.5 mm from the ONH significantly correlated with IOP 
burden (p < 0.05,Figure 44). Thus, there was a trend (not reaching statistical significance) 
suggesting that scleral stiffening using GP (but not MB) preserved retinal thickness at 0.5 
mm from the ONH in hypertensive eyes.  
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In contrast to the situation at 0.5 mm from the ONH, hypertensive GP eyes showed 
significantly larger mean total retinal thickness at 1.2 mm from the ONH compared to 
HBSS eyes (p < 0.0001,Table 3), potentially indicating a protective effect of GP against 
retinal changes (Figure 14B). No significant differences were observed in this measure of 
retinal thickness between hypertensive GP eyes and MB eyes, or between MB eyes and 
HBSS eyes. Total retinal thickness was significantly less in hypertensive experimental eyes 
compared to normotensive control eyes for HBSS eyes (p < 0.0001,Table 3: Adjusted 
means and simple comparisons for each parameter measured from rat microbead study. 
Two-way ANCOVAs were used to analyze each parameter with IOP burden as the 
covariate.) but not for GP or MB eyes. Representative OCT images shown in Figure 43 
reveal minor qualitative differences as well as indications of ‘cupping’ at higher IOP 
burdens. We conclude that GP, but not MB, treatment offers some protection against retinal 
thinning induced by OHT but that this thinning is spatially heterogeneous.  
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Figure 14: A) Total retinal thickness measured 0.5 mm from the ONH. Retinal thickness 
in hypertensive GP eyes was not different than in GP normotensive controls, while 
thickness in hypertensive HBSS eyes was significantly less than in HBSS normotensive 
controls. Thickness in hypertensive MB eyes was less than in hypertensive GP and HBSS 
eyes. B) Total retinal thickness measured 1.2 mm from the ONH. Thicknesses in both 
GP- and MB-treated hypertensive eyes were not significantly different from their 
respective contralateral eye (normotensive) thicknesses, while thickness in hypertensive 
HBSS-treated eyes was significantly less than in HBSS normotensive control eyes. 
Thickness in hypertensive GP eyes was significantly greater than in hypertensive HBSS-
treated eyes, suggesting a protective effect of GP against retinal thinning. C) Axon counts 
derived from ON cross-sections showed no significant protective effects of crosslinking. 
D) Percent axon loss in hypertensive experimental eyes (compared to normotensive 
control) ranked by rat number from least to greatest axon loss suggests that axon loss is 
decreased in GP and MB treated eyes. 
 
4.3.4 Axon Counts are not Preserved by Scleral Stiffening 
We quantified optic nerve axons using a machine learning-based software package [170]. 
No significant differences were found between any hypertensive eye treatment groups 
(Figure 14C and Table 3), with adjusted mean axon counts of 78,900 and 39,400 axons in 
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HBSS normotensive and hypertensive eyes, respectively; 82,400 and 46,200 axons in GP 
normotensive and hypertensive eyes, respectively; and 83,700 and 45,500 axons in MB 
normotensive and hypertensive eyes, respectively. Axon count and axon density were both 
lower in hypertensive experimental eyes compared to their respective normotensive 
controls (all p < 0.0001,Table 3). Axon counts and axon density were also significantly 
correlated with IOP burden (p < 0.001, Table 14 and Figure 40). Representative optic nerve 
images in Figure 42 qualitatively show an increase in axonal damage with increased IOP 
burden. As alternative measures of RGC axon count, we calculated axon density (axon 
count divided by ON cross-sectional area). We observed no significant differences between 
any hypertensive eye treatment groups (Table 3) when considering axon density and ON 
cross-sectional area, nor a significant correlation with IOP burden (Table 14).  
4.3.5 Eye Size Increased with IOP Burden 
Eye size was measured to understand possible sources of glaucomatous damage and 
physiological differences compared to clinical glaucoma. Hypertensive experimental eyes 
were significantly larger than normotensive control eyes for all three crosslinking treatment 
groups, as measured by axial length, equatorial width, and anterior chamber depth (all p < 
0.05,Table 3). Further, all eye size measurements were correlated with IOP burden (p < 
0.0001, Table 15 and Figure 47). No significant differences in any eye size measurements 
were found between any hypertensive eye treatment groups. This increase of eye size 
differs from the situation in human adult glaucoma, where elevated IOP is not known to 
lead to ocular enlargement. However, other rodent models of OHT have observed similar 
findings of OHT-induced globe enlargement[5,198]. 
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4.3.6 Visual Function is not Preserved by Scleral Stiffening 
Spatial frequency and contrast sensitivity thresholds were measured to assess possible 
preservation of visual function due to crosslinking treatment. No significant differences 
were found between mean resolved spatial frequencies of any hypertensive eye treatment 
groups. Spatial frequency and contrast sensitivity thresholds were significantly decreased 
in hypertensive experimental eyes compared to normotensive control eyes for all three 
crosslinking treatment groups (p < 0.0001,Figure 3). Both spatial frequency and contrast 
sensitivity were significantly correlated with IOP burden (p < 0.0001, Table 14). 
Hypertensive eye spatial frequency and contrast sensitivity were not significantly different 
for comparisons between crosslinking treatment groups 
4.3.7 RGC Function is not Preserved by Scleral Stiffening 
No significant differences in mean pSTR, nSTR, b-wave, nor oscillatory potential 3 (Figure 
15Figure 15C-F) amplitudes were found between any hypertensive eye treatment groups 
(Table 3). Significant decreases in mean pSTR, nSTR, b-wave, and oscillatory potential 3 
amplitudes were observed in hypertensive experimental eyes compared to normotensive 
control eyes for all three crosslinking treatment groups (all p < 0.05,Table 3). pSTR and 
Oscillatory potential 3 amplitudes were significantly correlated with IOP burden (p < 0.05, 
Table 14 and Figure 46). Hypertensive eye ERG outcomes were not significantly different 
for comparisons between crosslinking treatment groups, indicating that our treatments did 




Figure 15: Functional outcome measurements across crosslinking treatment groups. We 
show OMR measurement outcomes, namely A) spatial frequency and B) contrast 
sensitivity; and ERG outcomes, namely C) pSTR amplitude, D) nSTR amplitude, E) b-
wave amplitude, and F) oscillatory potential 3 amplitude. In all cases, a significant deficit 
was observed for hypertensive experimental eyes compared to normotensive control eyes. 
No significant differences were found between hypertensive eye treatment groups. These 
data indicate crosslinking did not preserve visual acuity or retinal function as measured 




4.3.8 Outcome Parameter Correlation Trends Differ by Treatment 
Parameters measured in the study were cross correlated to detect associations between 
biomechanical, morphological, and functional outcomes within treatment groups, and 
differences in these associations across treatment groups (Figure 16). We found that the 
strength of associations (either positive or negative) were different between groups, with 
ranking HBSS > GP > MB (ranked stronger to weaker). This was particularly evident for 
the comparison of morphological and functional outcomes with biomechanical insult. We 
believe this indicates that either: (1) MB treatment generally reduced the impact of 
biomechanical insult on morphological and functional outcomes, or (2) that MB-treated 
eyes experienced greater variability in the relationship between functional/morphological 




Figure 16: Parameters measured in hypertensive rat eyes were cross correlated and 
organized by mechanical, morphological, and functional categories for each crosslinking 
treatment. Stronger correlations were found for HBSS than for GP-treated rats, and for 
GP-treated rats compared to MB-treated rats, particularly in the relationship between 
morphological/functional with biomechanical parameters. Mechanical parameters 
included IOP burden, scleral strain, and eye dimensions. Morphological parameters 
include optic nerve size, axon count/density, and retinal thickness. Functional parameters 
include OMR and ERG data. A) HBSS hypertensive experimental eye matrix. B) GP 
hypertensive experimental eye matrix. C) MB hypertensive experimental eye matrix. 
Statistical significance was calculated for null hypothesis of zero correlation (significance 
indicated with “*” for the Bonferroni-corrected p<0.05 level). 
 
4.4 Discussion 
We assessed the effects of peripapillary (targeted) scleral stiffening and whole-globe 
scleral stiffening on glaucomatous outcomes in a microbead model of ocular hypertension 
in rats. We successfully stiffened the sclera, as confirmed by inflation testing of whole 
globes, and, as expected, we observed significant changes in morphological and functional 
outcomes in hypertensive eyes compared to normotensive eyes.  
In general, we did not observe significant protective effects of scleral stiffening on retinal 
ganglion cell function as measured by ERG, nor on visual function as measured by spatial 
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frequency or contrast sensitivity. Further, we did not observe a significant preservation of 
retinal ganglion cell axons by scleral stiffening. However, we did observe preservation of 
retinal thickness at 1.2 mm from the ONH in GP-treated eyes compared to HBSS treated 
eyes (although not in MB-treated eyes), suggesting that stiffening may confer some 
protective effects against hypertension-induced morphological changes in the retina. We 
conclude that scleral crosslinking did not preserve retinal or visual function but might slow 
the progression of morphological glaucomatous damage. Importantly, we saw no evidence 
to conclude that scleral stiffening worsens glaucomatous damage, in contrast to a previous 
report[5].  
4.4.1 Toxicity of Crosslinking Treatments May Have Contributed to RGC Loss 
We have previously evaluated the toxicity of HBSS, GP, and MB treatments in healthy rats 
at 4 weeks, 4 weeks, and 6 weeks (respectively) following injections. The average axon 
losses in these cohorts, compared to untreated controls, were 0%, 8%, and 24% for HBSS, 
GP, and MB respectively. Additionally, deficits in retinal function as measured by ERG 
were observed in MB-treated rats. In the current study, we observed deficits in visual 
function measured by OMR seven days following crosslinking treatments, but prior to 
microbead injections (Figure 39). Thus, GP and MB-treatments have inherent toxicity in 
the absence of ocular hypertension, which likely accounts for some of the damage observed 
in this study. With this understanding, one could interpret a finding of no difference in axon 
counts between stiffened eyes and sham-treated eyes as indicating protection by scleral 
stiffening against IOP-induced axon loss, which was offset by inherent toxicity of the 
stiffening agent. Indeed, there was a trend (that did not reach statistical significance) of 
axon preservation in GP- and MB-treated eyes, suggesting some inherent benefit of 
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stiffening due to IOP-induced axon loss. Unfortunately, it is difficult to statistically 
separate the contributions of treatment toxicity and hypertension-induced damage, and thus 
we cannot make definitive conclusions in this regard.  
4.4.2 Limitations of the Microbead Model Complicate Interpretation of Results 
Intracameral delivery of microbeads may be associated with some inflammation which 
could lead to retinal/RGC axon injury. It was thus of interest to estimate microbead 
procedure “toxicity”, which we did by extrapolating axon counts in low-IOP burden rats. 
More specifically, the y-intercept of the linear axon loss regression versus IOP burden can 
be considered to yield an estimated value of axon loss due to the microbead procedure 
alone without IOP elevation. These y-intercepts for the hypertensive HBSS, GP, and MB 
groups were 69,400 ± 14,000, 68,000 ± 9,000, and 62,300 ± 9,100 axons, respectively, 
which can be compared to average axon count values for normotensive controls in our 
study of 78,100 ± 7,200, 82,400 ± 4,700, and 83,800 ± 7,400 axons, respectively. 
Comparing the axon counts in low IOP burden rats to those of the normotensive controls, 
we estimate axon losses of 11% for HBSS, 17% for GP, and 26% for MB rats due to the 
crosslinking and microbead injections alone. These values are higher than the losses due 
to crosslinking treatment alone which were 0%, 8%, and 24% for HBSS, GP, and MB, 
respectively. Subtracting axon losses due to crosslinking toxicity alone from axon losses 
calculated in this study at low IOP burden, we find losses due to microbead treatment to be 
11%, 9%, and 2% for HBSS, GP, and MB treatments. These data support the hypothesis 
that the microbead procedure itself in Brown Norway rats leads to some axon loss, in an 
IOP-independent manner.  
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In interpreting our results, it is important to recall that the model of ocular hypertension 
that we used caused rapid and large pressure elevations after microbead delivery, 
representing a severe challenge compared to a typical IOP history seen in open-angle 
glaucoma. In other words, the biomechanical insult seen in our study was perhaps more 
severe than would be observed clinically. Furthermore, our 14-day study duration was far 
shorter than time scales in open-angle glaucoma with OHT, so that adaptive responses such 
as collagen remodeling in the sclera would have had less chance to take effect in our study. 
Therefore, we interpret the results of our study to conservatively support the conclusion 
that scleral stiffening does not worsen glaucomatous damage and may confer some 
protection against aggressive mechanical insult.  
4.4.3 Scleral Stiffening May Protect Against Morphological, but not Functional RGC 
Damage 
Interestingly, we did not observe functional protection due to crosslinking, yet did observe 
some evidence of structural protection (retinal thickness preservation, a trend towards RGC 
axon preservation). Previously it has been shown that axon loss precedes retinal thinning, 
which may explain the relatively large deficit in axon count observed compared to the more 
minor retinal thinning in our study [209]. We attribute the loss of retinal thickness in MB 
eyes at 0.5 mm distance from the ONH to localized toxicity of the photocrosslinking 
procedure. Recall that the region 0.5 – 1.0 mm from the ONH was selectively targeted for 
treatment in these eyes, likely inducing more damage at 0.5 mm than at 1.2mm. Another 
interpretation of this result is the potential of retinal edema which would balance out the 
loss of RGCs. However, histological analysis of the retina after GP and MB treatment alone 
did not show any signs of retinal edema (data not shown). 
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It should be noted that our OCT measurements are of total retinal thickness because we 
could not confidently resolve the retinal nerve fiber layer in our imaging. However, we 
suspect our measurement of total retinal thinning at both locations (0.5 mm and 1.2 mm 
from the ONH) was caused in part by retinal nerve fiber layer thinning since we also 
observed significant loss of RGC axons (Figure 14C) and RGC function (Figure 15C-F) in 
HBSS hypertensive experimental eyes compared to normotensive controls. 
Although we did not observe any significant differences in RGC axon counts among 
hypertensive experimental eyes treated with GP or MB compared to HBSS eyes, we did 
see a trend towards preservation of axons with both treatments (Figure 14C). We 
hypothesize that over the short timescale of our experiment (14 days) RGC bodies were 
still present in the retina despite RGC axonal death, which explains why we saw 
preservation of the retinal thickness, but not RGC axon counts.  
Although our ERG results suggest a loss of RGC function across all treatment groups, 
differences were not seen between HBSS and GP or MB groups, suggesting that variability 
in the ERG and OMR data was large compared to effect size, thus yielding statistically 
insignificant differences. Functional outcomes are perhaps most relevant to clinical 
translation irrespective of morphological changes. Although we observed some protection 
against retinal thinning, we hypothesize that remaining RGCs had impaired function which 
may indicate scleral stiffening can slow the progression of glaucomatous damage.   
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4.4.4 We Were Able to Successfully Stiffen the Posterior Sclera with Both Targeted and 
Non-targeted Treatments 
Scleral strain measured post mortem by whole globe inflation testing confirmed successful 
targeted peripapillary stiffening with MB and whole sclera stiffening with GP. We 
observed increasing strain values (decreased stiffness) with increasing IOP burden in 
HBSS eyes, indicating weakening of the sclera under hypertensive conditions in this study. 
These effects have been observed on short time scales previously [210].  
An unexpected observation in this study was the apparent similarity in measured strain 
values of HBSS eyes with those of GP and MB treated eyes at low IOP burdens. We have 
previously shown that MB and GP treatments reduce scleral strain significantly compared 
to HBSS in healthy rats. Since microbead-treated rats experiencing low IOP burdens should 
have scleral mechanical properties comparable to those of healthy rats, the observed 
similarity is difficult to explain. This observed effect could be an artifact of low sample (n 
= 2) size when only considering low IOP burden values, or due to inflammatory processes 
associated with the microbead model as discussed above. 
4.4.5 Key Differences Exist Between This Study and a Similar Previous Study 
It is of interest to compare our results with those of the related study of Kimball et al. To 
stiffen the sclera, Kimball et al. used glyceraldehyde in 100 mM sodium phosphate 
(Na3PO4), the latter having an osmolarity of 400 mOsm[5]. After addition of 500 mM 
glyceraldehyde, the solution’s final osmolarity would have been 900 mOsm, well in excess 
of the physiological osmolarity of 285-295 mOsm [47]. Therefore, some of the axon loss 
observed may be attributed to hyperosmolarity of the injection solution. 
 93 
Additionally, Kimball et. al did not assess any functional or morphological outcomes in 
glaucomatous eyes. We have expanded upon this previous research by including 
assessments of visual function (OMR), retinal function (ERG), and retinal thickness 
(OCT), helping to paint a more complete picture of the effects of scleral stiffening on 
clinically relevant outcomes. 
4.5 Conclusion 
Neither targeted peripapillary nor non-targeted posterior scleral stiffening worsened 
morphological and functional outcomes in a glaucomatous rat model. We found a modest 
potential preservation of total retinal thickness by genipin-induced scleral stiffening. 
Interpretation of these results is hindered by drawbacks of the microbead model of ocular 
hypertension (high variability, some inherent retinal toxicity). Further research is needed 
to investigate the impact of scleral stiffening on glaucomatous damage.  
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CHAPTER 5. THEORETICAL COMPUTATIONAL MODEL 
FOR COLLAGEN PHOTOCROSSLINKING IN THE EYE 
Note on Contribution: Data presented in this chapter were made possible by contributions 
from colleagues including Afsane Radmand who contributed to model development. 
Lauren Nichols collected data and calculated the diffusion constant of methylene blue in 
rat sclerae. Additionally, she assisted in collecting data pertaining to the study of methylene 
blue distribution in retrobulbar tissues. Amir Hejri assisted with experiments involved in 
calculating the diffusion constant of methylene blue in rat sclerae.  
5.1 Abstract 
Scleral photocrosslinking is increasingly investigated for treatment of myopia and 
glaucoma. In this study a computational model was developed to predict crosslinking 
efficiency of visible/NIR photosensitizers in the sclera. Photocrosslinking was validated 
against riboflavin corneal crosslinking experimental studies and subsequently modeled for 
the sensitizer, methylene blue, administered by retrobulbar injection to the posterior sclera 
and irradiated with a transpupillary light beam. Optimal ranges were determined for 
treatment parameters including light intensity, methylene blue concentration, injection 
volume, and inspired oxygen concentration. Additionally, sensitivity of crosslinking to 
various parameters was quantified. The most sensitive parameters (in order of greatest to 
least sensitive) were tissue parameters (including scleral thickness and choroidal melanin 
concentration), treatment parameters (including treatment duration and inspired oxygen 
concentration), and sensitizer parameters (including triplet quantum yield). 
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5.2 Introduction 
Glaucoma is the leading cause of irreversible blindness in the industrialized world affecting 
approximately 80 million individuals[1]. It is an optic neuropathy sensitive to elevated 
intraocular pressure resulting in retinal ganglion cell death leading to vision loss[32]. 
Specifically, pressure-induced strain at the optic nerve head mediated by tissue 
biomechanical properties causes retinal ganglion cell apoptosis[44–46]. Therefore, it is 
desirable to develop strategies to reduce optic nerve head strain. Recently, it has been 
shown that peripapillary scleral stiffening resulted in strain reduction at the optic nerve 
head in ex vivo porcine eyes, suggesting that peripapillary scleral stiffening may be a 
strategy to prevent retinal ganglion cell loss in glaucoma[4]. We have developed a 
photocrosslinking technique to selectively stiffen the peripapillary sclera in vivo using 
methylene blue excited by red light at 660 nm. In this study, we present a computational 
model to identify conditions which enable safe and effective scleral photocrosslinking with 
methylene blue and red light. 
To develop this model, we identified prior experimental ocular collagen crosslinking 
studies and found that there are multiple scenarios where changes in ocular tissue 
mechanical properties are implicated in disease. In addition to glaucoma, these include 
keratoconus and myopia[211,212]. Keratoconus prevalence is estimated to range between 
0.0003% and 2.3% of the population depending on geographic region studied. The 
condition is characterized by weakening of the cornea leading to refractive errors[213–
215]. Myopia affects 1.4 billion people worldwide and is characterized by elongation of 
the globe, resulting in refractive errors, and in severe cases, retinal detachment, choroidal 
neovascularization, and glaucoma[216–221]. Glaucoma is the second leading cause of 
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blindness in the world, and disease progression is believed to be linked to mechanical 
deformation of the lamina cribrosa and peripapillary sclera[154,222].   
Photoinduced crosslinking has been increasingly studied since the early 2000s as a method 
for modulating tissue mechanical properties by strengthening collagenous tissues in 
vivo[223,224]. We have recently shown that transpupillary activation of methylene blue 
(MB) stiffens rat sclerae in vivo and therefore may be a viable future stiffening strategy for 
treatment of glaucoma and myopia. Clinically, riboflavin corneal crosslinking is an FDA-
approved procedure for treatment of keratoconus[225].riboflavin’s absorbance of UV light 
results in crosslinking through either direct interaction of riboflavin excited state triplets 
with collagen amino acids or through generation of singlet oxygen which reacts with amino 
acids to form crosslinks[226,227]. On the other hand, photocrosslinking treatments for 
myopia are still in the research phase while only dark crosslinking has been investigated 
for glaucoma treatment[52,228]. To increase crosslinks, reduce treatment time, and 
improve safety profiles for riboflavin corneal crosslinking, experimental studies have 
aimed to optimize treatment parameters such as light intensity, crosslinker concentration, 
and irradiation duration[229–231].   
Riboflavin crosslinking is known to follow complex reaction dynamics involving the 
sensitizer molecule, oxygen, and collagen substrate[129,227]. Riboflavin may react with 
collagen through two different pathways (type I and type II) distinguished by the absence 
or presence of singlet oxygen[62,70]. The type I mechanism involves direct interaction of 
excited state sensitizer triplets with collagen amino acids, resulting in radical-mediated 
crosslinking. The type II mechanism is characterized by energy transfer from the excited 
riboflavin triplet to oxygen, producing singlet oxygen which reacts with collagen amino 
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acids. Exact mechanisms for each pathway have been a subject of great interest, and the 
relative importance of each pathway has been the subject of much debate.  
Computational models can be used to predict optimal crosslinking parameters used for 
clinical or research photocrosslinking applications. These models incorporate elements of 
light transmission/absorbance, chemical reactions, and diffusion of molecular 
species[129,130,148,232]. To date, extensive modeling has been performed for riboflavin 
corneal crosslinking, aided by the abundance of experimental data against which models 
may be validated. Experimental studies provide valuable test cases for validation of 
experimental models. Such studies are available primarily from riboflavin crosslinking 
literature and have investigated riboflavin and oxygen concentrations in situ during 
treatment and mechanical stiffness of the cornea after treatment[129,146,176,177].  
Towards development of efficient posterior scleral photocrosslinking strategies, we 
modeled transpupillary illumination of visible/NIR sensitizers delivered to the posterior 
sclera by retrobulbar injection. In this approach, sensitizers may be delivered to the 
posterior sclera by retrobulbar, sub-Tenon, or suprachoroidal injection. From any of these 
injection spaces, sensitizer molecules passively diffuse to the sclera in similar fashion to 
the diffusion of riboflavin into the corneal stroma during riboflavin crosslinking 
procedures. Subsequently, a light beam may be directed through the cornea/intraocular 
media to the sclera after passing through the retina, retinal pigmented epithelium, and 
choroid. We believe this transpupillary illumination approach holds promise for posterior 
photocrosslinking especially in light of recent advances in efficiency of posterior ocular 
drug delivery strategies[233,234]. 
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While riboflavin is a valuable sensitizer for corneal crosslinking, its use in the posterior 
sclera is limited due to the need to deliver light externally through more invasive surgical 
techniques and waveguides[158,228,235]. A transpupillary approach, on the other hand, 
would be inefficient for riboflavin excitation both due to toxicity concerns at the retina and 
energy absorbance in the cornea. However, for red to near infrared wavelengths, an optical 
phenomenon exists whereby biological tissues have reduced absorbance at 650-800nm 
wavelengths compared to surrounding wavelengths[67]. This optical window, we believe, 
makes possible transpupillary illumination of photosensitizers delivered to the sclera. A 
critical uncertainty exists as to whether light may pass sufficiently through the highly 
melanized retinal pigmented epithelium and choroid to satisfy crosslinking requirements 
in the sclera. While intensity may be increased, photothermal damage to the retina and 
retinal pigment epithelium (RPE) is a concern. Another constraint is the presumably rapid 
clearance of sensitizer from the extraocular tissues upon injection. The proper combination 
of light intensity, sensitizer concentration, oxygen concentration, excitation wavelength, 
and sensitizer molecule may enable scleral photocrosslinking with a transpupillary 
excitation beam despite these constraints. 
In this study, we developed a computational model to predict the efficiency of visible/NIR 
sensitizers for posterior scleral photocrosslinking. Specifically, we investigated the 
sensitizer MB delivered to the sclera by means of a retrobulbar injection. We first tested 
our model against existing riboflavin crosslinking literature data to confirm validity of the 
underlying model dynamics. Subsequently, we exchanged cornea/riboflavin-specific 
parameters for parameters of MB which efficiently absorbs red photons. Mass transport 
parameters for sensitizer diffusion after injection in the retrobulbar space were validated 
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experimentally in rats, as they can be expected to differ from those of topical delivery as 
in the case of riboflavin crosslinking. 
5.3 Materials and Methods 
5.3.1 Experimental Quantification of MB Distribution in Rat Eye Tissues after 
Retrobulbar Injection 
Brown Norway male retired breeder rats aged 6-12 months (Charles River Laboratories, 
Wilmington, MA) were placed under anesthesia with 5% isoflurane gas and 800mL/min 
oxygen flow rate. Topical anesthetic eye drops (Tetracaine Hydrochloride Ophthalmic 
Solution, Amici Pharmaceuticals, Melville, NY) were administered bilaterally followed by 
1% tropicamide eye drops (Tropicamide Ophthalmic Solution, Henry Schein, Melville, 
New York) administered bilaterally to induce pupillary dilation, thus replicating the 
conditions for scleral photocrosslinking procedures using a transpupillary light 
administration approach.  
A 30 mM solution of MB (Apollo Scientific, Stockport, UK) dissolved in Hank’s balanced 
salt solution was prepared by warming the solution to 100 °C and allowing the solution to 
cool to room temperature (20 – 25 °C). After inducing anesthesia, a 100 𝜇L volume of 30 
mM MB was administered by means of retrobulbar injection unilaterally with 100 𝜇L of 
Hank’s balanced salt solution (HBSS) administered similarly as a control in the 
contralateral eye using 0.3 mL volume, 31G insulin syringes/needles (BD Insulin Syringes 
with BD Ultra-Fine™ needle, Becton, Dickinson and Company, Franklin Lakes, NJ). 
Anesthesia was maintained for 30 minutes after which the rat was euthanized by inhalation 
of 100% CO2. All procedures involving animals were approved by the Georgia Institute of 
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Technology Institutional Animal Care and Use Committee (IACUC) and complied with 
the ARVO statement for the Use of Animals in Ophthalmic and Vision Research. 
Immediately after euthanasia, eyes were enucleated and dissected with tissues individually 
distributed into centrifuge tubes containing 2 mL radioimmunoprecipitation assay (RIPA) 
lysis buffer. The tissues collected included 1) a 1 mm diameter scleral disk centered at the 
scleral canal, 2) a 2mm diameter scleral annulus centered at the scleral anal (less the 1 mm 
scleral disk), and 3) a 3 mm diameter scleral annulus centered at the scleral canal (less the 
2 mm scleral annulus, all collected using biopsy punches, as well as 4) all remaining sclera 
not contained within 3 mm diameter of the scleral canal, and 5) the cornea, lens, vitreous, 
and retina (collectively termed “anterior globe” in this study).  
The mass of each sample was determined gravimetrically and used to calculate the 
approximate volume of the collected tissue based on an assumed density of 1 g/cm3. Each 
sample was then ultrasonicated for 1 min to disrupt tissue structures and thus facilitate MB 
release from the tissues into the lysis buffer. All samples were then allowed to rest, 
protected from light exposure, overnight (12-18 hours) before being centrifuged at 2400 
RPM for 10 minutes. The supernatant was then collected, serially diluted on a 96-well 
plate, and MB fluorescence intensity was analyzed using a Synergy H4 plate reader 
(BioTek, Winooski, VT). Fluorescence intensity was converted to sample concentration 
based on a reference standard calibration curve included for each plate. Average 
concentration of MB in each tissue was derived from the mass of MB calculated for each 
sample divided by the volume. 
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5.3.2 Experimental Determination of MB Diffusion Constant in Rat Sclera 
Brown Norway retired male breeder rats age 10-20 months (Charles River Laboratories, 
Wilmington, MA) were euthanized by exposure to 100% CO2. The cornea, vitreous, and 
retina were removed from each eye immediately after enucleation. From each eye, four 
scleral samples of approximately equal size were taken, one each from the superior, 
inferior, temporal, and nasal quadrants. Scleral thickness was measured with calipers. 
Glass Franz cells with an exposed circular tissue area of 3.14 mm2 were modified to 
accommodate the scleral samples (3-5 mm diameter) by sandwiching the tissues between 
two glass microscope slides customized with a 2mm drilled hole in the center (Figure 17). 
Scleral samples were centered on the 2mm holes between two slides. A rubber O-ring was 
placed on the flat flange joint of the receiving and donor components of the Franz cell, and 
the drilled cover slips holding the tissue were centered between the O-rings in order to 
prevent leakage. The Franz cell was clamped together, and the receiving chamber was filled 
with phosphate-buffered saline (PBS). A 1 mL volume of 3 mM MB solution prepared in 
PBS was placed in the donor chamber of the Franz Cell. 
The Franz cells were incubated at room temperature with a stir bar in the receiving 
chamber. For each scleral sample, 6 samples were taken from the receiving chamber at 1 h 
intervals, and the volume sampled was replenished with an equal volume of PBS. Collected 
samples were tested for MB concentration by spectrophotometry using a Synergy H4 plate 
reader (BioTek) with excitation set to 665nm and emission to 690nm. Diffusivity was 








where J is the flux of MB across the sclera, C is the concentration of the diffusing MB, D 
is the diffusion constant of MB, and x is the distance over which diffusion occurs. 
Upon testing, lag time was calculated and used to confirm that steady state diffusion had 
been achieved. Any sample that had not reached steady state during the procedure was 
excluded from analysis, as it would not have satisfied the conditions required to accurately 
measure the diffusion constant. A total of N = 9 samples were analyzed and mean diffusion 
constant and lag time were calculated. 
 
 
Figure 17 Schematic representation of Franz Cell apparatus used to determine MB 
diffusion constant through 3.14 mm surface area of Brown Norway rat sclerae. A 3 mM 
solution of MB was placed in the donor chamber for diffusion across the sclera and into 
the receiving chamber. The scleral samples were mounted between two glass microscope 
slides sealed with O-rings.  
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5.3.3 Model Validation Against Past Riboflavin Crosslinking Studies 
We validated our model predictions by comparing with data from three different studies of 
riboflavin crosslinking found in the literature. In the first study, Kamaev et al. measured 
oxygen concentration during riboflavin crosslinking treatment in ex vivo porcine 
eyes[236]. Experimental conditions described in that study were inserted into our model, 
and oxygen concentration predicted by the model was compared against that measured by 
Kamaev et al. as a validation of transport kinetics and reaction dynamics predicted by the 
model. Because oxygen concentration changes are derived from the intertwined 
photochemical reactions, diffusion, and light absorbance phenomena, the ability of the 
model to predict the complex oxygen concentration profile in Kamaev et al. provides a 
holistic measure of model validity.  
In the second study, Hammer et al. measured the change in stiffness in ex vivo porcine eyes 
treated with riboflavin crosslinking in accelerated and normal irradiation procedures[177]. 
In this study, light fluence was maintained at the traditional 5.4 J/cm2 dose (i.e. that is 
commonly used in clinical corneal crosslinking). Intensity was varied over a range of three 
different intensities of 3, 9, and 18 mW/cm2. Irradiation duration was adjusted(30, 10, and 
5 min, respectively), to maintain identical fluence across experiments. Using these data, 
we calculated the percent increase in stiffness compared to untreated control from the 
reported raw stiffness values in the Hammer study and compared these values to our 
computational model predictions at the same experimental parameters. We represented 
crosslinking predicted by our model as a fraction of total possible crosslinking sites utilized 
and took this as a surrogate and proportional measure of scleral stiffness.  Experimental 
conditions described in the Hammer study were inserted in our model, and percentage of 
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available sites crosslinked was generated and compared to the percentage increase in 
stiffness reported by Hammer et al.  
In the third study, Aldahlawi et al. investigated riboflavin crosslinking using similar 
experimental conditions to those of Hammer et al., but evaluated crosslinking using 
enzymatic degradation by measuring the dry weight remaining after 12 days[237]. We 
compared our model to the raw values of corneal dry weight that they reported.  
5.3.4 Theoretical Computational Model Structure 
We developed a theoretical model employing the method of lines using the ordinary 
differential equation solver function ode15s in MATLAB software (MathWorks, Natick, 
MA). The model considered a one-dimensional thickness of tissue discretized into 𝑛 finite 
segments (Figure 18) of width ∆𝑥 with index 𝑖 that was bounded on the left side by a 
reservoir of injected sensitizer solution in the retrobulbar space (or on the corneal surface) 
and bounded on the right side by the choroid (or the aqueous humor). Molecular diffusion, 
light propagation, and chemical reactions provided the physical bases for tracking crosslink 




Figure 18: Schematic representation of the model spatial domain including (left to right): 
choroid, sclera, Tenon capsule, injection reservoir. Light enters through the anterior 
surface of the choroid from a transpupillary illuminating source. Oxygen diffuses from 
the choroid (and to a lesser extent, from the retrobulbar tissue). The photosensitizer 
diffuses from the injection reservoir to the Tenon capsule, sclera and choroid (where 
vascular clearance can occur) as well as to the retrobulbar tissue (not shown) which is 
assumed to be a sink due to systemic clearance. The model uses the method of lines to 
discretize a system of partial differential equations in space, thus creating a system of 
ordinary differential equations in time. Node thickness (Δx) was uniform in the choroid 
and in the sclera, and non-uniform in the injection reservoir. 
 
5.3.5 Modeling Diffusion 
5.3.5.1 Fick’s Second Law and its Discretization 














where C represents concentration of the diffusing species, D represents its diffusion 
constant, and x and t represent position and time, respectively. A finite difference 
approximation was used to reduce the diffusion equation to a set of ordinary differential 









where 𝐶𝑖 represents the concentration of the diffusing species (photosensitizer, oxygen) at 
the ith node of the spatial domain.  
5.3.5.2 Derivation of Discretized Fick’s Second Law for Unequal Node Spacing 
To accommodate constraints modeling various tissue thicknesses on finite intervals as well 
as different diffusion constants between adjacent nodes, a modified form of equation (2) 
was employed which does not assume equal node distances or diffusivities. Unequal node 
spacing was accommodated using a rectangle approximation (adapted from the trapezoid 
approximation)[239]. Unequal diffusion constants were handled by calculating the 
harmonic mean of diffusion constants between adjacent nodes[240]. . To implement the 
rectangle approximation, we defined the distance between the ith node and adjacent nodes 
as h1 and h2 where h1 is the distance between the i
th and( i+1)th nodes and h2 is the distance 
between the ith and (i-1)th nodes (Figure 19).  
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Figure 19: Schematic representation of the 1-dimensional tissue discretization scheme 
showing three adjacent tissue slices of finite thickness, Δx. The ith node with (i-1)th and 
(i+1)th nodes are shown at left and right, respectively. Nodes were defined at the center of 
each tissue slice. Node spacings represented by h1 and h2 were allowed to vary as a 
function of tissue slice thickness in the model. Unequal node spacing was used to reduce 
computation time and provide increased spatial resolution in tissues of interest (sclera, 
choroid).  
 















where Δxi-1, Δxi, and Δxi+1 are the widths of the (i-1)
th, ith, and (i+1)th nodes, respectively. 
In order to additionally account for unequal diffusion constants between nodes, we elected 













such that D1 and D2 represent the diffusivities between the i
th and (i+1)th or (i-1)th tissue 
slices, respectively. The resulting discretized first order derivative accounting for unequal 
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where the left and right sides of Eq (17) represents the continuous and discretized forms of 
the second order derivative, respectively. Substitution of Eqs (10, 11, 12, 13) into Eq (17) 
results in the final discretized form of Fick’s Second Law used in this study. Table 4 shows 
the Dirichlet boundary conditions chosen for each diffusing species used to satisfy Eq (17). 
5.3.6 Modeling Sensitizer Dimerization 
Photosensitizers are known to readily dimerize or form higher order aggregates[140,241–







where [𝑀] and [𝐷] are the monomer and dimer concentrations of the sensitizer, 
respectively. The concentration of monomer or dimer can be calculated as a function of the 
total sensitizer concentration that would occur if all molecules were in the monomer form, 
[𝑆], by substituting Eq (18) with the following equation for total concentration (based on 
stoichiometry): 
 [𝑆] = [𝑀] + 2[𝐷] (19)  
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5.3.7 Boundary Conditions and Initial Conditions 
Boundary conditions were defined at the leftmost and rightmost nodes which represented 
the anterior surface of the choroid and the posterior surface of the retrobulbar tissue, 
respectively (Table 4). The choroid and retrobulbar tissues were assumed to act as sinks 
for MB and singlet oxygen. Note, singlet oxygen was modelled as a diffusing species and 
therefore was modelled with boundary conditions identical to MB. Triplet oxygen was 
modelled with constant concentration source boundary conditions defined according to 
literature derived values (Table 16)[244]. Finally, light intensity was assumed to be 
constant entering the leftmost node to simulate a transpupillary beam of light used for 
photoexcitation of MB. 
Initial conditions were defined at the moment of retrobulbar injection of MB at which point 
photons from the light source were also first introduced (Table 5). MB concentration 
therefore was 0 M in the tissues and equal to the injection concentration in the reservoir. 
Light intensity was 0 mW/cm2. As a result of having no MB or light in the tissue at the 
initial state, initial concentrations of excited state species (singlet oxygen and triplet MB) 
were set to 0 M. The initial concentration of triplet oxygen was assumed to have a linear 
profile over the choroid, sclera, and tenon capsule with the values at each boundary equal 
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to those defined in Table 4. Concentration of triplet oxygen in the reservoir was assumed 
to be that of atmospheric oxygen. Initial concentrations of amino acids and melanin were 
derived from literature (see Table 12 for values used in this study and Table 19 and Table 
20 for values pertaining to other species).   
Table 4: Boundary conditions for MB scleral photocrosslinking. C is the concentration of 
a given species. CR and CL represent the specific literature derived values for triplet 
oxygen concentration at the right and left boundaries, respectively. I represents light 
intensity, and I0 represents the specific value of light source intensity incident on the 
retinal surface.  
Species 
 
Right BC Left BC Justification 
Sensitizer* 𝐶 = 0 𝐶 = 0 Right BC: The retrobulbar tissue is assumed to 
act as a perfect sink, clearing MB 
systemically**. 
Left BC: The anterior (left) boundary of the 
choroid is assumed to act as a perfect sink, 
clearing MB systemically. 
Triplet 
Oxygen† 
𝐶 = 𝐶𝐿 𝐶 = 𝐶𝑅 Right BC: The choroid provides continuous 
replenishment of oxygen due to its heavy 
vascularization 
Left BC: Heavily vascularized retrobulbar 
tissues supply oxygen to the posterior sclera 
Light  − 𝐼 = 𝐼0 Left BC: Light source intensity is constant  
 
* The boundary conditions for sensitizer applied to both ground state and triplet excited 
state species as well as for singlet oxygen.  
** We assumed the retrobulbar tissue is a perfect sink, though the extent of clearance is 
uncertain. Our experimental studies (Figure 25) support this assumption. 
† Triplet oxygen represents the form of oxygen most commonly found in the atmosphere 





Table 5: Initial conditions for MB scleral photocrosslinking. C is concentration of the 
respective species, C0 MB is the initial total concentration of MB molecules if each 
molecule were in the monomeric state, and CR and CL are the concentrations of triplet 
oxygen at the right and left boundaries, respectively, and C0 (AA) represents the specific 
value of a particular amino acid (denoted by AA). KD is the dimerization equilibrium 
constant of MB. XChoroid, XSclera and XTenon are the thicknesses of the choroid, sclera, and 
Tenon tissues, respectively. Finally, x is the distance through the tissue with x = 0 
defined at the left boundary and x equal to the sum of the tissue and reservoir layer 
thicknesses at the right boundary. 
Species 
 









Initial concentration in 
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𝑋𝑐ℎ𝑜𝑟𝑜𝑖𝑑 + 𝑋𝑠𝑐𝑙𝑒𝑟𝑎 + 𝑋𝑇𝑒𝑛𝑜𝑛
× 𝑥 The choroid and retrobulbar 








𝐶 = 𝐶0 (𝐴𝐴) AA concentration is constant 
throughout Tenon capsule, 
sclera, and choroid.  
 
 
5.3.8 Modeling Light Absorbance by Sensitizer 
Absorption of photons was modeled according to the Beer-Lambert Law: 
 𝑑𝐼
𝑑𝑥
= −𝐼𝐶𝜀 (22) 
where I is light intensity and 𝐶 and 𝜀 are the concentration and molar absorptivity of light-
absorbing species, respectively. Eq. (23) is applicable for species having known 
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concentration and molar absorptivity. Our model specifically accounts for light absorbance 
by monomeric MB, dimeric MB, melanin, and absorbance by the tissue. The Beer-Lambert 
Law accounting for these absorbers becomes:  
 𝑑𝐼
𝑑𝑥
= −𝐼𝐶𝑀𝜀𝑀 − 𝐼𝐶𝐷𝜀𝐷 − 𝐼𝐶𝑀𝑒𝑙𝜀𝑀𝑒𝑙 − 𝐼𝜇 (23) 
where 𝐶𝑀 and 𝜀𝑀 are the concentration and molar absorptivity of monomeric MB, 
respectively, 𝐶𝐷 and 𝜀𝐷 are the concentration and molar absorptivity of dimeric MB, 
respectively, 𝐶𝑀𝑒𝑙 and 𝜀𝑀𝑒𝑙 are the concentration and molar absorptivity of melanin, 
respectively, and 𝜇 is the linear attenuation coefficient of the tissue. To calculate the 







where 𝑝 is the number of photons, 𝐸 is the energy of a single photon which may be 















where 𝐴 is Avogadro’s number. The fraction of photons absorbed by MB at any finite 
segment was assumed to be equal to MB’s absorbance as a fraction of total absorbance of 









𝜀𝑀𝐶𝑖 + 𝜀𝐷𝐶𝑖 + 𝜀𝑀𝑒𝑙𝐶𝑖 + 𝜇
 (28) 
Therefore, by combining Eqs. (26) and (27), the rate of formation of triplet MB is:  













where 𝜙𝑇 is the triplet quantum yield. We assumed that absorbance of a photon by 
monomeric MB exclusively would result in a triplet state MB molecule. Absorbance of 
photons by dimeric MB was assumed to result in quenching without generation of a triplet 
excited state capable of generating singlet oxygen. 
The reduction in intensity of light passing through at a spatial segment, ∆𝐼𝑖, depends upon 
absorbance in each upstream segment in the beam path, which is transient due to diffusion 
of absorbing species. Therefore, the light intensity entering the 𝑖𝑡ℎ  segment, 𝛼𝑖, is given 
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by the product of the source light intensity, 𝐼𝑠𝑜𝑢𝑟𝑐𝑒, and the fraction of light absorbed in 
each upstream segment. We derive the value of ∆𝐼𝑖 by integrating the Beer-Lambert Law 












 𝐼 = 𝛼𝑖10
−(𝐶𝑀𝜀𝑀+𝐶𝐷𝜀𝐷+𝐶𝑀𝑒𝑙𝜀𝑀𝑒𝑙+𝜇)∆𝑥 (31) 





= 10−(𝐶𝑀𝜀𝑀+𝐶𝐷𝜀𝐷+𝐶𝑀𝑒𝑙𝜀𝑀𝑒𝑙+𝜇)∆𝑥 (32) 
Finally, the light intensity loss in a discrete spatial step (∆𝐼𝑖) is the product of all the 
upstream fractional absorbances and the intensity of light reaching the sclera, 𝐼𝑆𝑐𝑙. We 
define the direction of light propagation to be from the 𝑖 = 1𝑠𝑡 segment to the  𝑖 =
𝑛𝑡ℎsegment. 
 











The light intensity reaching the sclera may be expressed as a product of the source intensity, 
𝐼𝑆𝑜𝑢𝑟𝑐𝑒  and the fraction of light intensity attenuated by the choroid and RPE, 𝜙𝑅𝑃𝐸: 
 𝐼𝑆𝑐𝑙 = 𝜙𝑅𝑃𝐸𝐼𝑆𝑜𝑢𝑟𝑐𝑒 (35)  
Substituting Eq. (35) into Eq. (34)  gives: 
 





Finally, substitution of Eq. (36) into Eq. (29) gives: 

















5.3.9 Modeling Chemical Reaction Network 
MB is known to act as a type II photosensitizer[245]. Previous studies have indicated that 
histidine, tryptophan, tyrosine, and lysine are likely involved in crosslinks resulting from 
a type II sensitization process[98–100,246–248]. Therefore, the type II reaction scheme 
shown in begins with excitation of MB monomers and results in crosslinking of histidine, 
tryptophan, and tyrosine residues. Lysine was omitted since it is not known to 
significantly partake in photocrosslinking chemistry other than the crosslink 
formation[101]. Furthermore, since it exists in excess concentration of the other amino 
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acids, lysine is assumed to react stoichiometrically in the crosslink formation step (Table 
18 and Table 19). See Table 6 for nomenclature pertaining to chemical processes and 
reactions. Chemical processes and reactions are tabulated in Table 7, Table 8, Table 9, 
Table 10, and Table 11. Parameters used in the model are tabulated in Table 12. 
 
Table 6: Nomenclature for chemical processes/reactions. 
Species Nomenclature 
Sensitizer Monomer S 
Sensitizer Dimer SD 
Sensitizer Singlet 1S 
Sensitizer Triplet 3S 
Sensitizer Semiquinone SH. 
Reduced Sensitizer SH2 
Absorbed Photon λ 
Triplet Oxygen 3O2 
Singlet Oxygen 1O2 
Hydrogen Peroxide H2O2 
Amino Acid AA 
Amino Acid Radical AA. 
Oxidized Amino Acid AAOx (without crosslink) 
Crosslink Xlink 
Melanin Monomer Mel 





Figure 20: Reaction network for MB photocrosslinking computational model showing 
modeled species and reaction rates. MB monomer absorbs a photon of red light at 660 
nm, resulting in an excited molecule of MB (triplet state). The MB triplet may be 
quenched physically and returned to the ground state, or it may excite triplet oxygen to 
the singlet state. Singlet oxygen may be quenched physically, or it may react with amino 
acids including histidine (His), methionine (Met), tryptophan (Trp), or tyrosine (Tyr). 
Reactions with His, Trp, and Tyr result in crosslink formation. Singlet oxygen may also 










Table 7: Photoexcitation of sensitizer monomer to singlet and triplet states. 
Process Rate Constant Reaction Number 
𝑆 + 𝜆 →  𝑆 
1 → 𝑆3 ΦT (1) 
 
 
Table 8: Type I reaction scheme. 
Reactions/Processes Rate Constant Reaction Number 
𝑆 
3 + 𝐴𝐴 → 𝑆𝐻. + 𝐴𝐴. k1 (2) 
𝐴𝐴. + 𝑂2 
3 → 𝐴𝐴𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒 k2 (3) 
𝐴𝐴𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒 + 𝐴𝐴 → 𝑋𝑙𝑖𝑛𝑘 k3 (4) 
𝑆𝐻. + 𝑆𝐻. → 𝑆 + 𝑆𝐻2 k4 (5) 
𝑆𝐻2 + 𝑂2 → 𝑆 + 𝐻2𝑂2 k5 (6) 
 
 
Table 9 Type II chemical reaction scheme. 
Reactions/Processes Rate Constant Reaction Number 
𝑆 
3 + 𝑂2 
3 → 𝑆 + 𝑂2 
1  k6 (7) 
𝑂2 




Table 10: Non-productive pathways. 
Reactions/Processes Rate Constant Reaction Number 
𝑆 
3 → 𝑆 k8 (9) 
𝑆 
3 + 𝑆 → 2𝑆 k9 (10) 
𝑆 
3 + 𝑆𝐷 → 𝑆 + 𝑆𝐷 k10 (11) 
𝑆 
3 + 𝐴𝐴 → 𝑆 + 𝐴𝐴 k11 (12) 
𝐴𝐴. → 𝐴𝐴 k12 (13) 
𝑂2 
1 → 𝑂2 
3  k13 (14) 
𝑂2 
1 + 𝐴𝐴 → 𝑂2 
3 + 𝐴𝐴 k14 (15) 
𝑆 + 𝑂2 
1 → 𝑆 + 𝑂2 
3  k15 (16) 
𝑆𝐷 + 𝑂2 
1 →  𝑆𝐷 + 𝑂2 
3  k16 (17) 
𝑂2 
1 + 𝐴𝐴 → 𝐴𝐴𝑜𝑥 k17 (18) 
𝑀𝑒𝑙 + 𝑂2 
1  →  𝑀𝑒𝑙𝑂𝑥 k18 (19) 
        
 
Table 11: Sensitizer dimerization scheme. 
Reaction Rate Constant Reaction Number 
2𝑆 → 𝑆𝐷 k19 (20) 




Table 12 Model parameters. 
Symbol 
  
Description Riboflavin Methylene Blue 
t Treatment duration 1800 s 1800 s 
Isource Light intensity 3 mW cm-2 424 mW cm-2 
C0 S Injection concentration 2.2 mM (0.1%) 3 mM (0.094%) 
λ Light wavelength 365 nm 660 nm 
X(Tissue) Thickness of cornea See Table 17 See Table 17 
XInj 
Thickness of injection 
reservoir 
0 mm 1.3 mm* 
XRetro 




Left boundary 3O2 
concentration 
See Table 16 See Table 16 
CR Right boundary 3O2 See Table 16 See Table 16 
C0 (AA) Initial AA concentration See Table 18 See Table 19 
C0 Mel Initial melanin concentration See Table 20 See Table 12 
ΦLumen Luminal fraction of choroid N/A 0.4[249] 
DRes 
Diffusion constant, S in 
injection 
4.20 x 10-6 cm2 s-1 [250] 4.60 x 10-6 cm2 s-1 [251] 
DScl 
Diffusion constant, S in 
sclera 
4.60 x 10-7 cm2 s-1 [252] 3.16 x 10-7 cm2 s-1** 
DOx 
Diffusion constant, O2 in 
sclera 
4.00 x 10-6 cm2 s-1[236] 4.00 x 10-6 cm2 s-1[236] † 
Kd S dimerization constant 125 M-1 [139] 10665 M-1 [253] 
ΦFundus 
Fraction light reflected by 
RPE 
N/A 0.096 [254] 
μ 
Attenuation coefficient of 
tissue 
17 cm-1 [232] N/A 
εM Molar absorptivity of S 10800 M-1 cm-1 [139] 79800 M-1 cm-1 [76] 
εD Molar absorptivity of SD 6500 M-1 cm-1 [139] 35300 M-1 cm-1 [76] 
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εMel Molar absorptivity of melanin N/A 646 M-1 cm-1 [255] †† 
ΦT 
Sensitizer triplet quantum 
yield 
0.61 [256] 0.52 [163] 
k1 
Chemical quenching of 3S by 
AA 
His: 5.22 x 107 M-1 s-1[257] 
Met: 6.36 x 107 M-1 s1[257] 
Trp: 1.75 x 109 M-1 s-1[257] 
Tyr: 1.40 x 109 M-1 s-1[257] 
N/A 
k2 Peroxide formation 4 x 106 M-1 s-1[258] N/A 





k5 Oxidation of SH2 by O2 Neglected N/A 
k6 1O2 generation by 3S 1.62 x 109 M-1 s-1[259] 2.6 x 109 M-1 s-1 [260] 
k7 
Chemical quenching of 1O2 
by AA resulting in 
crosslinking 
His: 1 x 108 M-1 s-1[143] 
Met: 0 
Trp: 3 x 107 M-1 s-1[143] 
Tyr: 8 x 106 M-1 s-1[143] 
His: 1 x 108 M-1 s-1[143] 
Met: 0 
Trp: 3 x 107 M-1 s-1[143] 
Tyr: 8 x 106 M-1 s-1[143] 
k8 
Physical quenching of 3S by 
solvent 
4.9 x 103 s-1[261] 1.3 x 104 s-1 [72] ‡ 
k9 
Physical quenching of 3S by 
S 
1.2 x 108 M-1 s-1[261] 4.1 x 107 M-1 s-1 [262] 
k10 




Physical quenching of 3S by 
AA 
N/A 
His: 2 x 106 M-1 s-1[142] 
Met: 1 x 108 M-1 s-1[142] 
Trp: 6 x 108 M-1 s-1[142] 
Tyr: 0 M-1 s-1 
k12 AA radical termination 100 M-1 s-1[258] N/A 
k13 1O2 solvent quenching 2.56 x 105 s-1 [263] ‡ 2.56 x 105 s-1 [263] ‡ 
k14 
Physical quenching of 1O2 by 
AA 
His: 0 M-1 s-1 
Met: 0 M-1 s-1 
Trp: 2.1 x 107 M-1 s-1[143] 
Tyr: 2.7 x 107 M-1 s-1 
[264,265]‡‡ 
His: 0 M-1 s-1 
Met: 0 M-1 s-1 
Trp: 2.1 x 107 M-1 s-1[143] 
Tyr: 2.7 x 107 M-1 s-1 
[264,265]‡‡ 
k15 
Physical quenching of 1O2 by 
S 
0 § 3 x 108 M-1 s-1[266] 
k16 




Chemical quenching of AA 
by 1O2 resulting in oxidized 
AA 
His: 0 
Met: 1.6 x 107 M-1 s-1[143] 
Trp: 0 
Tyr: 0 
His: 1 x 108 M-1 s-1[143] 
Met: 1.6 x 107 M-1 s-1[143] 
Trp: 3 x 107 M-1 s-1[143] 
Tyr: 8 x 106 M-1 s-1[143] 
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k18 
Chemical quenching of 1O2 
by Mel 
1.34 x 108 M-1 s-1[267] 1.34 x 108 M-1 s-1[267] 
k19 Dimer formation 1.09 x 109 M-1 s-1[241] §§ 1.09 x 109 M-1 s-1[241] 
k20 Dimer dissociation k19 x Kd-1 k19 x Kd-1 
 
* See reservoir volume calculation in supplemental materials 
** Measured in this study  
† Assumed identical to oxygen diffusivity in cornea 
†† Assumes melanin monomer molecular weight of 200 Da as in [267]. 
‡ Calculated as inverse of lifetime 
‡‡ Bertolotti[264] cites Garcia[265] for Tyr 
§ Assumed insignificant compared to chemical quenching 




We developed a computational model with the primary objective of using it to describe 
photocrosslinking in the sclera. Because experimental data on scleral photocrosslinking 
are lacking in the literature, we are validating the model by comparing model predictions 
of photocrosslinking in the cornea, where a number of studies report experimental results. 
Model predictions in the sclera and cornea were performed using not fitted parameters. 
All parameters were independently obtained from the literature or calculated (see Table 
12). 
5.4.1 Prediction of Oxygen Concentration during Riboflavin Crosslinking Procedure in 
Porcine Eye 
As a first validation for model predictions, we assess the model’s ability to replicate the 
oxygen depletion and recovery measured under a 130-μm flap of deepithelialized corneal 
stroma in ex vivo porcine eyes undergoing riboflavin crosslinking (Figure 21) as reported 
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in Kamaev et al.[129].  In the experimental study, an oxygen probe was used to measure 
oxygen concentration under the corneal flap after the eye had been incubated in riboflavin 
and irradiated with UV light.  
In the experimental data, oxygen concentration decreased rapidly within the first 20 s to 
<1% of the initial concentration, maintained a steady low-level state until approximately 5 
min into the procedure, and increased to approximately 10% of the initial oxygen 
concentration at 30 min(Figure 21). This unusual triphasic behavior results from the 
complex interaction between penetration of light, diffusion of chemical species and 
kinetics of chemical reactions. This complex behavior seen experimentally provides a 
stringent test of our model’s ability to accurately capture the many interdependent 
processes taking place during photocrosslinking under these conditions.  
Model predictions matched the experimental data well, capturing all three phases of the 
process, and quantitatively matching the experimentally measured oxygen concentrations 
despite having no fitted parameters in the model (Figure 21). To explain the reasons for the 
three phases of the process, the model predicted that the initial depletion of oxygen was 
caused by reaction of triplet riboflavin (created by absorption of photons from the light 
source) to produce singlet oxygen, which in turn reacts with amino acids of collagen in the 
corneal stroma to create crosslinks. In the intermediate phase from 20 s to 5 min, 
uncrosslinked amino acids were being depleted due to reaction with singlet oxygen (type 
II reaction processes) or through type I reaction processes. The rise in oxygen concentration 
after 5 minutes was, in our model, due to the depletion of amino acids which, in the 
intermediate phase, had been consuming oxygen. We found that oxygen consumption per 
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type I reaction dynamics were necessary to reproduce the experimental data from Kamaev 
et al.  
 
Figure 21: Experimental data from Kamaev et al. 2012 (filled circles) showing oxygen 
concentration under a 130 𝜇m corneal flap in ex vivo porcine eyes during riboflavin 
crosslinking procedure. Computational model prediction for oxygen concentration (solid 
line) showing good agreement with the experimental data. No parameters were fitted in 
the model to produce this result. 
 
5.4.2 Prediction of Riboflavin Crosslinking Data in the Literature 
As a further test of our computational model, we predicted crosslinking in ex vivo porcine 
eyes according to the procedure in Hammer et al.[177]. We found reasonable agreement 
between our model’s crosslink utilization prediction and stiffening in the Hammer study 
using linear regression (Figure 22D). The regression slope of 0.46 percent increase in 
elastic modulus per percent crosslinks utilized differed statistically significantly from 0 (p 
< 0.05) with goodness of fit of R2 = 0.9976.  
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In a similar manner, we compared our model predictions for crosslinking against 
experimental evidence for riboflavin crosslinking violation of the Bunsen-Roscoe Law 
demonstrated by enzymatic degradation as studied by Aldahlawi et al.[237]. In this study, 
Aldahlawi et al. used similar experimental conditions as in the Hammer study, maintaining 
a constant fluence of 5.4 J/cm2 for riboflavin crosslinking experiments in porcine eyes 
using irradiation intensities of 3, 9, and 18 mW/cm2 for 30, 10, and 5 minutes, respectively. 
Our model agrees with the Aldahlawi study (Figure 22E) generally, though the regression 
slope is not statistically significant for rejecting the null hypothesis that the slope is 
different from 0 (p = 0.0875). The slope of the regression line is 0.0001895 grams dry 
weight collagen per percent crosslinks utilized.  
The Hammer and Aldahlawi studies were designed to determine whether riboflavin 
crosslinking in the cornea follows the Bunsen Roscoe Law, which states that the extent of 
crosslinking should directly correlate with the light fluence[268]. These experimental 
studies showed that this was not the case, since each study examined three different 
conditions with the same fluence, but different light intensity and duration, and found that 
the extent of crosslinking decreased as light intensity increased and exposure duration 
decreased at constant fluence. These data demonstrate that photocrosslinking depended 
more strongly on exposure duration and less strongly on light intensity. The trend of this 
complex interplay among these parameters was captured by model predictions, which helps 
validate is predictive power.  
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Figure 22: Correspondence of computational model predicted crosslinking with 
experimental crosslinking. A) Computational model prediction for riboflavin crosslinking 
with constant fluence (5.4 J/cm2) at different intensities. Open circles represent the 
computational model output at light intensities corresponding with those experimentally 
tested in Hammer et al. and Aldahlawi et al. B) Percentage stiffness increase in porcine 
corneas treated with riboflavin crosslinking procedure calculated from Hammer et al. 
2014. C) Porcine cornea dry weight at 12 days after riboflavin crosslinking and 
enzymatic digestion reproduced from Aldahlawi et al. 2015. D) Computational model 
data plotted against Hammer et al. data with linear regression showing reasonable 
agreement. E) Computational model predicted fraction of crosslinks utilized as a function 
of cornea dry weight after enzymatic degradation showing reasonable correspondence. 
 
5.4.3 Experimental Determination of MB Diffusion Constant in Rat Sclera 
 A critical parameter for model predictions is the diffusion constant of MB in the rat 
sclera. We determined this value by measuring MB diffusion across rat scleral samples ex 
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vivo (Figure 23A) and calculated a diffusivity of (3.16 ± 1.11) x 10-7 cm2/s from the steady-
state region of these data (Figure 23B). The average lag time (time from onset of diffusion 
to formation of steady state concentration profile and flux) was 45 ± 29 min.  
 
 
Figure 23: Determination of MB diffusion constant in Brown Norway rat sclerae ex vivo. 
Diffusion constant was determined by A) measuring cumulative mass of MB transported 
across a fixed surface area of tissue over time. The slope was set equal to MB flux. B) 
The value of the MB diffusion constant was computed from flux in the steady-state 
region of transport. Data points represent A) mean ± standard deviation (n=9 replicates) 
or B) independently calculated values, with mean and standard deviations shown. 
 
5.4.4 Experimental Determination of MB Concentration in Sclera 30 Minutes Post-
injection 
MB concentration measured 30 minutes after retrobulbar injection in anesthetized Brown 
Norway rats was significantly different than in the same tissue of the control HBSS-
injected eyes in all cases except for the scleral region >1.5 mm from the center of the ON 
(Figure 24) as measured by two-way ANOVA. Sample size was N = 5 in all cases except 
for the ON fat which was N = 3 due to error in sample collection for two rats. MB 
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concentrations represented as a fraction of the injected concentration were 6.8 ± 2.2% for 
0-0.5 mm (p < 0.001), 14.4 ± 2.0% for 0.5-1 mm (p < 0.0001), 13.7 ± 2.8% for 1-1.5 mm 
(p < 0.0001), and 1.1 ± 0.7% for >1.5 mm (p =0.97) distance from the ON center. 
Additionally, there were significant differences from control eyes in the MB concentrations 
in the ON and ON fat. MB concentration in the ON was 6.8 ± 2.7% (p < 0.0001) and in 
the ON fat was 26.2 ± 7.5% (p < 0.0001). Mean concentration for the control eyes was 
calculated based on the threshold for fluorescence detection.  
 
 
Figure 24: MB concentration in ocular tissues measured 30 min after retrobulbar injection 
in vivo. A) Diagram of scleral sections dissected from rat eyes. Injections were 
performed under anesthesia with Brown Norway rats euthanized 30 min after injection to 
replicate the experimental conditions used in scleral crosslinking. B) Average MB 
concentration measured in ocular tissues 30 min post injection. Mean concentration for 
the control eyes was calculated based on the threshold for fluorescence detection in cases 
where fluorescence was below this threshold. Data represent mean + standard deviation 
from 5 replicates in all cases except for the ON fat which had only 3 replicates due to 
error in sample collection for two rats. *** p < 0.001, **** p < 0.0001 by two-way 
ANOVA. 
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5.4.5 Prediction of the Effects of Sensitizer Diffusivity and Injection Volume on Sensitizer 
Concentration in Sclera 
Because sensitizers other than MB might be of interest, we predicted the concentration of 
sensitizer in the sclera 30 min post retrobulbar injection over a range of diffusion constant 
(1.00 x 10-8 – 9.5 x 10-6 cm2/s, Figure 25). Light intensity was entered as 0 mW/cm2 to 
capture sensitizer behavior in the absence of MB photodegradation. Interestingly, the 
model predicts that MB concentration goes through a maximum value. Intuitively, as 
diffusion coefficient increases, sensitizer concentration in the sclera increases as the 
sensitizer is able to diffuse into the sclera more quickly. After reaching a peak 
concentration at a sensitizer diffusivity of approximately 4.80 x 10-8 cm2/s, sensitizer 
concentration decreases with increasing diffusivity because by the 30 min time point, a 
significant amount of sensitizer will have diffused across the sclera and been cleared by 
the choroidal vasculature. Thus, optimization of scleral concentration of sensitizer depends 
on both sensitizer diffusivity and time. 
We also investigated the model’s predicted effects of injection volume on the concentration 
of MB in the sclera at the 30 min time point (Figure 27A). Over the range 3.2 to 320 μl, 
injection volume was represented as injection reservoir thickness, the 1D distance from the 
posterior Tenon capsule surface to the retrobulbar muscle cone tissues. Normalized MB 
concentration remaining in the sclera after 30 min ranged from 6.0 x 10-6% to 38.9% of the 
injection concentration. A notable inflection point in the logarithmically scaled curve at 
around 40 μl, below which point normalized MB concentration in the sclera is 
comparatively small. This is likely caused by MB dose reaching a quantity sufficient to 
attenuate the impact of MB clearance on injection reservoir concentration over the 30 min 
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time scale studied. At low injection volumes, the clearance rate has a stronger impact on 
reservoir concentration and therefore on the total MB remaining in the sclera after 30 min. 
  
 
Figure 25: Computational model prediction of average sensitizer concentration in sclera 
30 minutes after retrobulbar injection represented as a percentage of the injected 
concentration. The experimental value for MB concentration (Figure 24) and the 
corresponding experimental value for MB diffusion constant (Figure 23B) are shown (red 
datapoint). Error bars represent ± standard deviation. Simulations were performed with 
light source intensity at 0 mW/cm2 to isolate the diffusion/clearance kinetics from 
possible effects of photodegradation. 
 
5.4.6 Prediction of the Effects of MB Concentration, Light Intensity, and Inspired Oxygen 
on Crosslinking 
We next used the model to predict the desired outcome of scleral photocrosslinking as a 
function of three parameters over which we have experimental control: MB concentration, 
light intensity, and inspired oxygen concentration (Figure 26). Inspired oxygen at 100% 
produced approximately 6-fold more tissue crosslinking than did 21% inspired oxygen at 
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our standard conditions of 3 mM MB and 424 mW/cm2  light intensity (Figure 26A,B). 
Increasing light intensity corresponded with an increase in crosslinking in all cases, where 
crosslinking depended roughly on light intensity.  
For MB concentration, effects on crosslinking were more complicated. For example, we 
found that crosslinking was similar for 3 mM and 30 mM MB, independent of light 
intensity over the range studied at 100% inspired oxygen (Figure 26A). In contrast, for the 
21% inspired oxygen case, the 30 mM MB concentration underperforms the 3 mM MB 
concentration (Figure 26B). To better isolate the effects of MB concentration, we varied 
MB concentration, holding light source intensity constant at our standard value of 424 
mW/cm2 (Figure 26C,D). In this case, MB crosslinking efficiency is characterized by local 
maxima at approximately 8 mM (32% predicted crosslink utilization) with 100% inspired 
oxygen and at approximately 4.5 mM (6% predicted crosslink utilization) with 21% 
inspired oxygen. For reference, our standard experimental condition of 3 mM MB with 
100% inspired oxygen corresponds to a 30% predicted crosslink utilization, which is close 
to the maximum value. Competing effects of insufficient sensitizer at low concentrations 
and sensitizer self-quenching at higher concentrations likely explains the local maxima.  
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Figure 26: Computational model prediction of MB photocrosslinking efficiency as a 
function of MB concentration, light intensity, and inspired oxygen. Crosslinking as a 
function of light intensity and MB concentration was modeled at A) 100% and B) 21% 
inspired oxygen concentrations corresponding to isoflurane anesthesia with 100% oxygen 
and anesthesia with subject breathing atmospheric oxygen, respectively. Crosslinking is 
also shown as a function of MB concentration when light intensity was held constant 
(424 mW/cm2) for both C) 100% and D) 21% inspired oxygen. Data points represent the 
results of simulations performed at the indicated conditions. 
 
5.4.7 Prediction of Effects of Injection Reservoir Volume on Crosslinking Efficiency 
Injection volume and MB injection concentration were investigated together for their 
effects on crosslinking efficiency as they are two important experimenter-selected 
determinants of MB transport during a photocrosslinking procedure (Figure 27). A trade-
off was found where similar crosslinking efficiency occurs for 3 mM MB injections with 
larger reservoir volumes (>100 μl) and for 30 mM MB injections at lower reservoir 
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volumes (20-60 μl). Lower MB concentrations did not achieve the same levels of maximum 
crosslinking on the investigated reservoir volume range. Interestingly, 30 mM MB 
crosslinking became less efficient at large reservoir volumes, supporting the previous 
finding that efficiency as a function of concentration experiences a local maximum. The 
local maximum in Figure 27C for 30 mM MB suggests that crosslinking efficiency 
increases when the injection volume is sufficiently low to allow significant crosslinker 
clearance over the course of the procedure, thus decreasing the MB concentration to levels 
more amenable to crosslinking. 
 
 
Figure 27: Injection volume and concentration affect MB distribution and crosslinking. 
A) Normalized MB concentration in the sclera at 30 minutes post injection increases with 
injection volume but is not affected by concentration. B) At all concentrations studied 
except for 30 mM MB, increasing injection reservoir volume improved crosslinking 
efficiency. At 30 mM MB concentration, crosslinking efficiency had a local maximum at 
approximately 1 mm reservoir volume. Injection volume was represented in the model by 
assuming a constant scleral surface area and calculating the injection reservoir volume 
defined as the distance from the posterior Tenon capsule surface to the retrobulbar 
muscle cone tissues which bounded the MB injection reservoir created by the injection. 




5.4.8 Prediction of MB Concentration during Photocrosslinking 
A quasi-steady state profile was reached for MB monomers and dimers after approximately 
the first 3 minutes of diffusion in the sclera/choroid (Figure 28). Over time, MB 
concentration decreased due to clearance through the choroid and retrobulbar tissues. Our 
standard MB photocrosslinking procedure used a 3 mM MB injection at which 
concentration most MB exists as dimers. MB dimers in (Figure 28B) generally outnumber 
the monomers (Figure 28A) due to the large dimerization equilibrium constant. However, 
this effect is less pronounced near the anterior surface of the choroid where MB 
concentration is lower, thus favoring the monomer species. The negative concavity of the 
MB monomer concentration profile over tissue distance can be attributed to the 




Figure 28: A) Monomeric and B) dimeric MB concentrations over time and distance 
through the choroid and sclera reach a quasi-steady state equilibrium after approximately 
3 minutes from which time they decline due to choroidal and retrobulbar clearance. Note 
concentration is plotted with a family of curves describing logarithmically spaced time 
points. 
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5.4.9 Prediction of Light Intensity across Choroid and Sclera 
Light penetration through the tissue maintained a relatively steady state profile with the 
greatest intensity at the anterior choroid and diminishing quickly towards the posterior due 
absorbance both by melanin and MB (Figure 29). The MB photocrosslinking procedure 
used a source light intensity of 424 mW/cm2, though only approximately 82 mW/cm2 
penetrated the RPE to reach the choroid. Light absorbance was strongest in the heavily 
pigmented choroid with lesser contribution from the lightly pigmented sclera. MB 
diffusion was responsible for increased light absorbance in the sclera over time in a manner 
proportional to MB concentration. However, MB diffusion to the choroid had little effect 
on the choroidal light intensity profile, as absorbance by melanin greatly exceeded that of 
MB. The model suggests that only a small percentage of light entering the choroid 
participates in photocrosslinking reactions with the majority being absorbed by tissue. 
 




5.4.10 Prediction of Triplet Oxygen Concentration  
Oxygen concentration depleted rapidly in the first minute of crosslinking in the sclera and 
posterior choroid, reaching a quasi-steady state equilibrium in the anterior choroid between 
choroidal oxygen diffusion and consumption reactions (Figure 30). There was a slight 
recovery in the penetration depth of oxygen at later time points due to depletion of amino 
acids and melanin which participate in oxygen-consuming reactions. Rapid consumption 
in the choroid where light intensity was strongest resulted in a steep concentration gradient 
from anterior to posterior choroid. This steep concentration gradient drove oxygen flux to 
the site of crosslinking despite there being decreased concentrations of oxygen compared 
to the pre-irradiation state.  
 
 
Figure 30: Triplet oxygen concentration over space and time during MB 
photocrosslinking. Note, concentration is plotted with logarithmically spaced time from 0 
to 30 minutes. 
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5.4.11 Prediction of Amino Acid Concentration  
The amino acids His, Trp, Met, and Tyr were all partially depleted in the choroid/sclera 
during the simulation (Figure 31). All were assumed to have lower initial concentrations 
in the choroid due to the vascular lumen where collagen is absent. Amino acid 
concentrations depleted over time due to crosslinking (assumed in the underlying model 
reactions for His, Trp, and Tyr) and non-productive oxidation (Met). Depletion was most 
prevalent at later time points near the anterior choroidal surface for all residues. His and 
Trp showed depletion in the anterior sclera to a lesser extent than in the choroid, while 
scleral depletion was minimal for Met and Tyr. We attribute this difference to the higher 
reaction rates of His and Trp (but especially His) with singlet oxygen as well as their 
relatively lower concentrations compared to Met and Tyr. Similar attribution might be 
given for the observation that His depleted more gradually over time than did the other 
amino acids with relatively sharp depletions in the choroid.  
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Figure 31: Amino acid concentrations during MB photocrosslinking procedure for A) 
histidine, B) methionine, C) tryptophan, and D) tyrosine. 
 
5.4.12 Prediction of Melanin Concentration  
Melanin, the most concentrated of the singlet-oxygen quenching species, was depleted in 
a manner most similarly resembling His. It showed a gradual decline after approximately 
10 minutes which accelerated towards complete depletion after 20 minutes in the anterior 
choroid (Figure 32). Melanin has a similar singlet oxygen chemical quenching rate constant 
to His (1.34 x 10-8 M-1s-1 vs 1x 10-8 M-1s-1,   
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Table 12), perhaps explaining the earlier onset and more gradual decline compared to Met, 
Trp and Tyr which have significantly slower reaction rates. 
 
Figure 32: Melanin concentration as a function of space and time during MB 
photocrosslinking. 
 
5.4.13 Prediction of Singlet Oxygen, MB Triplets, and Cumulative Degraded MB 
Changes in singlet oxygen, MB triplet, and degraded MB concentrations reflect the degree 
of photochemical reaction quenching by amino acids and melanin. Increased 
concentrations of all three species were seen late in the simulated treatment after 25 minutes 
in the anterior choroid (Figure 33). The timing and location of their increase paralleled the 
depletion of amino acids and melanin (Figure 31 and Figure 32). Absence of significant 
quencher concentrations supported longer-lived singlet and triplet species. Comparing the 
concentration of singlet oxygen with that of cumulative degraded MB in the anterior 
choroid, we see that despite having a concentration less than 3 x 10-7 M, singlet oxygen 
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was responsible for production of approximately 2 x 10-4 M concentration of degraded MB 
molecules in the last 5 minutes of treatment. This comparison illustrates that oxygen 
concentration alone is not a satisfactory indicator of reaction mechanism or magnitude in 
photocrosslinking procedures. Rather, the rates of consumption and formation are of equal 
importance. One might therefore erroneously assume that the low concentrations of triplet 
or singlet oxygen in the tissues after the first 3 minutes of irradiation would signal an 
anaerobic crosslinking mechanism.  
 
Figure 33: A) Singlet oxygen, B) MB triplet, and C) cumulative degraded MB 
concentrations modeled as a function of space and time. 
 
5.4.14 Prediction of Scleral and Choroidal Crosslinking 
Cumulative average crosslink concentration in the choroid and sclera increased 
approximately linearly over the 30-minute procedure duration (Figure 34A), reaching a 
total average concentration of 10.5 mM. Crosslink distribution over tissue thickness 
showed a discontinuity at the sclera-choroid interface. This discontinuity was caused by 
the large relative difference in melanin concentration between the two tissues. Higher 
melanin concentrations in the choroid quench photocrosslinking reactions more strongly 
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than in the sclera. This quenching effect is offset by the relatively higher light intensity and 
oxygen concentration in the choroid, resulting in similar crosslink concentrations in both 
tissues. However, the crosslink distribution in the sclera is more uniform than in the choroid 
where crosslinks are predominately found at the anterior surface. 
 
Figure 34: A) Cumulative average crosslink concentration over time in the choroid and 
sclera with individual contributions from His, Trp, and Tyr, and B) crosslink 
concentration over time and space during MB photocrosslinking procedure. 
 
5.4.15 Sensitivity Analysis of MB Photocrosslinking Predictions 
Model parameters were each individually increased by 1% of their default value, and the 
resulting increase in crosslinking was quantified from the model output. Parameter 
sensitivity was ranked and parameters were identified according to their common 
characteristics as experimental properties, sensitizer properties, or tissue properties (Figure 
35). Experimental properties were those under the control of the experimenter and not 
related to the sensitizer or tissue such as irradiation duration. Sensitizer properties were 
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physical/chemical characteristics such as absorbance wavelength and triplet quantum yield. 
Tissue properties were those inherently linked to tissue such as amino acid concentrations.  
Sensitivity values are reported as a percentage change in crosslinking for the given 1% 
change in parameter value. Only choroid thickness sensitivity (-1.02%) was of greater 
magnitude than 1%, indicating that no single parameter had an inordinate impact on the 
model for the case in question. Tissue properties such as choroid thickness (-1.02%), scleral 
thickness (-0.64%), and melanin concentration (-0.52%) comprised all the parameters 
inversely related to crosslinking. The two leading parameters with which crosslinking was 
directly related were experimental properties – irradiation duration (0.79%) and choroid 
oxygen concentration (0.60%). Sensitizer properties of note included the reaction rate of 
MB with singlet oxygen (0.15%), absorbance wavelength (0.14%), triplet quantum yield 
(0.14%), and monomer molar absorptivity (0.11%), none of which were in the top 10 most 




Figure 35: Ranked sensitivities of model parameters categorized by property type for the 
default MB photocrosslinking procedure considered in this study. Only parameters 
having a 0.1% or greater magnitude sensitivity were included in this figure. Choroid 
thickness, irradiation duration, and scleral thickness are among the properties most 




5.5.1 Model Agreement with Riboflavin Studies 
The model’s prediction of data from experimental riboflavin studies in the literature 
provides evidence for satisfactory correspondence of its mathematical assumptions with 
reality. Good agreement was found for experimental oxygen concentration measurements 
in porcine corneas, which is notable because the complex triphasic behavior observed 
experimentally was reproduced by the model[129]. Additionally, the model also predicted 
relative crosslinking efficiencies observed in experimental studies in the pig eye ex vivo. It 
is interesting to note that these studies were designed to test non-conformity of riboflavin 
crosslinking with the Bunsen-Roscoe Law[177,237]. Parameters were chosen in the 
Hammer study to test the applicability of the Bunsen-Roscoe Law, which implies that the 
extent of crosslinking should be proportional to fluence rather than intensity or irradiation 
duration. It was found that the Bunsen-Roscoe Law is violated in riboflavin crosslinking 
in agreement with others[145]. Correspondence of our model with these studies captures 
an unexpected and well-characterized nonlinear dynamic characteristic of riboflavin 
crosslinking, the replication of which, was important for model validation.  
5.5.2 Effects of MB Concentration, Light Intensity, Inspired Oxygen Concentration, and 
MB Injection Volume on Crosslinking 
Our model results suggest that crosslinking is increased by increases in light intensity over 
the studied range of 0-424 mW/cm2 with a nonlinear relationship. However, the effect on 
crosslinking increase for increasing light intensities is also dependent on MB 
concentration, with 3 mM and 30 mM concentrations performing best of the four 
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concentrations modeled (0.03, 0.3 3, and 30 mM). Additionally, the model predicts that 
inspired oxygen concentration is important, as an increase from 21% to 100% inspired 
oxygen produced an approximately 6-fold increase in crosslinking. This finding agrees 
with the model sensitivity analysis which, though only investigating local sensitivities on 
the range of +1%, found choroidal oxygen concentration to be among the most sensitive 
parameters correlating positively with crosslinking. This finding suggests that procedures 
should be performed on subjects breathing elevated levels of oxygen (as safely permitted) 
rather than atmospheric oxygen. 
To elucidate effects of MB diffusion/clearance kinetics on crosslinking, we found 
nonlinear effects on crosslinking efficiency modeled as a function of MB concentration 
and injection volume. Similar crosslinking efficiencies found for 30 mM MB at 20-60 μl 
injection volumes and 3 mM MB at >100 μl injection volume suggest that an optimal MB 
dose exists as a balance between injection concentration and volume.  
5.5.3 Key Model Findings for MB Photocrosslinking as a Function of Space and Time 
Light intensity was found to be relatively unchanging in the choroid/sclera throughout the 
procedure. This corresponds with the findings that 1) most light attenuation occurs in the 
anterior choroid, and 2) MB (which absorbs photons) diffusion reaches a quasi-steady state 
linear profile between the injection reservoir and choroid, where the concentration near the 
choroid is relatively stable. MB concentration decreases over time due to clearance through 
the choroid and retrobulbar muscle cone. Crosslinking occurs at the anterior choroid and 
sclera, which is especially pronounced at later time points (after 20 min) and corresponds 
with a depletion of amino acids and melanin at that location. We believe crosslinking was 
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favored at the anterior choroid since at that location: 1) oxygen was supplied by the choroid 
(modeled as a constant-concentration Dirichlet boundary condition), 2) light intensity was 
highest, and 3) MB dimerization would be lower than at any other location since total MB 
concentration was lowest near the choroidal sink boundary condition. Increases in 
concentrations of reactive species (triplet MB and singlet oxygen) corresponded directly 
with amino acids and melanin depletion near the anterior choroid surface. 
Since MB was assumed not to partake in type I reactions, singlet oxygen generation was 
the only pathway for crosslinking. Despite experiencing lowered oxygen concentrations 
after the first 3 min of photocrosslinking, the sclera and choroid still sustained significant 
crosslinking. We believe this can be explained by formation of an equilibrium state 
whereby oxygen diffuses to the choroid/sclera over a steep concentration gradient. Over 
the steep gradient, oxygen is rapidly consumed by photochemical processes. While oxygen 
concentration is decreased due to its rapid depletion by photocrosslinking reactions, we 
propose that concentration is not indicative of crosslink mechanism or magnitude. Rather, 
we propose that oxygen flux is most important for crosslinking as it is ultimately 
responsible for the total mass of oxygen reaching the tissue over time. This hypothesis 
differs from that of Kamaev et al. who concluded that the low oxygen concentration 
observed in ex vivo porcine eyes during riboflavin crosslinking indicated dominance of 
oxygen-independent type I reactions. In contrast, our model predicts that the observed 
decrease in oxygen near the anterior surface of a photocrosslinking procedure may in fact 
be explained by the activity of oxygen-dependent photocrosslinking mechanisms.  
To our knowledge, our model is the first to incorporate individual concentrations of His, 
Trp, Met, and Tyr, which are the amino acids mainly responsible for crosslinking and 
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quenching reactions. Additionally, we included melanin in our model, as it has significant 
presence in the choroid/sclera, unlike in the cornea, during photocrosslinking. Modeling 
each of these species provided a level of detail into the relative importance of each and 
deviation in behavior. For example, we found that depletion of His and melanin occurs at 
a more gradual rate than for other species. We speculate that 1) this is due to their higher 
chemical quenching rate constants with singlet oxygen relative to the other species, and 2) 
His and melanin are the dominant quenchers of singlet oxygen in early stages of the 
procedure, and thus deplete slowly at first when singlet oxygen chemical quenching is 
lowest. Trp and Tyr on the other hand have the highest rates of physical quenching of 
singlet oxygen and Trp and Met have the highest rates of physical quenching of triplet MB. 
When singlet oxygen generation increases due to depletion of His and melanin, subsequent 
onset of Trp, Tyr, and Met depletion would have an accelerative effect on singlet oxygen 
generation as they constitute a negative feedback on singlet oxygen generation through 
physical quenching of reactive species.   
Relative contribution of each amino acid to crosslinking was found to occur in the ordering 
of His > Trp = Tyr where concentration of His crosslinks occurs at 3-fold higher 
concentration than either Trp or Tyr, which have approximately equal crosslink 
concentrations. The overall rate of crosslink formation was approximately linear over time 
for MB photocrosslinking, though a nonlinearity was found in the concentration of Trp-
related crosslinks at approximately 18 min where rapid depletion in the choroid 
corresponded with a temporary jump in crosslinking. 
 
 149 
5.5.4 Sensitivity Analysis for MB Photocrosslinking 
Current scleral photocrosslinking treatments for glaucoma and myopia are still in early 
stages of pre-clinical research. Our model provides insights to the key parameters that 
should receive attention in designing future experiments to optimize crosslinking. Based 
on our sensitivity analysis, these include parameters linked closely to oxygen penetration 
(such as oxygen concentration in the choroid and oxygen diffusion constant in tissue) and 
light propagation (including melanin concentration in the choroid and melanin molar 
absorptivity). Of the top ten most sensitive parameters, eight were tissue properties and 
two were properties which can be controlled by the experimenter (irradiation duration and 
choroid oxygen concentration). However, since 100% inspired oxygen concentration was 
used in this calculation, it is unlikely that increasing the latter would be a feasible option. 
The strong representation of tissue properties in our sensitivity analysis suggests that much 
of the photocrosslinking success would depend on species studied or even individual-to-
individual variation. Future studies may attempt even to use this information to develop 
more creative crosslinking procedure designs.  
An unexpected finding of the MB photocrosslinking procedure sensitivity analysis was the 
relatively low sensitivity of sensitizer parameters. A 1% increase in sensitizer triplet 
quantum yield, for example, only produced a 0.14% increase in crosslinking. An 
uninformed assumption would reasonably have been that triplet quantum yield should be 
directly proportional to crosslinking on a one-to-one basis given it is a necessary step in 
crosslink formation. However, in light of studies for riboflavin crosslinking indicating 
violation of the Bunsen-Roscoe Law in that case, such non-linearities should not, perhaps, 
be surprising. We concluded that over the range of MB photocrosslinking parameters 
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studied, local optimization of sensitizer properties would likely not be an efficient path 
towards crosslinking optimization, contrary to our expectations. In this case, efforts would 
be better spent increasing treatment duration and possibly investigating new avenues of 
modifying intrinsic tissue properties and reactive sites.  
5.5.5 Oxygen Supply Influences Photocrosslinking 
Oxygen supply strongly affects scleral photocrosslinking in our model. Corneal 
crosslinking with riboflavin has been shown to be dependent upon oxygen 
availability[177]. Furthermore, it is known that the Bunsen-Roscoe Law is violated in 
riboflavin corneal crosslinking, suggesting that light dose is not solely responsible for 
crosslinking efficiency[145,177,237]. Instead, it points to the involvement of oxygen in the 
photochemical processes leading to crosslink generation. We proposed in our model that 
type I crosslink formation is predominately mediated by a two-step process described in 
literature: 1) radical formation on aromatic amino acids (we included histidine, tryptophan, 
and tyrosine), and 2) oxygen reaction with amino acid radicals to form a peroxide 
intermediate through which subsequent crosslink reactions may occur[258,269]. Since 
both type I and type II pathways are dependent on oxygen in our fundamental assumptions, 
our model agrees with Richoz et al. who found that under anaerobic conditions, corneas do 
not stiffen compared to controls[270].  
Recognizing that the pathway for type I-mediated crosslink formation is well under 
investigation, we anticipate future revision may be needed for the model’s type I reaction 
scheme. Nonetheless, we found good agreement for this scheme with the Kamaev et al. 
study elucidating oxygen concentration dynamics in ex vivo porcine eyes[236]. That study, 
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however, concluded that oxygen would not contribute to crosslinking after a rapid initial 
depletion. Our model shows the possibility that in fact, oxygen may be involved at all 
stages of the irradiation process, despite the observed changes in concentration. Previously 
it was suggested that low oxygen concentrations in the cornea during photocrosslinking 
indicated that an oxygen-independent mechanism was responsible for much of the 
crosslink formation. However, it is possible that concentration may be low, but flux may 
be high where oxygen participates in crosslinks in equilibrium with the rate of mass 
transfer, resulting in a steady and significant flux of oxygen to the reaction site, but low 
concentration.  
5.5.6 Data Representation Continuously over Space and Time 
In addition to the figures presented in this chapter showing the evolution of each modelled 
species over space and time, Appendix C contains corresponding heatmap figures for 
alternative visualization of these data (see Figure 49, Figure 50, Figure 51, Figure 52, and 
Figure 53). The MATLAB code used to generate the data in this chapter is included in 
Appendix D.  
5.5.7 Model Limitations 
While the model is intended to be comprehensive in its scope of physiological and physical 
factors considered, it not without limitations. First, the model is limited by the experimental 
accuracy of underlying parameters. For example, it is not uncommon to find large variation 
in reported literature values for reaction rate constants which could result in inaccurate 
model results, especially if compounded over many parameters. Interestingly, despite the 
presence of many reaction rate constants in the model, only two were among the most 
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sensitive parameters in our MB photocrosslinking sensitivity analysis (quenching of triplet 
MB by triplet oxygen and chemical quenching of His by singlet oxygen). Additionally, 
natural variation in tissue properties such as melanin concentration, tissue thicknesses, etc. 
may result in different experimental crosslinking outcomes in different people. Finally, 
certain assumptions were required due to the complexities of the posterior scleral 
environment and availability of known values. For example, we assumed the absence of 
sensitizer-melanin and sensitizer-collagen binding interactions which are, nonetheless, 
known to occur in the sclera/collagen[271,272]. Additionally, we assumed a 1-dimensional 
injection reservoir which can be explained as having thickness equal to the “average” 
thickness. In reality, the reservoir would likely take the shape of the muscle cone which is 
difficult to predict or model.  
In the case of sensitizer binding to substrate, multiple uncertainties exist. Binding would 
slow diffusion in the early stage of the treatment when the binding sites have not been fully 
saturated. Furthermore, binding would both directly quench excited state sensitizer 
molecules and promote aggregation which would magnify the quenching effect further. On 
the other hand, triplet state sensitizer interaction with collagen might enhance type I 
interactions if present. Interestingly, high melanin content of the choroid/RPE may serve 
as a natural barrier to sensitizer diffusion to the retina, thus reducing the risk of light-
activated sensitizer phototoxicity in the retina. 
Perhaps the most important limitation of the computational model is its inability to directly 
calculate changes in tissue mechanical stiffness but instead rely on crosslink utilization or 
density as a surrogate. Previous studies have characterized the crosslink density-stiffness 
relationship in collagen fibers and in low-modulus gels, but not in collagenous materials 
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similar to the cornea/sclera[149,150]. While they likely correlate positively, the nature of 
the relationship has not been, to our knowledge, characterized for collagen hydrogels of 
similar density and structure to those of the sclera or cornea. A highly non-linear 
relationship between crosslinking and elastic modulus would have a significant impact on 
the conclusions drawn for crosslinker performance. Though the magnitude of stiffening 
corresponding to changes in crosslinking procedure may not be exactly determined, the 
model yet provides useful information in the binary sense of increasing or decreasing 
crosslinking for comparison to a reference procedure. 
5.5.8 Future Applications 
Our model is useful for simulating photocrosslinking in a variety of potential scenarios. It 
makes use of common sensitizer parameters such as triplet quantum yield and molar 
absorptivity, as well as common reaction schemes such as the type I/II pathways, allowing 
different sensitizers to be compared to one another. Furthermore, it can be applied to 
multiple animal species with replacement of appropriate tissue properties. Finally, the 
model can be extended to retrobulbar, sub-Tenon, suprachoroidal, and topical sensitizer 
delivery methods, all of which may be useful for future scleral photocrosslinking 
applications. 
This study, in addition to providing a mathematical scheme consistent with experimental 
data, presents a consolidated list of literature parameters for sensitizer and tissue properties 
relevant for photocrosslinker modeling. Therefore, it is intended to serve as an aggregation 
of literature references for others seeking to model photocrosslinking in biological tissues. 
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While many parameters were collected directly from literature, others such as amino acid 
concentrations were derived from primary sources and may be useful in future studies.   
While many model input parameters are available for MB and riboflavin, less studied 
photosensitizers will require further fundamental research to elucidate these values[273]. 
Until then, reasonable estimates can be made using sensitivity analyses to assess the effect 
of such estimates. Future experimental studies elucidating the relationship between 
crosslinking and stiffness in the sclera and cornea will be of interest for improved 
predictive computational modeling for guiding expansion of research to new features such 
as emerging sensitizer molecules. Furthermore, future photocrosslinking studies 
paralleling those of the corneal crosslinking literature will be needed to validate the model 
in the case of significant effects from uncertainties such as melanin concentration and drug-
melanin interactions. 
5.6 Conclusion 
In this study, we developed a posterior scleral photocrosslinking model for sensitizer 
excitation using a transpupillary light beam. The computational model was first validated 
against existing experimental data for riboflavin corneal crosslinking and subsequently for 
posterior photocrosslinking using MB sensitizer and tissue parameters from literature. 
Notably, all model predictions were made using no fitted parameters; all parameters were 
determined experimentally or from the literature. Light intensity and sensitizer, oxygen, 
melanin, and amino acid concentrations were modeled over space and time. 
A sensitivity analysis of all model parameters revealed that MB scleral photocrosslinking 
was most sensitive to choroid thickness, irradiation duration, scleral thickness, choroid 
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oxygen concentration, diffusion constant of oxygen in the sclera, and choroid melanin 
content, which are parameters closely related to oxygen supply and light penetration, as 
these appear to be the rate-limiting components of photocrosslinking under the conditions 
used. Among these parameters, irradiation duration (limited by safety concerns) and 
choroid oxygen concentration (which cannot exceed that of 100% oxygen saturation in the 
blood) are to some extent controlled by experimental conditions, whereas the other 
parameters represent tissue properties that cannot be easily changed. 
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CHAPTER 6. DISCUSSION 
6.1 Targeted Scleral Photocrosslinking using MB 
Glaucoma is a leading cause of blindness and is thought to be associated with 
biomechanical properties of the sclera. We have demonstrated for the first time that 
transpupillary targeted photocrosslinking is feasible on the millimeter scale to stiffen 
posterior ocular tissues. While toxicity was found for MB photocrosslinking, considering 
the proximity of the target peripapillary sclera to both the sensitive optic nerve and retinal 
tissues and known toxicity of photosensitizers in general, we consider the results to be a 
promising starting point for future treatment optimization. Desirable criteria selected for 
development of a transpupillary targeted photocrosslinking approach were: 
1. Delivery strategy for introducing sensitizer to posterior sclera 
2. Photosensitizer absorbing in the phototherapeutic window (~650-800 nm) 
3. Efficient sensitizer production of crosslinks 
4. Light intensities which are non-toxic to the retina 
5. Sensitizer dark toxicity not damaging to optic nerve and retina 
6.1.1 Selection of Retrobulbar Injection as Drug Delivery Strategy 
After considering possible sensitizer delivery strategies including retrobulbar injection, 
sub-Tenon injection, suprachoroidal injection, and subconjunctival injection, we elected to 
use retrobulbar injections. Compared to sub-Tenon and suprachoroidal injections, 
retrobulbar and sub-conjunctival injections are far easier to execute without specialized 
equipment. Retrobulbar injection was chosen over sub-conjunctival injection as we believe 
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it more efficiently localizes the injection to the posterior sclera, though we have not 
performed a comparison study. A retrobulbar injection was chosen for these reasons, with 
an added reason that retrobulbar injection is routinely used in the clinic, thus aiding future 
clinical translation of the treatment.  
6.1.2 Selection of MB as Photocrosslinker 
Our selection of methylene blue as the photocrosslinker for our studies was made with 
consideration of its ease of handling (solubility), a substantial body of existing research on 
its photophysical properties and other clinical applications, its low cost, its absorbance in 
the phototherapeutic window (at 665nm), and its reasonable triplet quantum yield 
efficiency (0.54). Other sensitizers considered were rose bengal, chlorins, porphyrins, and 
phthalocyanines. However, those most amenable to crosslinking were often difficult to 
access due to expense or lack of general availability. In our studies, we elected to use MB 
concentrations similar to those of the existing riboflavin crosslinking procedure. 
6.1.3 Light Intensity Selection/Toxicity and MB Dark Toxicity 
We used a light intensity exceeding the maximum permissible intensity safety threshold 
(for humans), reasoning that localized damage at a small beam spot would be a necessary 
tradeoff for protection of the greater visual acuity preserved through protection against 
glaucomatous damage. Ultimately, we did not see this protective effect in our 
glaucomatous rat studies, but we also did not see any evidence for retinal damage from 
light alone despite exceeding the intensity limits. We believe there is room for future 
treatment parameter optimization to lower the light intensity if harmful effects are 
discovered in the future. 
 158 
Finally, we note that we did not study dark toxicity of MB in the retina or optic nerve 
explicitly. However, we believe MB alone was not toxic to the retina based on comparisons 
of histological sections in MB-injected eyes near the ONH and at more peripheral retinal 
regions. Peripheral regions did not show damage in contrast to the retina adjacent to the 
optic nerve where both MB and light were present. MB dark toxicity in the optic nerve is 
possible, especially since we found preferential accumulation of MB in the ON compared 
to sclera. 
6.1.4 Significance of Establishing Experimental Photocrosslinking Protocol 
Our experimental findings for targeted scleral photocrosslinking were significant not only 
for the demonstrated strain reduction effect, but also for the contribution of the targeted 
photocrosslinking methodology to the field. We constructed a microscope to 
simultaneously image the rat fundus and project an annular beam of prescribed dimensions 
around the ONH. This microscope utilized incoherent light at 660 nm near the peak 
absorbance of MB. It was mounted on a three-axis micropositioner stage for fine spatial 
targeting, and beam propagation through the cornea was facilitated by a commercially 
available refraction-negating contact lens. Future studies may be conducted using this 
methodology with various sensitizers by simply replacing the light source with one 
matching the sensitizer peak absorbance wavelength. Additionally, beam size may be 
adjusted to suit the needs of alternative localized crosslinking strategies or peripapillary 




6.2 Targeted Scleral Stiffening Effects on Glaucomatous Rats 
Having tested the effects of targeted peripapillary scleral crosslinking in glaucomatous  
rats, we believe there is not a significant worsening of glaucomatous effects due to 
crosslinking as was found by Kimball et al.[5]. Included in our studies were morphological 
and functional investigations of glaucomatous effects including axon count/density, retinal 
thickness, eye size, resolved spatial frequency, resolved contrast sensitivity, pSTR 
amplitude, nSTR amplitude, b-wave amplitude, and oscillatory potential amplitude. 
6.2.1 Potential Confounding Variable of Treatment Toxicity 
Though we could not conclude that stiffening improved glaucomatous outcomes 
definitively, we have reasons to believe that future studies may be adapted to better test 
this hypothesis. For example, it is possible that protective effects of MB photocrosslinking 
were present but negated by the treatment toxicity. Therefore, reduction of treatment 
toxicity alone may yield positive results. Additionally, we recognized over the course of 
the study major limitations of the commonly used rat microbead model of glaucoma.  
6.2.2 Microbead Rat Model Limitations 
Our study, while thorough in scope of morphological and functional measurements, had 
some limitations worth noting that impact on conclusions and future directions. In our 
study, IOP increases one to three days after microbead injection saw pressure levels 
approaching that of ischemic conditions. These pressures then often dropped after three to 
five days, sometimes to values even below those indicating ocular hypertension. Signs of 
inflammation or ocular trauma were sometimes observed at 1-5 days post injection, 
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including redness of the cornea/limbus, cloudiness of the cornea/lens, and fluid discharge 
from the site of intracameral injection. We speculate from these observations that 
microbead-induced damage observed may have been in part caused by a temporarily 
activated inflammatory state of the eye. Such a state could have induced morphological 
and functional damage superseding that of ocular hypertension alone. If in fact the effects 
of such damage superseded those due to ocular hypertension alone, then our study would 
not have primarily measured the scleral stiffening treatment effects for the intended disease 
conditions. The implications of this possibility are 1) that stiffening may have protected 
against ocular hypertension-induced damage, but we may not have resolved the effects, 
and 2) that a more carefully controlled animal model is needed for future glaucoma 
research.  Additional studies testing axon loss in rats treated with microbeads alone (where 
ocular hypertension does not result) may be used to adjust the axon count data reported in 
our studies. While this analysis technique does not allow for direct comparisons of axon 
loss in a contralateral control eye as in a paired design, it may reveal protective effects of 
crosslinking which were otherwise obscured by the microbead treatment.   
6.2.3 Study Duration Limitations 
Our study duration was limited to 14 days due to the frequent return of IOP to baseline by 
that time, indicating the microbead model was unable to sustain long-term ocular 
hypertension matching that of clinical glaucoma. It is possible that for rats having low but 
sustained IOP burdens tested for longer time scales, morphological and functional 
outcomes may have differed from the observations seen on the two-week time scale. Given 
that our MB photocrosslinking strain reduction effect was measured up to 6 weeks, the 
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stiffening treatment may be readily tested should an improved long-duration ocular 
hypertension animal model replace the microbead model. 
6.2.4 Clinical and Research Impact of Microbead Study 
From a clinical perspective, our microbead rat study does not support immediate 
investigation of photocrosslinking treatments for clinical translation. However, we are 
optimistic that stiffening treatments may find positive results in future studies with 
modified animal models where glaucomatous damage can be more precisely controlled. 
From a preclinical research perspective, this study provides a wealth of information against 
which future studies may be compared. For example, it contains control data for 
mechanical, ERG, OMR, OCT, eye size, and axon counts. It also contains baseline values 
in some cases for the effects of treatment parameters prior to crosslinking (as in the case of 
OMR).  
6.3 Computational Model for Scleral Photocrosslinking 
Having developed a computational model simulating corneal and scleral 
photocrosslinking, we discovered insights relevant to optimization of future MB 
crosslinking procedures. Additionally, we have demonstrated that a theoretical basis may 
be established to help explain existing photocrosslinking observations in riboflavin corneal 
photocrosslinking. This study expands an existing body of research traditionally focused 




6.3.1 Photocrosslinking Dynamics Insights Relevant for Riboflavin Crosslinking 
Though applied to a different sensitizer and tissue scenario than riboflavin crosslinking, 
the MB photocrosslinking simulation suggests that previous conclusions drawn for 
riboflavin crosslinking may require additional investigation. It has been suggested that 
oxygen-independent type I reactions must dominate in the low oxygen concentration 
environment observed in riboflavin crosslinking [236]. Our simulation, however, 
demonstrates that oxygen depletion may occur with continued oxygen-dependent 
crosslinking taking place despite low oxygen concentrations. We believe this phenomenon 
can be explained by the ever-present flux of oxygen over the steep concentration gradient 
in the anterior surface of the tissue undergoing crosslinking (choroid/sclera in the MB 
case). This finding has bearing on the ongoing discussion of whether type I or type II 
processes dominate riboflavin crosslinking. 
6.3.2 Elucidation of MB Diffusion and Clearance Kinetics in Retrobulbar Tissue 
Model development required accurate simulation of transport properties of MB in the 
retrobulbar tissue. Our experimental studies measuring the MB diffusion constant and 
concentration in the sclera 30 minutes post-injection not only enable the combined 
photocrosslinking model, but in themselves are useful for understanding retrobulbar 
transport of a small molecule. The complete photocrosslinking model is effectively 
comprised of three modules – the first encompassing light propagation/absorbance, the 
second encompassing chemical reactions, and the third encompassing transport phenomena 
(diffusion and clearance). The latter, describing retrobulbar transport phenomena, is itself 
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a useful tool even separate from the combined model for studying retrobulbar drug 
delivery.  
6.3.3 MB Photocrosslinking Dynamics Affected by MB Concentration  
After simulating our experimental MB photocrosslinking parameters with the 
computational model, we found a number of interesting results which have bearing on 
future treatment optimization. First, the finding that a local maximum in crosslinking 
efficiency exists as a function of sensitizer concentration is important for understanding 
photocrosslinking dynamics and practically for enhancing crosslink formation. We believe 
this maximum is likely caused by insufficient molecules for crosslinking at low 
concentrations and either dimerization, excessive light absorbance, or excessive oxygen 
consumption at high concentrations. Injection reservoir volume and MB concentration 
jointly determine total dose. Injection volume may be used to accommodate various 
sensitizer concentrations as the two appear to jointly influence crosslinking above 3 mM 
MB concentration. 
6.3.4 MB Photocrosslinking Dynamics Affected by Oxygen Concentration  
Oxygen concentration was found to have a substantial impact on crosslinking. Future 
studies should aim to supply oxygen to the sclera/choroid either through increased 
inspiration concentration or other means. For example, perhaps addition of oxygen 
generating species in the injection solution should be considered to enhance crosslinking. 
This strategy would require careful consideration as evolution of gasses within the tissue 
could have problematic consequences. Another possibility is injection of oxygen through 
a syringe to the retrobulbar space. In riboflavin crosslinking, the oxygen supply is naturally 
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higher than that of the interior tissues due to direct atmospheric exposure of the cornea. In 
the retrobulbar injection case, however, it is still possible to have a gaseous interface from 
which oxygen may be dissolved and diffused into tissue. We believe this approach would 
be safe, provided localized hyperoxia does not present toxicity issues.  
6.3.5 MB Photocrosslinking Dynamics Affected by Light Intensity  
Increased light intensities were found to improve crosslinking. Interestingly, for riboflavin 
crosslinking, this is not the case, and though MB photocrosslinking behaves differently, 
the effect of increasing intensity is still highly nonlinear, suggesting complex involvement 
of other processes such as oxygen diffusion. Longer wavelength excitation sources should 
improve crosslinking efficiency due to decreased absorbance by melanin and increased 
number of photons for a given fluence. The finding that MB photocrosslinking does not 
violate the Bunsen-Roscoe Law in the same way as does riboflavin crosslinking is an 
important finding which perhaps reflects the differences between type I and type II 
photosensitization processes.  
6.3.6 MB Photocrosslinking Sensitivity Analysis 
Finally, our sensitivity analysis revealed parameters of greatest importance for local 
parameter optimization in our MB photocrosslinking procedure. That tissue properties 
comprised eight out of the ten most sensitive parameters is an interesting finding which 
may have ramifications on studies conducted across various species. The two most 
sensitive parameters positively correlated with crosslinking were treatment duration and 
oxygen concentration in the choroid. We are optimistic that alternative strategies to 
improve crosslinking may be employed to enhance oxygen concentration at the site of 
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crosslinking. Perhaps unexpectedly, changes in sensitizer properties had relatively little 
impact on the magnitude of crosslinking. This may be encouraging as it perhaps opens the 
possibility to using less efficient sensitizers with more favorable toxicity profiles or other 
desirable properties. On the other hand, it indicates that improvement of crosslinking would 
need to come through other strategies. Naturally, the sensitivity analysis is relevant only to 
the specific parameters considered for our MB photocrosslinking treatment, and thus the 
results may vary under other combinations of default parameters. 
6.3.7 Extrapolation to Larger Eyes Based on Sensitivity Analysis 
The fact that choroid and scleral thicknesses were the two strongest negative correlates 
with crosslinking suggests that perhaps the transpupillary photocrosslinking approach will 
be less effective in larger eyes, though the sensitivity analysis should only be interpreted 
to the +1% parameter deviations analyzed. Should scaling to larger eyes prove to be 
difficult in future studies, transpupillary photocrosslinking may need to be enhanced with 
previously unexplored means. Perhaps crosslinking duration, for example, would need to 
be improved in a creative fashion harnessing natural light or other artificial sources over 
extended durations. Nonetheless, we reserve judgement on crosslinking efficiency in larger 
eyes until we have completed a future sensitivity analysis.  
6.3.8 Model Limitations and Assumptions 
Our model assumed a 1-dimensional spatial domain representative of a tissue cross-section 
in the peripapillary region where photocrosslinking would take place. The 1-dimensional 
assumption is inferior to a 2 or 3-dimensional assumption as a 1-dimensional model would 
not account for certain changes over more complex spatial domains. Parameters for which 
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inhomogeneous spatial distribution would be expected in such cases include light intensity 
and concentration of diffusing species. For example, light scattering was neglected in the 
model, but is likely to have resulted in decreased light intensities near the perimeter of the 
irradiated annular region. Photons entering the fundus near the perimeter may be scattered 
away from the peripapillary sclera, thus not inducing crosslinking. Additionally, oxygen 
concentration in the choroidal blood supply may become depleted differentially over the 
surface of the fundus. This may occur if MB present in the bloodstream becomes activated 
by incident light, thus consuming oxygen in photochemical processes within the blood 
vessels.  
The model includes several assumptions used to bridge gaps in available literature 
information, decrease computational expense, and/or focus on experimental circumstances 
of interest. Specifically, we: 
1. Neglected substrate-sensitizer binding interactions which could have increased 
quenching of sensitizer triplets 
2. Neglected higher order aggregation of sensitizer molecules in favor of simpler 
monomer-dimer model 
3. Assumed similar kinetics (but not equilibrium state) of sensitizer binding for 
riboflavin as for MB 
4. Assumed constant oxygen concentration in the choroid and retrobulbar tissue 
source conditions 
5. Assumed perfect clearance of sensitizer at the choroid and retrobulbar tissues 
6. Assumed the distance to clearance boundary condition in the retrobulbar 
muscles was equal to the thickness of the choroid 
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7. Assumed homogeneous distributions of the amino acids and melanin  
8. Assumed 100% of collagen was type I collagen 
9. Approximated injection reservoir layer thickness using an estimate for muscle 
cone geometry 
10. Neglected reaction of His, Trp, and Tyr residues with one another, instead 
assuming each reacted stoichiometrically with lysine which exists in excess 
concentration compared to these three 
11. Neglected non-productive oxidation products of His, Trp, and Tyr residues after 
chemical reaction with singlet oxygen 
12. Neglected kinetics and quenching of the singlet sensitizer, instead using triplet 
quantum yield to convert absorbed photons to triplet excited state species 
13. Assumed irradiation began instantaneously after injection, not accounting for 
the experimental lag time between injection and application of light 
14. The melanin concentration in the sclera was back calculated from melanin 
molar absorptivity and the approximate percentage of light known to penetrate 
the fundus 
These assumptions, while numerous, were necessary to approximate the complex 
photosensitization processes in vivo. Future studies will be needed to eliminate some 
assumptions where information is lacking in the literature. Our model sensitivity analysis 
showed that the most sensitive parameters were not among those affected by these 
assumptions. However, that analysis assessed local sensitivities, and it does not therefore 
inform an investigator of changes in model outcomes with drastic changes in underlying 
assumptions. 
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CHAPTER 7. CONCLUSIONS 
7.1 Targeted Scleral Photocrosslinking using MB 
7.1.1 Targeted Peripapillary Stiffening Achieved in Rats 
Our study is a proof of concept illustrating that MB photocrosslinking reduces scleral strain 
by as much as 56% at 6 weeks after treatment compared to untreated controls when excited 
with a transpupillary light source. Furthermore, stiffening was targeted to the peripapillary 
sclera, which we defined as the annular region having 2 mm outer diameter and 1 mm inner 
diameter centered on the optic nerve in the rat eye. To achieve targeted stiffening, we 
constructed a microscope capable of simultaneously projecting an annular beam onto the 
fundus while viewing the beam spot. Compared to the peripheral region of the treated eye, 
MB photocrosslinking reduced strain by as much as 47% in the peripapillary region 
compared to the peripheral region. Selective peripapillary crosslinking was therefore 
confirmed as successful using this approach.  
7.1.2 Toxicity Characterization 
Additionally, photocrosslinking procedure toxicity was characterized and found to have 
statistically significant effects on axon loss and retinal function. Axon count was decreased 
by 24% in rats receiving photocrosslinking treatment and ERG function was decreased 
with respect to pSTR amplitude, A-wave amplitude, B-wave amplitude, and PhNR 
amplitude. Damage was found to be localized to regions where both MB and light were 
present as indicated by histology. Light alone did not produce any visible damage in retinal 
histological sections.  
 169 
7.2 Targeted Scleral Stiffening Effects on Glaucomatous Rats 
7.2.1 Targeted Stiffening Confirmed in Glaucomatous Rats 
Despite not having found significant protective effects of targeted peripapillary 
photocrosslinking with MB, we did confirm targeted stiffening (supporting our initial 
studies in healthy rats). For example, mean strain at a pressure of 22 mmHg was 2.41% 
strain in MB treated peripapillary sclerae compared to 6.07% strain in HBSS-treated 
controls. Peripheral strains did not differ significantly between MB and HBSS-treated 
groups, with mean strains of 4.51% strain for MB and 4.52% strain for HBSS.    
7.2.2 Stiffening Did Not Worsen Glaucomatous Damage 
Overall, targeted photocrosslinking did not significantly prevent or exacerbate 
glaucomatous damage in a rat microbead model compared to control HBSS (vehicle). 
However, we do not conclude definitively that targeted peripapillary photocrosslinking is 
inefficacious due to experimental limitations of the microbead animal model. Future 
studies will be needed with an improved animal model to determine conclusively the 
effects of scleral stiffening on ocular hypertension-induced glaucomatous damage. 
7.2.3 Comparison with Stiffening Study of Kimball et al. 
Targeted peripapillary scleral stiffening did not confer significant protective or damaging 
effects in a rat microbead model of glaucoma. Importantly, these data contrast with the 
study by Kimball et al. in which increased damage was found in mice with whole-sclera 
stiffening with glyceraldehyde in a microbead model of ocular hypertension[5]. The 
contrasting conclusions of these two studies is difficult to explain and could involve the 1) 
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difference in species, 2) difference in crosslinking agent, and 3) difference in crosslinking 
location. It is possible, for example, that the volume and concentration of injections in the 
Kimball et al. study resulted in additional toxicity that we did not observe in our study. In 
our studies, genipin served as an important positive control for whole-sclera stiffening. It 
was found that genipin, while stiffening the whole sclera, did not produce axon loss in 
excess of control eyes as was seen in the Kimball study, suggesting that either a difference 
existed in the stiffening extent/location or that treatment toxicity may explain the observed 
axon deficit seen in the Kimball study. 
7.3 Computational Model for Scleral Photocrosslinking 
We developed a theoretical predictive computational model simulating photocrosslinking 
dynamics in corneal and transpupillary scleral photocrosslinking scenarios that required no 
fitted parameters. The model used a finite difference scheme in 1-dimensional space to 
create and solve a system of ordinary differential equations in time for diffusion, light 
propagation, and chemical reaction phenomena. The model was validated against existing 
literature experimental data for riboflavin corneal crosslinking and subsequently used to 
model MB scleral photocrosslinking by substituting parameters available from the 
literature for the appropriate sensitizers and tissues involved.   
7.3.1 Model Validation against Existing Riboflavin Crosslinking Experimental Studies 
As an important validation step, our model was able to replicate oxygen concentration 
reported in literature by Kamaev et al. for ex vivo riboflavin crosslinking in porcine eyes 
[236]. Oxygen concentration was chosen for this important validation step because it 
depends in a complex way on all three model components – diffusion kinetics, light 
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propagation, and reaction dynamics. Furthermore, oxygen is central to crosslink chemistry 
and is the subject of much interest for understanding the relative involvement of type I and 
type II photochemical processes in crosslinking. This is the first time to our knowledge that 
a computational model was used to successfully replicate this experiment.   
In addition, we demonstrated good agreement of the computational model’s prediction for 
crosslinking magnitude by comparing with stiffening and enzymatic degradation studies 
investigating lack of concurrence of riboflavin crosslinking with the Bunsen-Roscoe Law. 
Our model shows good agreement with the data of Hammer et al. and Aldahlawi et al. who 
both showed that riboflavin crosslinking violates the Bunsen-Roscoe Law using 
mechanical tensile testing and enzymatic degradation, respectively. Both methods assess 
crosslink density implicitly by measuring corneal resistance to mechanical force and 
chemical degradation. Therefore, together, they provide two different points of reference 
supporting the experimental correspondence of crosslink formation with our model’s 
prediction. 
7.3.2 Measurement of Retrobulbar Clearance/Diffusion Kinetics 
Having validated the computational model’s underlying assumptions in the riboflavin 
crosslinking cases, we experimentally measured clearance and diffusion kinetics of MB in 
the retrobulbar space, determining the diffusion coefficient of MB to be 3.16 x 10-7 cm2/s. 
Additionally, we measured the concentration of MB remaining in the sclera of Brown 
Norway rats at 30 minutes post-injection to be 14.4% of the initial injection concentration. 
Together, these experimentally derived values showed excellent agreement with our 
computational model’s mass transport assumptions which predicted a scleral MB 
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concentration of 13.8% at 30 minutes post-injection, well within one standard deviation of 
our experimental measurement.  
7.3.3 Effects of Experimentally Controlled Parameters on MB Scleral Photocrosslinking   
We analyzed effects on crosslinking of parameters most easily controlled by experimental 
design in photocrosslinking studies including light intensity, injected sensitizer 
concentration, injection volume, and inspired oxygen concentration. Our model predicted 
that approximately 30% of all available crosslinking sites were utilized for the 
experimental conditions used in our proof of concept studies. We found that light intensity 
is generally positively correlated with crosslinking but depends on MB concentration. 
Crosslinking magnitude, for example, was similar for 30 mM MB injection concentration 
as for 3 mM injection concentration despite an order of magnitude difference (for 100% 
inspired oxygen case). Injection volume also importantly influenced crosslinking with 
larger injection volumes being more advantageous in all cases except for high MB 
concentrations (30 mM) where crosslinking goes through a local maximum at 
approximately 42 μl injection volume. An inspired oxygen concentration of 100% was 
found to be more advantageous for all MB concentrations studied (0.03, 0.3, 3, 30 mM), to 
be more advantageous with crosslinking magnitudes being approximately 6-fold higher for 
the conditions used in our MB photocrosslinking procedure. These results suggest that if 
our procedure were conducted with rats breathing atmospheric oxygen, the crosslinking 
magnitude would be significantly decreased compared to anesthesia with isoflurane and 
100% oxygen. Finally, crosslinking as a function of MB concentration experiences a local 
maximum at around 8 mM resulting in 32% crosslinks utilized compared to 30% crosslinks 
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utilized at 3 mM. Below 3 mM and above approximately 15 mM, efficiency declines below 
30% crosslinks utilized. 
7.3.4 Evolution of Model Components over Time and Space 
Additionally, we simulated the evolution of reactive species involved in MB 
photocrosslinking including light, MB, oxygen, amino acids, and melanin over time and 
space (choroid/sclera). Light intensity and MB concentration were found to quickly reach 
quasi-steady state profiles. Oxygen concentration was rapidly depleted through most of the 
sclera/choroid, resulting in a steep concentration gradient near the anterior choroid. The 
amino acids His, Met, Trp, and Tyr along with melanin were consumed by photochemical 
generation of singlet oxygen. Their initial depletion, which reduced both their chemical 
and physical quenching magnitudes locally at the anterior choroid surface, lead to their 
accelerating depletion over time. As a result of the observed changes in oxygen 
concentration and amino acids/melanin, we concluded that oxygen flux is important for 
supplying the oxygen-dependent crosslinking reactions and that oxygen flux is more 
important than oxygen concentration.  
7.3.5 MB Scleral Photocrosslinking Parameter Sensitivity Analysis 
Finally, we conducted a sensitivity analysis for the MB photocrosslinking model 
parameters using the conditions from our previous experimental proof of concept studies 
as a baseline against which deviations were compared. Crosslinking, represented as a 
percentage of available crosslinks utilized, was used as the model output for which effects 
of underlying parameter deviations were compared. We found that parameters related to 
tissue properties such as choroid and sclera thickness, melanin concentration in the choroid, 
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and diffusion constant of oxygen in the choroid/sclera, comprised eight of the top ten most 
sensitive parameters. Only irradiation duration and oxygen concentration in the blood were 
experimental parameters unrelated to tissue properties within the top ten most sensitive 
parameters. However, these were the two parameters having the largest positive impact on 
crosslinking.  
7.4 Summary 
In conclusion, we have 1) demonstrated the viability of MB photocrosslinking for inducing 
locally targeted scleral stiffening at the peripapillary sclera, 2) tested targeted MB scleral 
photocrosslinking effects on visual and morphological outcomes in glaucomatous rats, and 
3) created a computational model demonstrating concurrence with existing riboflavin 
crosslinking experiments and predicting MB scleral photocrosslinking dynamics in 
space/time, providing insights for future treatment optimization. These studies represent 
the first use of a targeted transpupillary scleral photocrosslinking approach on the 
millimeter length scale, the first investigation of targeted peripapillary scleral crosslinking 
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CHAPTER 8. FUTURE DIRECTIONS 
8.1 Targeted Scleral Photocrosslinking using Methylene Blue 
Scleral photocrosslinking holds promise for the future of glaucoma and myopia treatment. 
In addition to these two clinical applications, there exist two technical challenges upon 
which future research may expand: 1) improved precision in crosslink spatial resolution, 
and 2) improved safety/efficacy profiles. We believe both areas may be addressed by 
ongoing research expanding the field of available sensitizers with enhanced properties 
suitable for these applications. 
Improved spatial resolution of the crosslinked area will be an important future technical 
objective for treatment of both glaucoma and myopia for different reasons. In the case of 
glaucoma, peripapillary region requiring crosslinking has been shown to be linked to 
lamina cribrosa strain, but the exact diameter of the peripapillary space requiring 
crosslinking to reduce lamina cribrosa strain is yet uncertain. Increasing crosslinking 
spatial control will allow for localization to an even finer length scale having the dual 
effects of 1) reducing off-target stiffening, and 2) increasing the possible treatment 
strategies available. With finer spatial control, for example, targeting may eventually be 
localized to precise tissue depths rather than simply to two-dimensional regions defined by 
a light projected on the fundus. Addition of spatial control in the depth axis would 
potentially enable direct crosslinking of the lamina cribrosa in addition to, or in place of, 
peripapillary scleral crosslinking.  
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In the case of myopia, it may be advantageous to have greater spatial control of crosslinking 
in order to not only slow elongation of the eye, but perhaps even to reverse and nullify 
refractive errors through spatial modification of mechanical properties. For example, a 
patterned stiffening approach may cause collagen remodeling and redistribution of force at 
un-crosslinked regions. Clinically, non-uniform beam intensity profiles have been used to 
improve refractive error in riboflavin corneal crosslinking for treatment of keratoconus, 
suggesting the importance of spatial crosslink density for altering tissue shape[274,275].  
Photocrosslinking safety should be a subject of importance in future studies and may be 
improved through increased spatial control and through advancement of new sensitizers 
with increased crosslinking efficiency. Improved spatial control will reduce the area 
affected by the crosslinking procedure, thus decreasing the total potential damage caused 
to the fundus and surrounding tissue. Improved crosslinker efficiency will allow for 
reduced light intensities to be used which would have the dual effects of decreasing the 
dose of photons to which the retina will be exposed as well as decreasing the potential for 
sensitization of non-targeted tissues by scattered photons. 
Emergence of new photocrosslinkers will aid in reducing photocrosslinking procedure 
toxicity through a few different possible strategies. First, sensitizers enabling use of longer 
wavelengths would enhance photocrosslinking efficiency and safety. Second, the fundus is 
less absorptive at longer wavelengths, thus reducing the input energy dose required to 
achieve photocrosslinking. Third, longer wavelength photons are lower energy, meaning 
more photons are generated by the light source for an equivalent total energy dose 
compared to shorter wavelengths. Already, there exist sensitizers with absorbance at longer 
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wavelengths such as WST11 and indocyanine green holding promise for posterior targeted 
photocrosslinking[276,277]. 
Overall, scleral photocrosslinking is an area of ongoing active investigation, and this work 
contributes to the body of literature by demonstrating feasibility of a spatially targeted 
transpupillary crosslinking strategy. It is our desire that this work will inspire additional 
studies to improve photocrosslinking procedure toxicity using a transpupillary illumination 
source. Additionally, we hope applications for treatment of previously unconsidered ocular 
pathologies may be explored due to expanded access to posterior targeted scleral 
crosslinking described in this works. 
8.2 Targeted Scleral Stiffening Effects on Glaucomatous Rats 
While microbead-induced glaucomatous damage was not mitigated by targeted 
peripapillary scleral stiffening in this study, the effects of such scleral crosslinking on 
treatment of glaucoma are yet uncertain. Certain limitations of the study prevent us from 
making definitive conclusions. Specifically, the microbead rat model had significant 
limitations in its ability to replicate long-term hypertensive glaucomatous damage and 
therefore leaves room for future investigation. For example, in Chapter 4 it was explained 
that exclusion criteria were needed to remove rats from the study which had retinal 
electroretinography deficits uncharacteristic of glaucomatous damage. Additionally, it is 
unclear to what extent treatment toxicity may have played a role in lack of protective effects 
observed in this study. 
Future studies should seek to develop improved glaucomatous animal models more closely 
replicating ocular hypertension-induced damage. Additionally, these models should be 
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well characterized over the extended time scales necessary to assess effects of 
biomechanical alterations on hypertension-induced damage. Protective effects of targeted 
peripapillary scleral stiffening may be efficacious in preventing glaucomatous damage on 
these longer time scales, although they were not observed over the short duration of our 
studies.   
Photocrosslinking treatment toxicity alone was characterized in our studies to be moderate 
and is therefore a difficult effect to disentangle from the damaging effects of the microbead 
model. Future studies should seek to disentangle these effects, or better, to eliminate 
photocrosslinking procedure toxicity. We found that exceeding maximum permissible 
intensity limits for beam intensity by a factor of approximately 3-fold did not cause 
observable damage to the retina. This finding may be explained by the fact that maximum 
permissible ocular intensity limits have a 10-fold safety factor adjustment from the 
intensity at with 50% probability of minimum visible lesion is expected[123]. 
8.3 Computational Model for Scleral Photocrosslinking 
In this study, a computational model was developed from experimental data in literature 
for riboflavin corneal crosslinking and substituted for parameters corresponding to 
methylene blue photocrosslinking in the posterior sclera. The model enables a host of 
future predictive studies which may be used to support future clinical procedure execution 
as well as experimental research towards advancement of photocrosslinking procedures in 
both the sclera and cornea. 
Assuming scleral photocrosslinking finds future clinical use, our model may be used to 
tailor the treatment parameters to individual patients. For example, variations in individual 
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tissue thicknesses and melanin content may be accounted for to adjust light intensity, 
injection concentration, and treatment duration. Interestingly, the individual-specific 
parameters mentioned here are ones for which crosslinking was found to be most sensitive 
in our model’s sensitivity analysis.  
Our model can be adapted to predict photocrosslinking efficiency as a function of injection 
location not only in the retrobulbar space, but also for suprachoroidal injections, sub-Tenon 
injections, sub-conjunctival injections, and topical photosensitizer delivery. These may be 
achieved by simply modifying the spatial domain properties of the tissue layers considered 
while maintaining the photophysical and transport properties. However, in some cases, 
additional transport phenomena may need to be elucidated experimentally. For example, 
for a suprachoroidal injection, adjacency of the injection reservoir to the choroid opens the 
possibility of convective flux in addition to diffusive flux. 
The model may additionally be used for various taxonomic species of interest. We have 
compiled literature data for humans, pigs, and rats pertaining to tissue thicknesses and 
amino acid concentrations. Therefore, sensitizer performance may be predicted in humans 
for clinical interest as well as for pre-clinical studies. Differences in photocrosslinking 
efficiencies in humans and animals would not be surprising, and the model can therefore 
provide important predictive capabilities to determine which species would be most 
appropriate for preclinical studies. Alternatively, in cases where human clinical translation 
is not of interest, but rather fundamental research is of interest, the model may be able to 
assist in species selection.   
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Finally, the model is useful for comparing efficacy of various sensitizers if sensitizer-
specific input parameters are available. As fundamental research continues to expand the 
selection of available sensitizers, the need to predict which properties will be most suitable 
for crosslinking under circumstances of interest will increase. Additionally, our model may 
be used to inform future fundamental studies seeking to design sensitizers with optimal 
properties for specific crosslinking applications. Therefore, the model may be likened to 
existing computational models used to predict pharmacokinetics in vivo as it can be used 
both for predicting performance of existing sensitizers and may be used to predict optimal 
sensitizer properties which future research should aspire to emulate.  
  
 182 
APPENDIX A. SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
8.4 OCT Images 
OCT imaging was performed on the cohort of rats receiving light only (n=3). There is no 
apparent damage from light alone, further supporting retinal histology findings indicating 
that light alone does not damage the retina.  
 
Figure 36: Representative OCT images from rat eyes treated with a targeted light beam 
without methylene blue. A) Control (untreated eye receiving no light exposure) and B) 
Contralateral eye exposed to 424 mW/cm2 660 nm light treatment for 30 min without 
methylene blue using the same apparatus and protocol as used for selective 
photocrosslinking. 
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8.5 Surface area of sclera affected by targeted photocrosslinking 
The photocrosslinked peripapillary sclera area represents a fraction of the total eye surface 








where r1 and r2 are the inner and outer radii of the annular light beam, and R is the radius 
of a rat eye. Thus, for the annulus size referenced (1 mm outer radius, 0.5 mm inner radius) 
and a rat eye diameter assumed to be 7 mm, the fraction of total eye surface area with 
reduced compliance would be 1.5%. Therefore, a large majority of the eye’s compliance 
would be preserved with targeted scleral stiffening.  
8.6 Calculation of percent strain reduction from Coudrillier et al [4] 
Coudrillier et al. stiffened the peripapillary sclera of ex vivo porcine eyes and reported 
average strain versus pressure in Figure 7c of that manuscript. From this figure, we 
extracted the average peripapillary strain values at a pressure of 22 mmHg, which was used 
in our study. The extracted values were 21.5 mStrain for control and 13.3 mStrain for 





where ε% is the percent decrease in strain, εctrl is the strain of the control eye, and εexp is the 
strain of the experimentally stiffened eye. The calculated percent decrease in strain at 22 
mmHg in the Coudrillier et al. study was therefore 38% according to this calculation. 
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8.7 Calculation of maximum permissible intensity for 660nm red light 
8.7.1 Maximum Permissible Radiant Power 
We calculated the maximum permissible intensity for our photocrosslinking protocol based 
on guidance from the standards developed by the American National Standards Institute 
(ANSI) using the approach reported in Delori et al. [123]. From Table 3 in the Delori paper, 
maximum permissible radiant power, MP𝞍, (Watts) for an 1800s illumination exposure 
time is given by: 
𝑀𝑃Φ = 6.93 × 10−4𝐶𝑇𝐶𝐸𝑃
−1𝑡−0.25 
where CT and CE are functions of wavelength, P is a function of wavelength and the light 
source’s angular subtense, and t is time in seconds. Using the derived values of these 
parameters shown below, we arrived at the value of MP𝞍 = 4.96 mW spread over our 




where r2 and r1 are the outer (0.1 cm) and inner (0.05 cm) beam annulus radii, respectively. 
We calculated A to be 0.0236 cm2. Dividing MP𝞍 by A, we arrived at the final maximum 
permissible intensity of 211 mW/cm2. 
Closer examination on the ANSI standard shows that the permissible illumination intensity 
has a factor of 10 margin of safety built into it below the intensity at which damage is 
expected with 50% probability. This suggests intensities exceeding the maximum 
permissible intensity may be tolerated with relatively low incidence of damage. 
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8.7.2 Angular Subtense, α 
The beam’s angular subtense, α, was calculated according to the equation on page 1252 of 
the Delori paper which is a small angle approximation: 







where dr is the diameter of retinal exposure and fe is the eye’s focal length, assumed to be 
1.7cm. Assuming dr to be 0.2 cm, we calculated α = 117.6 mrad. 
 
8.7.3 Value of Parameter, CT 
CT for a 660 nm light source is 1, according to Table 3 in the Delori paper. 
 
8.7.4 Value of Parameter, CE 
CE for an “extended” light source having an angular subtense greater than 100 mrad, 
according to Table 2 in the Delori paper, is: 
𝐶𝐸 = 6.67 × 10
−3𝛼2 




8.7.5 Value of parameter, P 
The pupil factor, P, for a 660 nm light source and illumination time greater than 0.7 seconds 
is: 
𝑃 = 100.0074(700−𝜆) 
where 𝝺 is the wavelength in the light source in nanometers. Since our source is 660 nm, 
we calculated P = 1.977. 
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APPENDIX B. SUPPLEMENTAL INFORMATION FOR CHAPTER 4 
 
Figure 37: Chemical crosslinker genipin (left inset) or photocrosslinker methylene blue 
(right inset) were injected by retrobulbar injection to induce scleral crosslinking. Genipin 
induced non-targeted crosslinking. Methylene blue was activated with a transpupillary 
light beam to selectively crosslink peripapillary sclera. 
 
 
Figure 38: A) Image of BN rat fundus viewed through refraction-negating corneal contact 
lens showing optic nerve head and retinal vasculature. The lens created a clear optical 
path facilitating B) projection of an annular beam (measuring 2 mm outer diameter, 1 mm 
inner diameter) of 660 nm incoherent light from a custom-designed microscope to the 
peripapillary sclera following retrobulbar injection of MB. The inset shows an image of 
the beam projected onto a BN rat fundus as viewed using the microscope’s camera (inset 
scale bar = 1 mm).   
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Table 13: Table of experimental variables investigated in this study compared with those 
of the Kimball et al. 2014 study which investigated effects of scleral crosslinking on 




Table 14: Two-way ANCOVA outcomes for measured parameters including main effects 
of crosslinking treatment (HBSS, GP, MB) and microbead treatment (normotensive, 





Figure 39: Resolved A) spatial frequency and B) contrast sensitivity of normotensive 
control eyes at Days -7, 0, 7, and 14 with respect to induction of hypertension at Day 0. 
Significant differences were found at Day 7 and Day 14 compared to Day -7 (baseline) 
for spatial frequency and for contrast sensitivity in all crosslinking treatment groups. 
These findings suggest the presence of a hyperacuity effect in the normotensive eye after 
induction of hypertension in the contralateral eye C) Spatial frequency differed between 
Day -7 (baseline) and Day 0 (after stiffening treatment) for GP (p < 0.01) and MB (p < 
0.0001). D) Contrast Sensitivity differed between Day -7 (baseline) and Day 0 (after 




Figure 40: A) Axon density and B) optic nerve cross-sectional area were measured from 
sectioned optic nerves. Axon density was calculated as the measured axon count divided 
by measured area (B). 
 
Figure 41: Correlations of baseline control and experimental eye values prior to 
treatments. “Control” indicates eyes designated to be normotensive. “Experimental” 
indicates eyes designated to be normotensive (microbead injection). A) pSTR amplitude, 
B) nSTR amplitude, C) b-wave amplitude, D) oscillatory potential 3 amplitude, E) retinal 
thickness at 0.5 mm from the ON, F) retinal thickness at 1.2 mm from the ON, G) spatial 
frequency, and H) contrast sensitivity, showed no significant correlation at baseline 
between eyes of the same rat. 
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Figure 42: No qualitative differences were found in optic nerve cross-sections of 
hypertensive eyes between crosslinking treatment groups. Representative images from 
each treatment in specified range of IOP burden are shown. Images were taken from the 
central region of each nerve. Scale bar = 10 µm. Damage qualitatively increases with 
increasing IOP burden. 
 
Figure 43: Representative experimental eye optic nerve/retina OCT images from each 
treatment in specified range of IOP burden. Damage qualitatively increases with 
increasing IOP burden. Vertical yellow lines on each image indicate (from left to right), -
1.2 mm, -0.5 mm, 0 mm, 0.5 mm, 1.2 mm distances from center of optic nerve head at 
which retinal thickness measurements were taken. Scale bar = 0.5 mm. Specifically, 
cupping at the optic nerve head increases in all groups. 
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Table 15: Tabulated average IOP burden of rats included in each outcome parameter 









Figure 45: OCT retinal thickness measurements as a function of IOP burden at A) 0.5 
mm from the ONH and B) 1.2 mm from the ONH. 
 
 
Figure 46: ERG outcomes vs IOP burden for A) pSTR amplitude, B) nSTR amplitude, C) 
b-wave amplitude, and D) oscillatory potential 3 amplitude. 
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Figure 47: Eye size parameters vs IOP burden including A) anterior chamber depth, B) 
equatorial width, and C) axial length. 
 
 
Figure 48: A) Axon count, B) axon density, and C) optic nerve cross-sectional area as 
functions of IOP burden. 
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APPENDIX C. SUPPLEMENTAL INFORMATION FOR CHAPTER 5 
8.8 Calculation of Retrobulbar and Choroidal Dissolved Oxygen Concentrations 
Yu et al. measured the oxygen tension in the rat retina/choroid as a function of tissue 
depth[244]. The peak oxygen tension was found in the choroid to be approximately 44 
mmHg under 20% inspired oxygen, and 228 mmHg under 100% inspired oxygen. 
Assuming the oxygen gradient is similar on the anterior and posterior sides of the choroid, 
the oxygen concentration at a distance of 125 μm from the peak choroid oxygen tension 
was used as an estimate for the concentration in the posterior surface of the Tenon capsule. 
The tension at 125 μm distance from peak choroidal tension was 21 mmHg for 20% 
inspired oxygen and 98 mmHg for 100% inspired oxygen. 
Oxygen concentration was derived using Henry’s Law: 
 𝐶 = 𝛼𝐻 × 𝑝 (39) 
   
where C is the concentration of oxygen, αH  is the Henry solubility constant, and p is the 
partial pressure of oxygen in the tissue[278]. The value of αH is 0.022 mL oxygen/1 mL 
solvent per 760 mmHg pressure (1 atmosphere) for blood plasma at 35 °C[279]. Using the 








Where f is the factor for converting concentration from oxygen volume fraction to molarity, 
R is the gas constant (62.363 mmHg L mol-1 K-1), and T is the absolute physiological 
temperature (assumed to be 308.15 K). The resulting Henry’s Law with conversion factor, 
f, is: 
 𝐶 = 𝛼𝐻 × 𝑝 × 𝑓 (41) 
 





Calculated Dissolved O2 
Concentration 
20% Choroid 42 mmHg  4.81 x 10-5 M 
20% Retrobulbar 19 mmHg 2.18 x 10-5 M 
100% Choroid 228 mmHg 26.10 x 10-5 M 
100% Retrobulbar 93 mmHg 10.65 x 10-5 M 
    
* Based on Yu et al. [244]. Choroidal oxygen partial pressures were taken directly from 
the text. Retrobulbar oxygen partial pressures were derived from figure 2 taking pressure 
at a distance of 125 μm (scleral + Tenon thickness) from the center of the choroid. 
 
8.9 Calculation of Amino Acid Concentrations in the Sclera 
Concentrations of scleral amino acids were determined using the product of scleral 
collagen mass fraction and collagen amino acid mass fraction. Mass fraction of collagen in 
the sclera is approximately 22.5% and assumed to be composed of type I collagen [97]. 
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The mass fraction (mg amino acid/mg collagen) of each amino acid was determined using 
the type I collagen alpha chain sequence[280]. The resulting values for rat, pig, and human 
are documented in Table 18 and Table 19. In the choroid, we assumed that the amino acid 
composition would be identical to that of the sclera, but the concentration was reduced by 
40%, using the estimated volume fraction of the choroid occupied by vasculature estimated 
based on collagen content[249]. 
Table 17: Tissue dimensions by species 
Tissue Rat Porcine Human 
Cornea  156 µm [281] 833 µm [282] 502 µm [146] 
RPE 10 μm [283] 15 µm[284] 26 μm[285] 
Choroid 45 μm [286] 
57 μm [287] 
140 μm [288] 150 μm [288] 
162 μm (PP), 
195 μm (Avg) [289] 
Sclera 104 μm [287] 1100 μm (PPS), 
560 μm (Eq)[290] 
390 μm (PPS), 
650 μm (Eq)[291] 
Tenon 26 μm*  208 μm* 113 μm[292] 
* Estimated to be 25% thickness of sclera 
 
Table 18: Calculated corneal amino acid concentrations in rat, pig, and human cornea 
Residue Rat Cornea Porcine Cornea Human Cornea 
Histidine 5.29 x 10-3 M 5.32 x 10-3 M 2.52 x 10-3 M 
Methionine 8.81 x 10-3 M 7.68 x 10-3 M 6.71 x 10-3 M 
Tryptophan 3.53 x 10-3 M 3.54 x 10-3 M 0.84 x 10-3 M 
Tyrosine 8.23 x 10-3 M 8.86 x 10-3 M 2.52 x 10-3 M 





Table 19: Calculated scleral amino acid concentrations in rat, pig, and human sclerae 
Residue Rat Sclerae Porcine Sclerae Human Sclerae 
Histidine 12.39 x 10-3 M 12.46 x 10-3 M 5.90 x 10-3 M 
Methionine 20.66 x 10-3 M 18.00 x 10-3 M 15.73 x 10-3 M 
Tryptophan 8.26 x 10-3 M 8.31 x 10-3 M 1.97 x 10-3 M 
Tyrosine 19.28 x 10-3 M 20.77 x 10-3 M 5.90 x 10-3 M 
Lysine 78.50 x 10-3 M 77.55 x 10-3 M 74.72 x 10-3 M 
 
Table 20: Melanin Concentration by Tissue and Species* 
Tissue Rat Porcine Human 
RPE 8.50 x 10-2 M† [293] 8.50 x 10-2 M [293] 7.35 x 10-2 M [293] 
Choroid 30.50 x 10-2 M†[293] 30.50 x 10-2 M [293] 6.00 x 10-2 M [293] 
Sclera 6.00 x 10-2 M [294] 3.96 x 10-2 M § [295] 7.48 x 10-2 M [295] 
* Concentration was calculated assuming a molecular weight of 200 Da[267]. 
† Assumed similar to porcine sclera concentration 
§ We selected the value for Yucatan minipig. Alternatively, concentration for Gottingen 
minipig is 1.41 x 10-2 M [295]. 
 
8.10 Estimate of Retrobulbar Injection Reservoir Depth 
We assumed the distance from the posterior Tenon surface to extraocular 
muscles/blood could be approximated as a cylinder with radius equivalent to that of the 









For example, for a rat eye of radius, R = 3.205 mm (see Hughes et al.) and injection volume 
of 100 μl, the equivalent reservoir depth would be 3.10 mm[296]. 
8.11 Estimate for Sub-Tenon Injection Reservoir Depth 
We assumed the average distance from the posterior Tenon surface to extraocular 
muscles/blood vessels could be approximated as a spherical half shell covering the 
posterior half of the globe. Therefore, the thickness, x, of the half shell was calculated and 
used as the value for reservoir depth based on eye radius, r, and injection volume, V. The 
radius of the sphere defined as encompassing the eye and the injection reservoir was given 






























− 𝑟 (46) 
For a rat eye of radius 3.205 mm and injection volume of 100 μl, the reservoir thickness 
would equate to 1.12 mm. 
8.12 Calculation of Light Entering the Choroid: 
 The fundus reflects light with reflectivity of 𝞍R defined as the fraction of incident 
light reflected. The fraction of light transmitted over the RPE can be calculated using the 
Beer-Lambert Law: 
 1 − 𝑓𝐴𝑏𝑠 = 1 − 10
−(𝜀𝑀𝑒𝑙𝑎𝑛𝑖𝑛𝐶𝑀𝑒𝑙𝑎𝑛𝑖𝑛𝑥) (47) 
 
where fAbs is the fraction of light transmitted, εMelanin is the molar absorptivity of melanin, 
CMelanin is the concentration of melanin in the RPE, and x is the thickness of the RPE. The 
fraction of the source light reaching the choroid, fChoroid is the product of the light 
transmitted after accounting for reflection and absorbance in the RPE: 
 𝑓𝐶ℎ𝑜𝑟𝑜𝑖𝑑 = 1 − (1 − 𝜙𝑅) × (10
−(𝜀𝑀𝑒𝑙𝑎𝑛𝑖𝑛𝐶𝑀𝑒𝑙𝑎𝑛𝑖𝑛𝑥)) (48) 
Given the values for each parameter as previously stated, we calculated the fraction of 
incident light reaching the choroid for a transpupillary 660 nm light beam in a rat to be 
20%. When also accounting for the absorbance of light in the choroid in a similar manner 
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to the RPE (though reflection was not considered at the choroid), the fraction of light 
energy reaching the sclera is approximately 18% of the incident energy on the RPE.  
8.13 Optical Properties of Sclera 
 We found discrepancies in experimental estimates for scleral melanin 
concentration, molar absorptivity, and light absorbance in the literature. Experimental 
evidence suggests the absorbance of light in the human sclera is approximately 10% of 
incident energy at 660 nm[297]. If the linear absorption coefficient of approximately 1.75 
cm-1 from Bashkatov et al. is used, the percentage absorbed light at 660 nm is 
approximately 23% (they reported 660 μm sclerae were used) [298]. This is in good 
agreement with Vogel’s estimate since Vogel et al. accounted for an approximately 60% 
loss due to reflection of light entering the sclera[297]. However, if the scleral melanin 
concentration is 74.8 mM as in Durairaj et al., and if the molar absorptivity of melanin 
(monomeric) is 600 M-1cm-1, then the expected absorbance from melanin in a 650 μm 
thickness sclera would be >99%[295]. Literature values for melanin concentration in the 
sclera and choroid are similar, though qualitative visual evidence would suggest that scleral 
melanin concentrations are much lower than those of the choroid. Taking Bashkatov’s 
finding of 1.75 cm-1 for the scleral linear absorption coefficient, the melanin concentration 
in human sclera would have to be 3 mM to produce the same degree of light absorption. 




8.14 Model Simulation 2D Heatmaps 
 
Figure 49: Spatiotemporal profiles of A) crosslink concentration, and B) light intensity 
model predictions over the choroid and sclera during 30-min MB photocrosslinking 
procedure. The dashed line demarcates the boundary of choroid (left) and sclera (right). 
A) The model predicts that crosslinking increases over time with the highest number of 
crosslinks in the choroid. In both the choroid and sclera, the anterior surfaces experience 
more crosslinking than the posterior surfaces. B) Light intensity maintains a relatively 
steady profile throughout the procedure due to relatively fast diffusion of MB which 




Figure 50: Spatiotemporal profiles of A) MB monomers, B) MB dimers, C) MB triplets, 
and D) degraded MB. The dashed line demarcates the boundary of choroid (left) and 
sclera (right). Note, degraded MB is a cumulative sum over time and does not account for 
diffusion dynamics in order to simply visualize the locations at which degradation was 
most prevalent. MB monomers, dimers, and triplets, on the other hand are represented as 
absolute values subject to all model diffusion and reaction dynamics.  
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Figure 51: A) Triplet oxygen and B) singlet oxygen concentrations over space and time 
during MB photocrosslinking treatment in rat sclera/choroid. The dashed line demarcates 
the boundary of choroid (left) and sclera (right). A) Triplet oxygen is rapidly depleted in 
the sclera at early stages in the treatment, reaching a relatively steady state profile as 
diffusion equilibrates with photochemical consumption. B) Singlet oxygen generated 
throughout the course of the treatment reaches increased concentration late in the 




Figure 52: Spatiotemporal profiles of amino acid concentrations in the choroid and sclera 
during MB photocrosslinking. The dashed line demarcates the boundary of choroid (left) 
and sclera (right). A) Histidine, B) tryptophan, C) methionine, and D) tryptophan 
concentrations were modeled as they are believed to be the predominate species involved 




Figure 53: Spatiotemporal profiles of melanin concentration over space and time during 
MB photocrosslinking shows a gradual depletion in the choroid. The dashed line 
demarcates the boundary of choroid (left) and sclera (right). Initial concentration is 
higher in the choroid than in the sclera. Almost complete depletion of melanin occurs in 
the anterior choroid late in the procedure (>20 min). 
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APPENDIX D. COMPUTATIONAL MODEL CODE: RIBOFLAVIN 
CORNEAL CROSSLINKING 
%Brandon Gerberich 













% Intensity=[3 6 9 20 34 45 50 60 67 90]/1000; 





clearvars -except ploton Intensity Duration mastercounter mastervector 
 




BCMBres=0;                  %1 if reflection, otherwise Dirichlet 
BCMBchor=1;                 %1 if reflection, otherwise Dirichlet 
BCO2res=0;                  %1 if reflection, otherwise Dirichlet 
BCO2chor=0;                 %1 if reflection, otherwise Dirichlet 
BMBHres=0;                  %1 if reflection, otherwise           
 
C0_MBres=0;                 %0.0027 for 0.1%, 0.00082 for 20 minute 
presoak 
C0_MBchor=0.00194*0; 
O23res=1.94e-4*0;           %1.94e-4 Concentration of oxygen at tenon-
reservoir interface [M] 




fexp=1;                     %Reduction of amino acid concentration 
fexp2=1;                    %Fraction of the triplet quenching rate of 
amino acids 
fexp3=1;                    %Fraction of 3MB which is physically quenched 
(returns 3MB to MBm, chemical quenching consumes 3MB 
fbleach=1;                  %Fraction of TRP, MET, and TYR which is 
degraded after quenching 3MB, consumes TRP,MET,TYR only 
fanlink=1;                  %Fraction of TRP, MET, and TYR which form 
xlinks after quenching 3MB and returns MBm 
fhisbleach=0;               %Fraction of HIS which is degraded after 
quenching 3MB 
fxl=1;                      %Fraction of 3MB quenched by histidine which 
form Xlinks 
fdiff=1;                    %Fraction of diffusion constant for MB 
oxdeg=1;                    %1 if oxygen is consumed in oxidation of MBH 
and MBH2, 0 if not 
type2=1;                    %Fraction of type II reaction rates 
 
C0_HIS=0.0053/fexp;         %Concentration of histidine in the sclera 
[M], Edwards & Prausnitz 1998 
C0_TRP=0.0035/fexp;         %Concentration of tryptophan in the sclera 
[M], Edwards & Prausnitz 1998 
C0_MET=0.0088/fexp;         %Concentration of methionine in the sclera 
[M], Edwards & Prausnitz 1998 
C0_TYR=0.0082/fexp; 
C0_MEL=0;                   %Concentration of melanin [M] 
 





PhiDeg=0.012;               %Photolysis, Default 0.012 
 







Keq=125;                    %Equilibrium constant for dimerization 
defined as K=[Dimer]/[Monomer]^2, [M]^-1, 2910 default. K=kf/kr=[D]/[M]^2 
kfm=10.93e8;                %Forward rate constant for dimerization, from 
Spencer 1979 
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krd=kfm/Keq;                %Reverse rate constant. Assuming the value 
for kfm allows back calculation from K which is more widely available. The 
value of kfm just needs to be large so reaction happens quickly if want to 
assume instant dimerizastion 
k_singlet=1.62e9;            %Reaction rate for 3MB (triplet MB) and 3O2 
(triplet oxygen), [M^-1 s^-1] 
k_mbdeg=9.66E8;             %Reaction rate for 1O2 (singlet oxygen) and 
MB leading to degradation of MB, [M^-1 s^-1], 3E8 default (Schmidt 1980 
referenced in Wilkinson 1995) 
k_mb2deg=k_mbdeg;           %Reaction rate for 1O2 with MB2 - 2*k_mbdeg 
because the effective concentration of monomers is doubled for dimers 
k_triplet=2.56E5;            %Rate for 1O2 (singlet oxygen) relaxation to 
3O2 (triplet oxygen), [M^-1 s^-1], 2.5E5 default.  
k_MB3relax=4.9E3;           %Relaxation rate of MB3 to MB calculated from 
lifetime of 77us (Alacron 2012), [s^-1], 1.3E5 default            
kMBquench=1.2E8;            %Rate of ground state monomer quenching 3MB 
kMB3HIS=5.22E7*fexp2;       %Reaction rate for physical quenching of 3MB 
by histidine, [M^-1 s^-1], 2E6 default  
kMB3TRP=1.75E9*fexp2;       %Reaction rate for physical quenching of 3MB 
by tryptophan, [M^-1 s^-1], 6E8 default  
kMB3MET=6.36E7*fexp2;       %Reaction rate for physical quenching of 3MB 
by methionine, [M^-1 s^-1], 1E8 default  
kMB3TYR=1.4e9*fexp2;        %Reaction rate for physical quenching of 3MB 
by tyrosine, [M^-1 s^-1] 
kMB3ann=8.9e8*0;            %Rate of MB3 annihilation 
k3MBMB2=kMBquench;                  %Rate of MB3 quenching by dimer         
kHIS=1E8;                   %Reaction rate for 1O2 (singlet oxygen) and 
histidine leading to crosslinks, [M^-1 s^-1], 5E7 default 
kTRP=3E7;                   %Reaction rate for chemical quenching of 
singlet oxygen by tryptophan, [M^-1 s^-1], 4E6 default  
kMET=1.6E7;                 %Reaction rate for chemical quenching of 
singlet oxygen by methionine, [M^-1 s^-1], 5E6 default 
kTYR=8e6;                   %Reaction rate for chemical quenching of 
singlet oxygen by tyrosine, [M^-1 s^-1] 
k1O2HIS=0;                  %Reaction rate for physical quenching of 1O2 
by histidine, [M^-1 s^-1], 4.2E7 default  
k1O2TRP=2.1E7;              %Reaction rate for physical quenching of 1O2 
by tryptophan, [M^-1 s^-1], 4.6E7 default  
k1O2MET=0;                  %Reaction rate for physical quenching of 1O2 
by methionine, [M^-1 s^-1], 2.5E7 default  
k1O2TYR=0;                  %Reaction rate for physical quenching of 1O2 
by tyrosine, [M^-1 s^-1] 
kMEL=1.34E8;                %Reaction rate for melanin with singlet 
oxygen, [M^-1 s^-1], 1.34E8 default 
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kMBradq=7e5*type2*0;          %Reaction rate for 2 MB semiquinones with 1 
triplet O2, returning 2MB ground state and 1 triplet O2?? (assumes peroxyl 
and/or H2O2 quickly return 3O2) 
kMBH=4e6*type2*1;        %3e8 * 0.08 NOW RXN OF AA RADICALS WITH O2 
kMBH2MB=5.8e5*type2*0;      %Reaction rate for formation of 2 semiquinone 
radicals from MB and MBH2 
kMBH2ox=1e2*type2;        %1e3 NOW SELF RELAXATION OF AA RADICALS 
 
avogadro=1/(6.022*10^23);   %Avogadro's number - converts number of 
molecules to Moles, [Mole/units] 
planck=6.62607004*10^-34;   %Planck's constant, [J*s] 
ls=299792458;               %Speed of light, [m/s] 
Energy=planck*ls/lambda;    %Energy of a photon, [J] 
 
%Calculate #X Slices 
XS=Resx+Tenx+Sclx+Chorx;    %Number of x-steps 
















DO2=4e-6;                   %Diffusivity of oxygen in sclera, [cm^2/s], 
1.7E-5 default. 4E-6 according to Kamaev 2012 (porcine sclera) 
























%Calculate Space & Time Intervals 





I0=(1-Retchorabs)*I0/Energy*avogadro/dx*1000;           %Converts 






%Set Initial Conditions 
load('DiffusionICWernli57.mat','MBprofile'); 
% MBsemiinf=flip(0.5*C0_MBchor*erfc((1:N)/N*xmax/(2*sqrt(Dscl*1200))));    
%semi infinite condition 
MBm=(-1+sqrt(1+8*Keq*MBprofile))/(4*Keq); 
MBd=0.5*(MBprofile-(-1+sqrt(1+8*Keq*MBprofile))/(4*Keq)); 
% MBm=linspace(MBmres,MBmchor,N);   %Steady state 
% MBd=linspace(MBdres,MBdchor,N);   %Steady state 
 
%For creating new initial profile (presoaking). Uncomment first two lines 
% MBm=MBmchor*zeros(1,XS); %MBm(Chor)=0; 




Light=10.^(-(e_M*MBm+e_D*MBd+mu)*dx);       %Pct transmitted in each step 
MB3=zeros(1,XS); 
MBdeg=zeros(1,XS); 













Xlinkspossible=mean(C0_HIS+C0_TRP+C0_TYR); %Max possible mean 
concentration 
 
%Define Domains of DYDT 
A=1:XS; B=A+XS; C=B+XS; D=C+XS; E=D+XS; F=E+XS; G=F+XS; H=G+XS; I=H+XS; 
J=I+XS; K=J+XS; L=K+XS; M=L+XS; N=M+XS; O=N+XS; 
%Define "Middle" Domains of DYDT 
a=2:(XS-1); b=a+XS; c=b+XS; d=c+XS; e=d+XS; f=e+XS; g=f+XS; h=g+XS; 
i=h+XS; j=i+XS; k=j+XS; l=k+XS; m=l+XS; n=m+XS; o=n+XS; 
 





    TS=10000 
    tspan=linspace(0,tmax,TS); 
    disp('TS increased to 10000') 
else if TS>300000 
        TS=300000 
        tspan=linspace(0,tmax,TS); 
        disp('TS reduced to 300000') 
    end 
end 
 
%0 = zeros 
%1 = 0th diagonal     REACTIONS 
%2 = 0,1 diagonals 
%3 = -1,0,1 diagnoals DIFFUSION 
%4 = upper triangular 
%5 = upper triangular with diffusion 
jcell = {... 
   %a b c d e f g h i j k l m n o 
    4 3 3 1 1 1 0 1 1 1 0 0 1 1 1;        %a Light 
    4 3 1 1 1 1 0 1 1 1 0 0 1 1 1;        %b MBm 
    0 1 3 1 0 1 0 0 0 0 0 0 0 0 0;        %c MBd 
    4 1 1 3 1 0 0 1 1 1 0 0 1 0 1;        %d 3MB 
    0 0 0 1 3 1 0 1 1 1 1 0 1 1 1;        %e 3O2 
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    0 1 1 1 1 3 0 1 1 1 1 0 1 0 0;        %f 1O2 
    4 1 1 0 1 1 0 0 0 0 0 0 0 0 1;        %g MBdeg 
    0 0 0 1 0 1 0 1 0 0 1 0 0 0 0;        %h HIS 
    0 0 0 1 0 1 0 0 1 0 0 0 0 1 0;        %i TRP 
    0 0 0 1 0 1 0 0 0 1 0 0 0 0 0;        %j MET 
    0 0 0 1 0 1 0 1 1 0 1 0 1 0 0;        %k MEL (HIS radical) 
    0 0 0 0 1 1 0 1 1 0 1 0 1 1 1;        %l Xlink 
    0 0 0 1 0 1 0 0 0 0 0 0 1 0 1;        %m TYR 
    0 0 0 1 0 1 0 0 0 0 0 0 0 1 0;        %n MBH    (TRP radical) 
    0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 ...     %o MBH2 (TYR radical) 





    if jcell{counter}==0 
        jcell{counter}=zeros(XS); 
         
    elseif jcell{counter}==1 
        jcell{counter}=diag(ones(1,XS),0); 
         
    elseif jcell{counter}==2 
        jcell{counter}=diag(ones(1,XS-1),1)+diag(ones(1,XS),0); 
         
    elseif jcell{counter}==3 
        jcell{counter}=diag(ones(1,XS-1),1)+diag(ones(1,XS-1),-
1)+diag(ones(1,XS),0); 
         
    elseif jcell{counter}==4 
        jcell{counter}=triu(ones(XS)); 
     
    elseif jcell{counter}==5 
        jcell{counter}=triu(ones(XS))+diag(ones(1,XS),0); 






6,'AbsTol', 1E-8, 'JPattern',jsparse(Jsparse));  %Sets options for solver 
y0=[Light' MBm' MBd' MB3' O23' O21' MBdeg' HIS' TRP' MET' MEL' Xlink' 












%Calculate Plot Grid Mesh 
xpoints=(1:XS)*dx; 
xpoints=xpoints'; 






logswitch='linear';                                                     
%toggles linear or log scale plots 
 
if strcmp(logswitch,'log')==1 
    t=round(logspace(0,log10(length(tspan)),plotlength)); 
    tspan=tspan/60; 
end 
 






Abs=[Lightbeg Lightmid Lightend]; 
 
LI1=fliplr(cumprod(fliplr(y(:,A)),2))*I0; %Light intensity from Pct 
Transmitted 
 
%Another check for the Light Intensity 
LI2F=10.^(-(e_M*y(:,B)+e_D*y(:,C)+mu)*dx);     %Fraction light 
transmitted at each step 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
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ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 
title('Fraction Light 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 









xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 









xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 
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xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 







xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 







xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 







xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
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ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 









xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 






xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Time [s]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 














xlabel('Distance [cm]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 

















[min]','FontSize',11,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Riboflavin Concentration [10^-5 
gr/cm^3]','FontSize',11,'FontWeight','bold','Color','k')                                             
%Adds y-label 















% xlabel('Time [min]','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
% ylabel('[3O2]','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 





xlabel('Time, min','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('3MB Concentration','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 










xlabel('Time, min','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('1O2 Concentration','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 
title('Brandon Model','FontSize',16,'FontWeight','bold','Color','k')  
xlim([0.01 100]) 








xlabel('Time, min','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('MBm Concentration','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 
title('Brandon Model','FontSize',16,'FontWeight','bold','Color','k')  
xlim([0.01 100]) 









xlabel('Time, min','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Xlinks','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 
title('Brandon Model','FontSize',16,'FontWeight','bold','Color','k')  
xlim([0.01 100]) 








xlabel('Depth (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Xlinks','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 




xlabel('Time, min','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Oxygen Concentration, 
mg/L','FontSize',14,'FontWeight','bold','Color','k')                                             
%Adds y-label 



























plot(mins,Inorm, 'Color', [0 190/256 0], 'LineStyle', '--') 
hold on 
plot(mins, Jnorm, 'Color', [0 100/256 0],'Linestyle', '-.') 
hold on 
plot(mins, Mnorm, 'Color', [0 200/256 0]) 
hold on  
plot(mins, Gnorm, 'Color', [0 0 150/256]) 
hold on  
plot(mins, Nnorm, 'Color', [138 43 226]/256) 
hold on  















if L1~=L2 || L1~=PAbs 





Xlinkstot=mean(y(end,L([Res Ten Scl Chor]))) %Actually average 














ach, kMBradq, kMBH, kMBH2MB, kMBH2ox,fexp3, oxdeg, Dair, DO2air,BMBHres) 
%Function containing differential equations 
 
% The first and last equations will be defined explicitly 
% The middle equations will have relative references 




abeg=1; bbeg=abeg+XS; cbeg=bbeg+XS; dbeg=cbeg+XS; ebeg=dbeg+XS; 
fbeg=ebeg+XS; gbeg=fbeg+XS; hbeg=gbeg+XS; ibeg=hbeg+XS; jbeg=ibeg+XS; 
kbeg=jbeg+XS; lbeg=kbeg+XS; mbeg=lbeg+XS; nbeg=mbeg+XS; obeg=nbeg+XS; 
aend=XS; bend=aend+XS; cend=bend+XS; dend=cend+XS; eend=dend+XS; 
fend=eend+XS; gend=fend+XS; hend=gend+XS; iend=hend+XS; jend=iend+XS; 








DiffB=[(y(bbeg+1)-2*y(bbeg)+MBmres)/dx^2;    (y(b+1)-2*y(b)+y(b-1))/dx^2;             
(MBmchor-2*y(bend)+y(bend-1))/dx^2]; 
DiffC=[(y(cbeg+1)-2*y(cbeg)+ MBdres)/dx^2;   (y(c+1)-2*y(c)+y(c-1))/dx^2;             
(MBdchor-2*y(cend)+y(cend-1))/dx^2]; 
DiffD=[(y(dbeg+1)-2*y(dbeg)+0)/dx^2;         (y(d+1)-2*y(d)+y(d-1))/dx^2;             
2*(-y(dend)+y(dend-1))/(dx)^2]; 
DiffE=[(y(ebeg+1)-2*y(ebeg)+O23res)/dx^2;    (y(e+1)-2*y(e)+y(e-1))/dx^2;             
(O23chor-2*y(eend)+y(eend-1))/dx^2];     
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DiffF=[(y(fbeg+1)-2*y(fbeg)+0)/dx^2;         (y(f+1)-2*y(f)+y(f-1))/dx^2;             
2*(-y(fend)+y(fend-1))/(dx)^2];     
DiffN=[(y(nbeg+1)-2*y(nbeg)+0)/dx^2;         (y(n+1)-2*y(n)+y(n-1))/dx^2;             
2*(-y(nend)+y(nend-1))/(dx)^2]; 
DiffO=[(y(obeg+1)-2*y(obeg)+0)/dx^2;         (y(o+1)-2*y(o)+y(o-1))/dx^2;             
2*(-y(oend)+y(oend-1))/(dx)^2]; 
 
if BCMBres==1  
%     DiffB(1)=DiffB(2); 






%     DiffB(end)=DiffB(XS-1); 
















    DiffN(1)=2*(y(nbeg+1)-y(nbeg)+0)/dx^2; 





DBDTbeg = DMB(1)*DiffB(1) -    PhiT*(1-
y(abeg))*y(aend)*prod(y(a),1)*I0.*FLmon(1)-    PhiDeg*(1-
y(abeg))*y(aend)*prod(y(a),1)*I0.*FLmon(1) -   2*kfm*y(bbeg).^2 - 
kfm*y(bbeg).*y(dbeg) + 2*krd*y(cbeg) + k_MB3relax*y(dbeg) + 
kMB3ann*y(dbeg).^2 + (kMB3HIS*y(dbeg).*y(hbeg) + kMB3TRP*y(dbeg).*y(ibeg) 
+ kMB3MET*y(dbeg).*y(jbeg) + kMB3TYR*y(dbeg).*y(mbeg)) + 
k3MBMB2*y(dbeg).*y(cbeg) + k_singlet*y(dbeg).*y(ebeg) + 
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k_mb2deg*y(cbeg).*y(fbeg) - k_mbdeg*y(bbeg).*y(fbeg) 
+kMBquench*(y(bbeg)).*y(dbeg);         
DBDT =    DMB(mid).*DiffB(mid) -       PhiT*(1-
y(a)).*cumprod(y(a+1),1,'reverse')*I0.*FLmon(mid) - PhiDeg*(1-
y(a)).*cumprod(y(a+1),1,'reverse')*I0.*FLmon(mid) - 2*kfm*y(b).^2 - 
kfm*y(b).*y(d)+    2*krd*y(c) +    k_MB3relax*y(d) +      kMB3ann*y(d).^2 
+(kMB3HIS*y(d).*y(h) + kMB3TRP*y(d).*y(i) + kMB3MET*y(d).*y(j) + 
kMB3TYR*y(d).*y(m)) + k3MBMB2*y(d).*y(c) +       k_singlet*y(d).*y(e) +       
k_mb2deg*y(c).*y(f) -       k_mbdeg*y(b).*y(f) + kMBquench*(y(b)).*y(d);  
DBDTend = (2*DMB(end)*Dair)/(DMB(end)*Dair)*DiffB(end) - PhiT*(1-
y(aend))*I0.*FLmon(end) - PhiDeg*(1-y(aend))*I0.*FLmon(end) - 
2*kfm*y(bend).^2 - kfm*y(bend).*y(dend) + 2*krd*y(cend) + 
k_MB3relax*y(dend) + kMB3ann*y(dend).^2 + (kMB3HIS*y(dend).*y(hend) + 
kMB3TRP*y(dend).*y(iend) + kMB3MET*y(dend).*y(jend) + 
kMB3TYR*y(dend).*y(mend)) + k3MBMB2*y(dend).*y(cend) + 
k_singlet*y(dend).*y(eend) + k_mb2deg*y(cend).*y(fend) - 
k_mbdeg*y(bend).*y(fend) + kMBquench*(y(bend)).*y(dend);               
 
DCDTbeg = DMB(1).*DiffC(1) +   kfm*y(bbeg).^2 + kfm*y(bbeg).*y(dbeg)- 
krd*y(cbeg) - k_mb2deg*y(cbeg).*y(fbeg); 
DCDT =    DMB(mid).*DiffC(mid) +        kfm*y(b).^2 + kfm*y(b).*y(d)-    
krd*y(c) -    k_mb2deg*y(c).*y(f); 
DCDTend = (2*DMB(end)*Dair)/(DMB(end)*Dair).*DiffC(end) + kfm*y(bend).^2 




(e_M*y(bbeg)+e_D*y(cbeg)+mu(1))*dx);       
dydt(bbeg) = DBDTbeg; 
dydt(cbeg) = DCDTbeg; 
dydt(dbeg) = DMB(1).*DiffD(1) + PhiT*(1-
y(abeg))*y(aend)*prod(y(a),1)*I0.*FLmon(1) - k_MB3relax*y(dbeg) - 
kfm*y(bbeg).*y(dbeg) - kMB3HIS*y(dbeg).*y(hbeg) - kMB3TRP*y(dbeg).*y(ibeg) 
- kMB3MET*y(dbeg).*y(jbeg) -kMB3TYR*y(dbeg).*y(mbeg)- 
kMBquench*(y(bbeg)).*y(dbeg) - 2*kMB3ann*y(dbeg).^2 - 
k3MBMB2*y(dbeg).*y(cbeg) - k_singlet*y(dbeg).*y(ebeg); 
dydt(ebeg) = DO2(1).*DiffE(1) - k_singlet*y(dbeg).*y(ebeg) + 
k_triplet*y(fbeg) + k1O2HIS*y(fbeg).*y(hbeg) + k1O2TRP*y(fbeg).*y(ibeg) + 
k1O2MET*y(fbeg).*y(jbeg) + k1O2TYR*y(fbeg).*y(mbeg) -
kMBH*(y(kbeg)+y(nbeg)+y(obeg)).*y(ebeg); 
dydt(fbeg) = DO2(1).*DiffF(1) + k_singlet*y(dbeg).*y(ebeg) - 
k_triplet*y(fbeg) - k1O2HIS*y(fbeg).*y(hbeg) - k1O2TRP*y(fbeg).*y(ibeg) - 
k1O2MET*y(fbeg).*y(jbeg) -k1O2TYR*y(fbeg).*y(mbeg) - 
k_mb2deg*y(cbeg).*y(fbeg) - k_mbdeg*y(bbeg).*y(fbeg) - 
kHIS*y(fbeg).*y(hbeg) - kTRP*y(fbeg).*y(ibeg) - kMET*y(fbeg).*y(jbeg) - 
kTYR*y(fbeg).*y(mbeg); 
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% dydt(gbeg) = PhiDeg*(1-y(abeg))*y(aend)*prod(y(a),1)*I0.*FLmon(1) + 
k_mb2deg*y(cbeg).*y(fbeg) + k_mbdeg*y(bbeg).*y(fbeg) + 
kMBH2ox*y(obeg).*y(ebeg); 
dydt(gbeg) = 0; 
dydt(hbeg) = -kHIS*y(fbeg).*y(hbeg)-(fbleach)*kMB3HIS*y(dbeg).*y(hbeg)+ 
kMBH2ox*y(kbeg); 
dydt(ibeg) = -kTRP*y(fbeg).*y(ibeg) - (fbleach)*kMB3TRP*y(dbeg).*y(ibeg)+ 
kMBH2ox*y(nbeg); 
dydt(jbeg) = -kMET*y(fbeg).*y(jbeg) - (fbleach)*kMB3MET*y(dbeg).*y(jbeg); 
dydt(kbeg) = fbleach*kMB3HIS*y(dbeg).*y(hbeg)-kMBH*y(kbeg).*y(ebeg)-
kMBH2ox*y(kbeg);   
dydt(lbeg) = kHIS*y(fbeg).*y(hbeg) + 
kTRP*y(fbeg).*y(ibeg)+kTYR*y(fbeg).*y(mbeg)+ 
kMBH*(y(kbeg)+y(nbeg)+y(obeg)).*y(ebeg); 









(e_M*y(b)+e_D*y(c)+mu(mid))*dx);       
dydt(b) = DBDT; 
dydt(c) = DCDT; 
dydt(d) = DMB(mid).*DiffD(mid) + PhiT*(1-
y(a)).*cumprod(y(a+1),1,'reverse')*I0.*FLmon(mid) - k_MB3relax*y(d) - 
kfm*y(b).*y(d)- kMB3HIS*y(d).*y(h) - kMB3TRP*y(d).*y(i) - 
kMB3MET*y(d).*y(j)-kMB3TYR*y(d).*y(m) - kMBquench*(y(b)+y(o)).*y(d) - 
2*kMB3ann*y(d).^2 - k3MBMB2*y(d).*y(c) - k_singlet*y(d).*y(e); 
dydt(e) = DO2(mid).*DiffE(mid) - k_singlet*y(d).*y(e) + k_triplet*y(f) + 
k1O2HIS*y(f).*y(h) + k1O2TRP*y(f).*y(i) + k1O2MET*y(f).*y(j) + 
k1O2TYR*y(f).*y(m)  -kMBH*(y(k)+y(n)+y(o)).*y(e); 
dydt(f) = DO2(mid).*DiffF(mid) + k_singlet*y(d).*y(e) - k_triplet*y(f) - 
k1O2HIS*y(f).*y(h) - k1O2TRP*y(f).*y(i) - k1O2MET*y(f).*y(j) - 
k1O2TYR*y(f).*y(m) - k_mb2deg*y(c).*y(f) - k_mbdeg*y(b).*y(f)  - 
kHIS*y(f).*y(h) - kTRP*y(f).*y(i) - kMET*y(f).*y(j)- kTYR*y(f).*y(m) ; 
% dydt(g) = PhiDeg*(1-y(a)).*cumprod(y(a+1),1,'reverse')*I0.*FLmon(mid) + 
k_mb2deg*y(c).*y(f) + k_mbdeg*y(b).*y(f) + kMBH2ox*y(o).*y(e); 
dydt(g) = 0; 
dydt(h) = -kHIS*y(f).*y(h)-(fbleach)*kMB3HIS*y(d).*y(h) + kMBH2ox*y(k); 
dydt(i) = -kTRP*y(f).*y(i) - (fbleach)*kMB3TRP*y(d).*y(i)+ kMBH2ox*y(n); 
dydt(j) = -kMET*y(f).*y(j) - (fbleach)*kMB3MET*y(d).*y(j); 
dydt(k) = fbleach*kMB3HIS*y(d).*y(h)-kMBH*y(k).*y(e)-kMBH2ox*y(k);   
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dydt(l) = kHIS*y(f).*y(h) + kTRP*y(f).*y(i)+kTYR*y(f).*y(m)+ 
kMBH*(y(k)+y(n)+y(o)).*y(e); 
dydt(m) = -kTYR*y(f).*y(m) - (fbleach)*kMB3TYR*y(d).*y(m)+ kMBH2ox*y(o); 
dydt(n) = fbleach*kMB3TRP*y(d).*y(i)-kMBH*y(n).*y(e)-kMBH2ox*y(n); 




(e_M*y(bend)+e_D*y(cend)+mu(end))*dx);   %Normal light propagation 
dydt(bend) = DBDTend; 
dydt(cend) = DCDTend; 
dydt(dend) = DMB(end).*DiffD(end) + PhiT*(1-y(aend))*I0.*FLmon(end) - 
k_MB3relax*y(dend)- kfm*y(bend).*y(dend) - kMB3HIS*y(dend).*y(hend) - 
kMB3TRP*y(dend).*y(iend) - kMB3MET*y(dend).*y(jend) -
kMB3TYR*y(dend).*y(mend)- kMBquench*(y(bend)).*y(dend) - 
2*kMB3ann*y(dend).^2 - k3MBMB2*y(dend).*y(cend) - 
k_singlet*y(dend).*y(eend); 
dydt(eend) = (2*DO2(end)*DO2air)/(DO2(end)+DO2air).*DiffE(end) - 
k_singlet*y(dend).*y(eend) + k_triplet*y(fend) + k1O2HIS*y(fend).*y(hend) 
+ k1O2TRP*y(fend).*y(iend) + k1O2MET*y(fend).*y(jend) + 
k1O2TYR*y(fend).*y(mend)-kMBH*(y(kend)+y(nend)+ y(oend)).*y(eend); 
dydt(fend) = DO2(end).*DiffF(end) + k_singlet*y(dend).*y(eend) - 
k_triplet*y(fend) - k1O2HIS*y(fend).*y(hend) - k1O2TRP*y(fend).*y(iend) - 
k1O2MET*y(fend).*y(jend) - k1O2TYR*y(fend).*y(mend) - 
k_mb2deg*y(cend).*y(fend) - k_mbdeg*y(bend).*y(fend)  - 
kHIS*y(fend).*y(hend) - kTRP*y(fend).*y(iend) - kMET*y(fend).*y(jend)- 
kTYR*y(fend).*y(mend); 
% dydt(gend) = PhiDeg*(1-y(aend))*I0.*FLmon(end) + 
k_mb2deg*y(cend).*y(fend) + k_mbdeg*y(bend).*y(fend) + 
kMBH2ox*y(oend).*y(eend); 
dydt(gend) = 0; 
dydt(hend) = -kHIS*y(fend).*y(hend)-
(fbleach)*kMB3HIS*y(dend).*y(hend)+kMBH2ox*y(kend); 
dydt(iend) = -kTRP*y(fend).*y(iend) - 
(fbleach)*kMB3TRP*y(dend).*y(iend)+kMBH2ox*y(nend); 
dydt(jend) = -kMET*y(fend).*y(jend) - (fbleach)*kMB3MET*y(dend).*y(jend); 
dydt(kend) = fbleach*kMB3HIS*y(dend).*y(hend)-kMBH*y(kend).*y(eend)-
kMBH2ox*y(kend);   
dydt(lend) = kHIS*y(fend).*y(hend) + 
kTRP*y(fend).*y(iend)+kTYR*y(fend).*y(mend)+ 
kMBH*(y(kend)+y(nend)+y(oend)).*y(eend); 








% a = Light 
% b = MBm 
% c = MBd 
% d = MB3 
% e = O23 
% f = O21 
% g = MBdeg 
% h = HIS 
% i = TRP 
% j = MET 
% k = MEL 
% l = Xlink 
% m = TYR 
% N = MBH 








jcell = {... 
   %a b c d e f g h i j k l 
    4 3 3 1 1 1 0 1 1 1 0 0;        %a Light 
    4 3 1 1 1 1 0 1 1 1 0 0;        %b MBm 
    0 1 3 0 0 1 0 0 0 0 0 0;        %c MBd 
    4 1 1 1 1 0 0 1 1 1 0 0;        %d 3MB 
    0 0 0 1 3 1 0 1 1 1 0 0;        %e 3O2 
    0 0 1 1 1 1 0 1 1 1 1 0;        %f 1O2 
    4 1 1 0 0 1 0 0 0 0 0 0;        %g  
    0 0 0 1 0 1 0 1 0 0 0 0;        %h  
    0 0 0 1 0 1 0 0 1 0 0 0;        %i  
    0 0 0 1 0 1 0 0 0 1 0 0;        %j  
    0 0 0 0 0 1 0 0 0 0 1 0;        %k  
    0 0 0 1 0 1 0 1 0 0 0 0 ...     %l  




APPENDIX E. COMPUTATIONAL MODEL CODE: MB SCLERAL 
PHOTOCROSSLINKING 
% Brandon Gerberich 
% Last updated: 2020-04-13 
 
clear all       %Clears all variables  
pause(0.5)      %Pauses for 0.5 seconds to allow time for memory to clear 
clc             %Clears command line text 
close all       %Closes all MATLAB figure windows (graphs) 
 
tic             %Starts timer to report code run time upon completion 
(useful for estimating future run time) 
format compact  %Changes command line text format to compact mode 
format long g   %Changes command line number format to show decimals 
 
ploton=0;               %Set to 1 if you want to plot the output data, 0 
if not. 
Agent='MB';             %Prints the sensitizer name in graphs (change if 
using other sensitizer) 
Lighttype='660nm';      %Prints the light name in graphs (change if using 
other sensitizer) 
 
Concentration=3/1000;   %Molar 
counter2=0;             %Set loop counter to 0 
 
for mastercounter=1:length(Concentration) 
%Clears only the selected variables to reduce memory usage. These will 
need to be adjusted based on what value you are changing each loop.  
pause(1) 
    clearvars -except counter2 ploton Agent Lighttype mastercounter 
mastervector    
pause(1) 
 
counter2=counter2+1;    %Increase counter by 1; 
 
%Set boundary conditions - this is a logical value used in the "odefcn" 
where I defined the mathematical equations 
BCMBres=0;                  %1 if reflection, otherwise Dirichlet. BC for 
MB at retrobulbar tissue (posterior reservoir surface) 
BCMBchor=0;                 %1 if reflection, otherwise Dirichlet. BC for 
MB at choroid anterior surface 
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BCO2res=0;                  %1 if reflection, otherwise Dirichlet. BC for 
oxygen at retrobulbar tissue (posterior reservoir surface) 
BCO2chor=0;                 %1 if reflection, otherwise Dirichlet. BC for 
oxygen at choroid anterior surface 
 
%Select boundary conditions. Comment/uncomment desired set for oxygen. 
Note, these only apply if Dirichlet condition is selected above. 
% O23res=2.18e-5;             %20% O2 (normoxia), Concentration of oxygen 
at tenon-reservoir interface [M] 
% O23chor=4.81e-5;            %20% O2 (normoxia), Concentration of oxygen 
in choroid [M] 
O23res=10.65e-5;          %100% O2 (hyperoxia), Concentration of oxygen 
at tenon-reservoir interface [M] 
O23chor=26.10e-5;         %100% O2, (hyperoxia),Concentration of oxygen 
in choroid [M] 
 
C0_MBres=0;                 %Concentration of MB at muscle cone         
C0_MBchor=0;                %Concentration of MB at choroid 
 
%Set crosslinking treatment parameters 
Isource=0.424;              %Define light intensity (W/cm2) 
tmax=1800;                  %Procedure duration (Seconds) 
C0_MBinj=0.003;             %Initial condition for concentration of MB in 
the injection reservoir 
O23inj=1.94e-4;             %Initial condition for concentration of 
oxygen in injection solution [M] asssumed to be solubility limit at 
atmospheric pressure 
 
%These parameters are not physical inputs. Rather, they are multipliers 
that allow you to quickly include/exclude certain parameters for testing. 
Ordinarily, users need not change these. 
fexp=1;                     %Reduction of amino acid concentration 
fexp2=1;                    %Reduction of the triplet quenching rate of 
amino acids 
fdiff=1;                    %Fraction of diffusion constant for MB 
fbleach=0;                  %Fraction of TRP and MET which is degraded 
after quenching 3MB, consumes MBm 
fanlink=0;                  %Fraction of TRP and MET which form xlinks 
after quenching 3MB and returns MBm 
fhisbleach=0;               %Fraction of HIS which is degraded after 
quenching 3MB 
fxl=0;                      %Fraction of 3MB quenched by histidine which 
form Xlinks 
 
%Set initial concentrations of amino acids, melanin 
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C0_HIS=0.0124*fexp;         %Concentration of histidine in the sclera 
[M], Edwards & Prausnitz 1998 
C0_TRP=0.0083*fexp;         %Concentration of tryptophan in the sclera 
[M], Edwards & Prausnitz 1998 
C0_MET=0.0207*fexp;         %Concentration of methionine in the sclera 
[M], Edwards & Prausnitz 1998 
C0_TYR=0.0193*fexp;         %Concentration of tyrosine ""  
C0_MELscl=0.003;            %Concentration of melanin in sclera [M] 
C0_MELchor=0.305;           %Concentration of melanin in choroid [M] 
C0_MELrpe=0.085;            %Concentration of melanin in rpe [M] 
Chorlumen=0.4;              %Fraction of choroid which is blood vessels 
(not collagen) 
 
%Set initial photophysical parameters 
lambda= 660*10^-9;          %Wavelenght of light, [m], 660 default 
Retchorabs=0.096;           %Fraction of light reflected by retina 
e_M=79800;                  %Molar absorptivity (epsilon) of sensitizer 
monomer 
e_D=35300;                  %" " of sensitizer dimer 
e_MEL=646;                  %" " of melanin 
PhiT=0.52;                  %Triplet quantum yield of sensitizer 
PhiDeg=6.7e-6;              %Photodegradation quantum yield of sensitizer 
mures=0;                    %Linear attenuation coefficient of reservoir 
muten=1.75*0.001;           %" " of tenon. Set effectively to 0 for MB in 
sclera 
muscl=1.75*0.001;           %" " of sclera. " " 
muchor=1.75*0.001;          %" " of choroid. " " 
 
%Set tissue dimension parameters 
Scleralength=0.0104;    %[cm] 833 microns from Heichel 2016 
Tenlength=0.0026;       %[cm] 26 microns 
Reslength=0.31;         %[cm] Calculated from injection volume 0.10885       
Chorlength=0.0045;      %Length of choroid [cm] 
RPElength=0.001;        %Length of RPE [cm] 
Cleardist=0.0045;       %Distance from reservoir to boundary condition in 
the retrobulbar tissue 
 
Tenx=10;                %# Nodes in tenon layer 
Sclx=100;                %# Nodes in sclera 
Chorx=70;               %# Nodes in choroid 
Resfold=1.4;            %Used to compute uneven reservoir 
nodes/thicknesses. Maximum ratio of adjacent node widths. 
 
%Kinetic rate constants 
Keq=10665;              %Equilibrium constant for dimerization defined as 
K=[Dimer]/[Monomer]^2, [M]^-1, 2910 default. K=kf/kr=[D]/[M]^2 
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kfm=10.93e8;            %Forward rate constant for dimerization, from 
Spencer 1979 
krd=kfm/Keq;            %Reverse rate constant. Assuming the value for 
kfm allows back calculation from K which is more widely available. The 
value of kfm just needs to be large so reaction happens quickly if want to 
assume instant dimerizastion 
k_singlet=2.6e9;        %Reaction rate for 3MB (triplet MB) and 3O2 
(triplet oxygen), [M^-1 s^-1] 
k_mbdeg=3E8*0;          %Reaction rate for 1O2 (singlet oxygen) and MB 
leading to degradation of MB, [M^-1 s^-1] 
k_mb2deg=2*k_mbdeg;     %Reaction rate for 1O2 with MB2 - 2*k_mbdeg 
because the effective concentration of monomers is doubled for dimers 
k_triplet=2.56E5;       %Rate for 1O2 (singlet oxygen) relaxation to 3O2 
(triplet oxygen), [s^-1], 2.5E5 default.  
k_MB3relax=1.3E4;       %Relaxation rate of MB3 to MB calculated from 
lifetime of 77us (Alacron 2012), [s^-1], 1.3E5 default            
kMBquench=4.1E7;        %Rate of ground state monomer quenching 3MB Kamat 
1981 "Photoinduced electron..." 
kMB3HIS=2E6*fexp2;      %Reaction rate for physical quenching of 3MB by 
histidine, [M^-1 s^-1], 2E6 default  
kMB3TRP=6E8*fexp2;      %Reaction rate for physical quenching of 3MB by 
tryptophan, [M^-1 s^-1], 6E8 default  
kMB3MET=1E8*fexp2;      %Reaction rate for physical quenching of 3MB by 
methionine, [M^-1 s^-1], 1E8 default  
kMB3TYR=0*fexp2;        %Reaction rate for physical quenching of 3MB by 
tyrosine, [M^-1 s^-1]  
kMB3ann=8.9e8*0;        %Rate of MB3 annihilation 
k3MBMB2=kMBquench;      %Rate of MB3 quenching by dimer         
kHIS=1E8;               %Reaction rate for 1O2 (singlet oxygen) and 
collagen leading to crosslinks, [M^-1 s^-1], 5E7 default 
kTRP=3E7;               %Reaction rate for chemical quenching of singlet 
oxygen by tryptophan, [M^-1 s^-1], 4E6 default  
kMET=1.6E7;             %Reaction rate for chemical quenching of singlet 
oxygen by methionine, [M^-1 s^-1], 5E6 default  
kTYR=8e6;               %Reaction rate for chemical quenching of singlet 
oxygen by tyrosine, [M^-1 s^-1] 
k1O2MB=3e8;             %Physical quenching of 1O2 by MB. 3E8 default 
(Schmidt 1980 referenced in Wilkinson 1995) 
k1O2MB2=k1O2MB;         %Physical quenching of 1O2 by MB2. Estimated 
based on monomer physical quenching of 1O2 
k1O2HIS=0;              %Reaction rate for physical quenching of 1O2 by 
histidine, [M^-1 s^-1], 4.2E7 default  
k1O2TRP=2.1E7;          %Reaction rate for physical quenching of 1O2 by 
tryptophan, [M^-1 s^-1], 4.6E7 default  
k1O2MET=0;              %Reaction rate for physical quenching of 1O2 by 
methionine, [M^-1 s^-1], 2.5E7 default  
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k1O2TYR=2.7e7;          %Reaction rate for physical quenching of 1O2 by 
tyrosine, [M^-1 s^-1] 
kMEL=1.34E8;            %Reaction rate for melanin with singlet oxygen, 
[M^-1 s^-1], 1.32E8 default 
 
%Diffusion Constants [cm2/s] 
Dres=4.6e-6*100;        %MB in reservoir. Multiplied by 100 to simulate 
well-mixed condition 
Dten=3.16e-7*fdiff;     %MB in tenon 
Dscl=3.16e-7*fdiff;     %MB in sclera 
Dchor=3.16e-7*fdiff;    %MB in choroid 
DO2scl=4e-6;            %Oxygen in sclera 
DO2res=4.6e-6*100;      %Oxygen in water. Multiplied by 100 to simulate 
well-mixed condition 
 
%Light conversion to energy 
avogadro=1/(6.022*10^23);   %Avogadro's number (inverse) - converts 
number of molecules to Moles, [Mole/units] 
planck=6.62607004*10^-34;   %Planck's constant, [J*s] 
ls=299792458;               %Speed of light, [m/s] 
Energy=planck*ls/lambda;    %Energy of a photon, [J] 
 
% DEFINITION OF PARAMETERS ENDS HERE. BELOW BEGINS CONSTRUCTION OF 
VECTORS 
% FOR MODEL INPUT 
 
%Define node thickness vectors. Indicates width of each node  
Scldx=Scleralength/Sclx;                %Sclera node thicknesses 
Tendx=Tenlength/Tenx;                   %Tenon node thicknesses 
Chordx=Chorlength/Chorx;                %Choroid node thicknesses 
 
%Below we calculate the undeven node spacing of reservoir. Selects 
resfold to span the distance 
%defined by Reslength. Allows power spacing of reservoir slice 
thicknesses 
%using a flexible value calcualted for the power, RESFOLD 
 
resl=0; %Counter for # nodes to span reservoir. Changes on each 
iteration. 










Resx=2*resl+2;        %Need to double the reslength because the vector is 
mirrored 
Resdx=[Tendx*resf.^([0 1:resl]) fliplr(Tendx*resf.^([0 1:resl]))]; 
%Mirroring the Resdx vector - symmetry makes  
 







%Calculate #X Slices 
XS=Resx+Tenx+Sclx+Chorx;            %Number of nodes in model 
xmax=Scldx+Chordx;           
xspace=1:XS;                         
plotlength=length([Ten Scl Chor]); 
 







DMBright=circshift([Dscl DMB Dchor],-1); 
DMBright=DMBright([2:(end-1)]); 
DMBleft=circshift([Dscl DMB Dchor],1); 
DMBleft=DMBleft([2:(end-1)]); 
 




DO2right=circshift([DO2scl DO2 DO2scl],-1); 
DO2right=DO2right(2:(end-1)); 
DO2left=circshift([DO2scl DO2 DO2scl],1); 
DO2left=DO2left(2:(end-1)); 
 
















dxVright=circshift([Scldx dxV Chordx],-1);    %Creates i+1 spatial 
thickness vector for numerical diffusion equation 
dxVright=dxVright(2:(end-1)); 
dxVleft=circshift([Cleardist dxV Chordx],1);      %Creates i-1 spatial 
thickness vector for numerical diffusion equation 
dxVleft=dxVleft(2:(end-1)); 
 
%Calculate Space & Time Intervals 
Dmax=max([Dres Dten Dscl Dchor DO2]); 
% dt=dx^2/Dmax; 




I0=I0fchor*Isource/Energy*avogadro./dxV*1000;           %Converts 













% O23=O23res+(1:XS)/(XS+1)*(O23chor-O23res);  
O23=zeros(1,XS); 




HIS=C0_HIS*ones(1,XS); HIS(Res)=0; HIS(Chor)=HIS(Chor)*(1-Chorlumen); 
TRP=C0_TRP*ones(1,XS); TRP(Res)=0; TRP(Chor)=TRP(Chor)*(1-Chorlumen); 
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MET=C0_MET*ones(1,XS); MET(Res)=0; MET(Chor)=MET(Chor)*(1-Chorlumen); 
MEL=zeros(1,XS); MEL(Chor)=C0_MELchor; MEL(Scl)=C0_MELscl; 
TYR=C0_TYR*ones(1,XS); TYR(Res)=0; TYR(Chor)=TYR(Chor)*(1-Chorlumen); 
Xlink=zeros(1,XS); 
Light=10.^(-(e_M*MBm+e_D*MBd+e_MEL*MEL+mu).*dxV);       %Pct transmitted 





Xlinkspossible=sum((HIS([Scl Chor])+TYR([Scl Chor])+TRP([Scl 
Chor])).*dxV([Scl Chor]))/sum(dxV([Scl Chor])); 
 
%Define Domains of DYDT 
A=1:XS; B=A+XS; C=B+XS; D=C+XS; E=D+XS; F=E+XS; G=F+XS; H=G+XS; I=H+XS; 
J=I+XS; K=J+XS; L=K+XS; M=L+XS; N=M+XS; O=N+XS; P=O+XS; 
%Define "Middle" Domains of DYDT 
a=2:(XS-1); b=a+XS; c=b+XS; d=c+XS; e=d+XS; f=e+XS; g=f+XS; h=g+XS; 
i=h+XS; j=i+XS; k=j+XS; l=k+XS; m=l+XS; n=m+XS; o=n+XS; p=o+XS; 
 
sizey=length([A B C D E F G H I J K L M N O P]); 




    TS=10000 
    tspan=linspace(0,tmax,TS); 
    disp('TS increased to 10000') 
else if TS>300000 
        TS=300000 
        tspan=linspace(0,tmax,TS); 
        disp('TS reduced to 300000') 
    end 
end 
 
%0 = zeros 
%1 = 0th diagonal     REACTIONS 
%2 = 0,1 diagonals 
%3 = -1,0,1 diagnoals DIFFUSION 
%4 = upper triangular 
%5 = upper triangular with diffusion 
jcell = {... 
   %a b c d e f g h i j k l m n o p 
    4 3 3 1 1 1 0 1 1 1 1 1 0 0 0 0;        %a Light 
    4 3 1 1 1 1 0 1 1 1 1 1 0 0 0 0;        %b MBm 
    0 1 3 1 0 1 0 0 0 0 0 0 0 0 0 0;        %c MBd 
 237 
    4 1 1 3 1 0 0 1 1 1 1 1 0 0 0 0;        %d 3MB 
    0 1 1 1 3 1 0 1 1 1 1 0 0 0 0 0;        %e 3O2 Unique from V33_RF 
    0 0 1 1 1 3 0 1 1 1 1 1 0 0 0 0;        %f 1O2 
    4 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0;        %g MBdeg 
    0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0;        %h HIS 
    0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0;        %i TRP 
    0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0;        %j MET 
    0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0;        %k TYR 
    0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0;        %l MEL 
    0 0 0 1 0 1 0 1 1 0 1 0 0 0 0 0;        %m Xlink 
    0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0;        %n probe1 
    0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0;        %o probe2 
    0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 ...     %p probe3 





    if jcell{counter}==0 
        jcell{counter}=zeros(XS); 
         
    elseif jcell{counter}==1 
        jcell{counter}=diag(ones(1,XS),0); 
         
    elseif jcell{counter}==2 
        jcell{counter}=diag(ones(1,XS-1),1)+diag(ones(1,XS),0); 
         
    elseif jcell{counter}==3 
        jcell{counter}=diag(ones(1,XS-1),1)+diag(ones(1,XS-1),-
1)+diag(ones(1,XS),0); 
         
    elseif jcell{counter}==4 
        jcell{counter}=triu(ones(XS)); 
     
    elseif jcell{counter}==5 
        jcell{counter}=triu(ones(XS))+diag(ones(1,XS),0); 






12,'AbsTol', 1E-14, 'JPattern',jsparse(Jsparse));  %Sets options for 
solver 
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y0=[Light' MBm' MBd' MB3' O23' O21' MBdeg' HIS' TRP' MET' TYR' MEL' 














%Calculate Plot Grid Mesh 
% xpoints=(1:XS)*dx; 
xpoints2=cumsum(dxV); 
xpoints=xpoints2-xpoints2(Ten(1));                                        




s=[Scl Chor];  %Index positions of the desired points for graphing  
% xpoints3=flip(xpoints(s)-min(xpoints(s)))*10000; 
xpoints3=flip(cumsum(dxV(flip(s)))*10000); 
% s=round(linspace(1,length(xpoints'),plotlength));                       





logswitch='linear';                                                       
%toggles linear or log scale plots 
 
tfam = round([0.001 5 10 15 20 25 30]/30*length(tspan)); 
% tfam = round([0.001 0.1 0.3 1 3 10 30]/30*length(tspan)); 




legendstring=["0 min"; "5 min"; "10 min"; "15 min"; "20 min"; "25 min"; 
"30 min"]; 
% legendstring=["0 min"; "0.1 min"; "0.3 min"; "1 min"; "3 min"; "10 




    t=round(logspace(0,log10(length(tspan)),plotlength)); 
    tspan=tspan/60; 
end 
 






Abs=[Lightbeg Lightmid Lightend]; 
 
LI1=fliplr(cumprod(fliplr(y(:,A)),2))*Isource*I0fchor; %Light intensity 
from Pct Transmitted 
 
%Another check for the Light Intensity 
LI2F=10.^(-(e_M*y(:,B)+e_D*y(:,C)+e_MEL*y(L)+mu).*dxV);     %Fraction 
light transmitted at each step 






set(z, {'color'}, num2cell(cmapset,2)); 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k');                                            
%Adds x-label 
ylabel('Fraction Light 
Transmitted','FontSize',14,'FontWeight','bold','Color','k');                                     
%Adds z-label 
title('Fraction Light 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 








set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')   
title([Agent ' ' 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 








set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 







x1.LabelVerticalAlignment = 'bottom'; 
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x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 







set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 
title([Agent ' ' 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 








set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 




title('O_2 Triplet','FontSize',16,'FontWeight','bold','Color','k') %Adds 
title 
x1=xline(45,'--',{'Sclera'},'Linewidth',2); 
x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 











set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 







x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 









set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 
title('Cumulative Degraded 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 








set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 








x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 
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set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')   






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 







set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
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x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 







set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 






x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 








set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 







x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 







set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 
xlabel('Distance (\mum)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 









x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 







plot(mins,sum(y(1:TS,M([Scl Chor])).*dxV([Scl Chor]),2)/(sum(dxV([Scl 
Chor]))),'k','LineWidth',2); 
plot(mins,sum(y(1:TS,N([Scl Chor])).*dxV([Scl Chor]),2)/(sum(dxV([Scl 
Chor]))),'r','LineWidth',2); 
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plot(mins,sum(y(1:TS,P([Scl Chor])).*dxV([Scl Chor]),2)/(sum(dxV([Scl 
Chor]))),'b','LineWidth',2); 
plot(mins,sum(y(1:TS,O([Scl Chor])).*dxV([Scl Chor]),2)/(sum(dxV([Scl 
Chor]))),'g','LineWidth',2); 
xlabel('Time (min)','FontSize',14,'FontWeight','bold','Color','k')                                            
%Adds x-label 
ylabel('Concentration (M)','FontSize',14,'FontWeight','bold','Color','k')                                     
%Adds z-label 
title('Cumulative 
Crosslinks','FontSize',16,'FontWeight','bold','Color','k') %Adds title 













set(z, {'color'}, num2cell(cmapset,2)) 
set(gcf, 'Color', [1 1 1]); set(gca, 'color', 'w'); 











x1.LabelVerticalAlignment = 'bottom'; 
x1.LabelHorizontalAlignment = 'right'; 
x1.LabelOrientation = 'horizontal'; 
x2=xline(45,'--',{'Choroid'},'Linewidth',2); 
x2.LabelVerticalAlignment = 'bottom'; 
x2.LabelHorizontalAlignment = 'left'; 











if L1~=L2 || L1~=PAbs 
























%Function containing differential equations 
 
% The first and last equations will be defined explicitly 
% The middle equations will have relative references 




abeg=1; bbeg=abeg+XS; cbeg=bbeg+XS; dbeg=cbeg+XS; ebeg=dbeg+XS; 
fbeg=ebeg+XS; gbeg=fbeg+XS; hbeg=gbeg+XS; ibeg=hbeg+XS; jbeg=ibeg+XS; 
kbeg=jbeg+XS; lbeg=kbeg+XS; mbeg=lbeg+XS; nbeg=mbeg+XS; obeg=nbeg+XS; 
pbeg=obeg+XS; 
aend=XS; bend=aend+XS; cend=bend+XS; dend=cend+XS; eend=dend+XS; 
fend=eend+XS; gend=fend+XS; hend=gend+XS; iend=hend+XS; jend=iend+XS; 
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% DiffB=[(y(bbeg+1)-2*y(bbeg)+0)/Reslength^2;    (y(b+1)-2*y(b)+y(b-
1))/dx^2;             (MBmchor-2*y(bend)+y(bend-1))/dx^2]; 
% DiffC=[(y(cbeg+1)-2*y(cbeg)+0)/Reslength^2;   (y(c+1)-2*y(c)+y(c-
1))/dx^2;             (MBdchor-2*y(cend)+y(cend-1))/dx^2]; 
% DiffE=[(y(ebeg+1)-2*y(ebeg)+0)/Reslength^2;    (y(e+1)-2*y(e)+y(e-
1))/dx^2;             (O23chor-2*y(eend)+y(eend-1))/dx^2];     
     
if BCMBres==1  
%     DiffB(1)=DiffB(2); 







%     DiffB(end)=DiffB(XS-1); 

















DBDTbeg = DiffB(1) -    PhiT*(1-
y(abeg))*y(aend)*prod(y(a),1).*I0(1).*FLmon(1)-    PhiDeg*(1-
y(abeg))*y(aend)*prod(y(a),1).*I0(1).*FLmon(1) -   2*kfm*y(bbeg).^2 -
kfm*y(bbeg).*y(dbeg) + 2*krd*y(cbeg) + k_MB3relax*y(dbeg) + (1-fxl-
fhisbleach)*kMB3HIS*y(dbeg).*y(hbeg) + (1-
fbleach)*kMB3TRP*y(dbeg).*y(ibeg) + (1-fbleach)*kMB3MET*y(dbeg).*y(jbeg)+ 
(1-fbleach)*kMB3TYR*y(dbeg).*y(kbeg) + kMBquench*y(bbeg).*y(dbeg) + 
2*kMB3ann*y(dbeg).^2 + k3MBMB2*y(dbeg).*y(cbeg) + 
k_singlet*y(dbeg).*y(ebeg) + k_mb2deg*y(cbeg).*y(fbeg) - 
k_mbdeg*y(bbeg).*y(fbeg);         
DBDT =    DiffB(mid) -       PhiT*(1-
y(a)).*cumprod(y(a+1),1,'reverse').*I0(mid).*FLmon(mid) - PhiDeg*(1-
y(a)).*cumprod(y(a+1),1,'reverse').*I0(mid).*FLmon(mid) - 2*kfm*y(b).^2 - 
kfm*y(b).*y(d) +    2*krd*y(c) +    k_MB3relax*y(d) +    (1-fxl-
fhisbleach)*kMB3HIS*y(d).*y(h) +       (1-fbleach)*kMB3TRP*y(d).*y(i) +       
(1-fbleach)*kMB3MET*y(d).*y(j)+   (1-fbleach)*kMB3TYR*y(d).*y(k)+     
kMBquench*y(b).*y(d) +       2*kMB3ann*y(d).^2 +    k3MBMB2*y(d).*y(c) +       
k_singlet*y(d).*y(e) +       k_mb2deg*y(c).*y(f) -       
k_mbdeg*y(b).*y(f);  
DBDTend = DiffB(end) - PhiT*(1-y(aend)).*I0(end).*FLmon(end) - PhiDeg*(1-
y(aend)).*I0(end).*FLmon(end) - 2*kfm*y(bend).^2 - kfm*y(bend).*y(dend) + 
2*krd*y(cend) + k_MB3relax*y(dend) + (1-fxl-
fhisbleach)*kMB3HIS*y(dend).*y(hend) + (1-
fbleach)*kMB3TRP*y(dend).*y(iend) + (1-fbleach)*kMB3MET*y(dend).*y(jend)+ 
(1-fbleach)*kMB3TYR*y(dend).*y(kend) + kMBquench*y(bend).*y(dend) + 
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2*kMB3ann*y(dend).^2 + k3MBMB2*y(dend).*y(cend) + 
k_singlet*y(dend).*y(eend) + k_mb2deg*y(cend).*y(fend) - 
k_mbdeg*y(bend).*y(fend);               
 
DCDTbeg = DiffC(1) +   kfm*y(bbeg).^2 + kfm*y(bbeg).*y(dbeg)- krd*y(cbeg) 
- k_mb2deg*y(cbeg).*y(fbeg); 
DCDT =    DiffC(mid) +        kfm*y(b).^2 + kfm*y(b).*y(d)-    krd*y(c) -    
k_mb2deg*y(c).*y(f); 
DCDTend = DiffC(end) + kfm*y(bend).^2 + kfm*y(bend).*y(dend) - 




(e_M*y(bbeg)+e_D*y(cbeg)+e_MEL*y(lbeg)+mu(1))*dxV(1));       
dydt(bbeg) = DBDTbeg; 
dydt(cbeg) = DCDTbeg; 
dydt(dbeg) = DiffD(1) + PhiT*(1-
y(abeg))*y(aend)*prod(y(a),1).*I0(1).*FLmon(1) - k_MB3relax*y(dbeg) - 
kfm*y(bbeg).*y(dbeg) - kMB3HIS*y(dbeg).*y(hbeg) - kMB3TRP*y(dbeg).*y(ibeg) 
- kMB3MET*y(dbeg).*y(jbeg)- kMB3TYR*y(dbeg).*y(kbeg) - 
kMBquench*y(bbeg).*y(dbeg) - 2*kMB3ann*y(dbeg).^2 - 
k3MBMB2*y(dbeg).*y(cbeg) - k_singlet*y(dbeg).*y(ebeg); 
dydt(ebeg) = DiffE(1) - k_singlet*y(dbeg).*y(ebeg) + k_triplet*y(fbeg) + 
k1O2HIS*y(fbeg).*y(hbeg) + k1O2TRP*y(fbeg).*y(ibeg) + 
k1O2MET*y(fbeg).*y(jbeg)+k1O2TYR*y(fbeg).*y(kbeg) + 
k1O2MB*y(fbeg).*y(bbeg) + k1O2MB2*y(fbeg).*y(cbeg); 
dydt(fbeg) = DiffF(1) + k_singlet*y(dbeg).*y(ebeg) - k_triplet*y(fbeg) - 
k1O2HIS*y(fbeg).*y(hbeg) - k1O2TRP*y(fbeg).*y(ibeg) - 
k1O2MET*y(fbeg).*y(jbeg)- k1O2TYR*y(fbeg).*y(kbeg) - 
k_mb2deg*y(cbeg).*y(fbeg) - k_mbdeg*y(bbeg).*y(fbeg) - 
kMEL*y(lbeg).*y(fbeg) - kHIS*y(fbeg).*y(hbeg) - kTRP*y(fbeg).*y(ibeg) - 
kTYR*y(fbeg).*y(kbeg) -kMET*y(fbeg).*y(jbeg) -k1O2MB*y(fbeg).*y(bbeg)-
k1O2MB2*y(fbeg).*y(cbeg); 
dydt(gbeg) = PhiDeg*(1-y(abeg))*y(aend)*prod(y(a),1).*I0(1).*FLmon(1) + 
k_mb2deg*y(cbeg).*y(fbeg) + k_mbdeg*y(bbeg).*y(fbeg); 
dydt(hbeg) = -kHIS*y(fbeg).*y(hbeg)-
(fhisbleach+fxl)*kMB3HIS*y(dbeg).*y(hbeg); 
dydt(ibeg) = -kTRP*y(fbeg).*y(ibeg) - 
(fbleach+fanlink)*kMB3TRP*y(dbeg).*y(ibeg); 
dydt(jbeg) = -kMET*y(fbeg).*y(jbeg) - 
(fbleach+fanlink)*kMB3MET*y(dbeg).*y(jbeg); 
dydt(kbeg) = -kTYR*y(fbeg).*y(kbeg) - 
(fbleach+fanlink)*kMB3TYR*y(dbeg).*y(kbeg); 
dydt(lbeg) = -kMEL*y(lbeg).*y(fbeg);   
dydt(mbeg) = kHIS*y(fbeg).*y(hbeg)+ kTYR*y(fbeg).*y(kbeg) + 
kTRP*y(fbeg).*y(ibeg)+ fxl*kMB3HIS*y(dbeg).*y(hbeg)+ 
 253 
fanlink*kMB3TRP*y(dbeg).*y(ibeg) + fanlink*kMB3MET*y(dbeg).*y(jbeg)+ 
fanlink*kMB3TYR*y(dbeg).*y(kbeg); 
dydt(nbeg) = kHIS*y(fbeg).*y(hbeg); 
dydt(obeg) = kTRP*y(fbeg).*y(ibeg); 
dydt(pbeg) = kTYR*y(fbeg).*y(kbeg); 
%Middle  
dydt(a) = -dxV(mid).*log(10).*(e_M*DBDT+e_D*DCDT).*10.^(-
(e_M*y(b)+e_D*y(c)+e_MEL*y(l)+mu(mid)).*dxV(mid));       
dydt(b) = DBDT; 
dydt(c) = DCDT; 
dydt(d) = DiffD(mid) + PhiT*(1-
y(a)).*cumprod(y(a+1),1,'reverse').*I0(mid).*FLmon(mid) - k_MB3relax*y(d) 
- kfm*y(b).*y(d) - kMB3HIS*y(d).*y(h) - kMB3TRP*y(d).*y(i) - 
kMB3MET*y(d).*y(j)- kMB3TYR*y(d).*y(k) - kMBquench*y(b).*y(d) - 
2*kMB3ann*y(d).^2 - k3MBMB2*y(d).*y(c) - k_singlet*y(d).*y(e); 
dydt(e) = DiffE(mid) - k_singlet*y(d).*y(e) + k_triplet*y(f) + 
k1O2HIS*y(f).*y(h) + k1O2TRP*y(f).*y(i) + k1O2MET*y(f).*y(j)+ 
k1O2TYR*y(f).*y(k) + k1O2MB*y(f).*y(b)+ k1O2MB2*y(f).*y(c); 
dydt(f) = DiffF(mid) + k_singlet*y(d).*y(e) - k_triplet*y(f) - 
k1O2HIS*y(f).*y(h) - k1O2TRP*y(f).*y(i) - k1O2MET*y(f).*y(j)- 
k1O2TYR*y(f).*y(k) - k_mb2deg*y(c).*y(f) - k_mbdeg*y(b).*y(f) - 




k_mb2deg*y(c).*y(f) + k_mbdeg*y(b).*y(f); 
dydt(h) = -kHIS*y(f).*y(h)-(fhisbleach+fxl)*kMB3HIS*y(d).*y(h); 
dydt(i) = -kTRP*y(f).*y(i) - (fbleach+fanlink)*kMB3TRP*y(d).*y(i); 
dydt(j) = -kMET*y(f).*y(j) - (fbleach+fanlink)*kMB3MET*y(d).*y(j); 
dydt(k) = -kTYR*y(f).*y(k) - (fbleach+fanlink)*kMB3TYR*y(d).*y(k); 
dydt(l) = -kMEL*y(l).*y(f); 
dydt(m) = kHIS*y(f).*y(h)+kTYR*y(f).*y(k) + kTRP*y(f).*y(i)+ 
fxl*kMB3HIS*y(d).*y(h) + fanlink*kMB3TRP*y(d).*y(i) + 
fanlink*kMB3MET*y(d).*y(j) + fanlink*kMB3MET*y(d).*y(k); 
dydt(n) = kHIS*y(f).*y(h); 
dydt(o) = kTRP*y(f).*y(i); 




(e_M*y(bend)+e_D*y(cend)+e_MEL*y(lend)+mu(end))*dxV(end));   %Normal light 
propagation 
dydt(bend) = DBDTend; 
dydt(cend) = DCDTend; 
dydt(dend) = DiffD(end) + PhiT*(1-y(aend)).*I0(end).*FLmon(end) - 
k_MB3relax*y(dend) - kfm*y(bend).*y(dend)- kMB3HIS*y(dend).*y(hend) - 
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kMB3TRP*y(dend).*y(iend) - kMB3MET*y(dend).*y(jend) - 
kMB3TYR*y(dend).*y(kend) - kMBquench*y(bend).*y(dend) - 
2*kMB3ann*y(dend).^2 - k3MBMB2*y(dend).*y(cend) - 
k_singlet*y(dend).*y(eend); 
dydt(eend) = DiffE(end) - k_singlet*y(dend).*y(eend) + k_triplet*y(fend) 
+ k1O2HIS*y(fend).*y(hend) + k1O2TRP*y(fend).*y(iend) + 
k1O2MET*y(fend).*y(jend) +k1O2TYR*y(fend).*y(kend) + 
k1O2MB*y(fend).*y(bend)+ k1O2MB2*y(fend).*y(cend); 
dydt(fend) = DiffF(end) + k_singlet*y(dend).*y(eend) - k_triplet*y(fend) 
- k1O2HIS*y(fend).*y(hend) - k1O2TRP*y(fend).*y(iend) - 
k1O2MET*y(fend).*y(jend)- k1O2TYR*y(fend).*y(kend) - 
k_mb2deg*y(cend).*y(fend) - k_mbdeg*y(bend).*y(fend) - 
kMEL*y(lend).*y(fend) - kHIS*y(fend).*y(hend) - kTRP*y(fend).*y(iend) - 
kMET*y(fend).*y(jend)- kTYR*y(fend).*y(kend) -k1O2MB*y(fend).*y(bend)-
k1O2MB2*y(fend).*y(cend); 
dydt(gend) = PhiDeg*(1-y(aend)).*I0(end).*FLmon(end) + 
k_mb2deg*y(cend).*y(fend) + k_mbdeg*y(bend).*y(fend); 
dydt(hend) = -kHIS*y(fend).*y(hend)-
(fhisbleach+fxl)*kMB3HIS*y(dend).*y(hend); 
dydt(iend) = -kTRP*y(fend).*y(iend) - 
(fbleach+fanlink)*kMB3TRP*y(dend).*y(iend); 
dydt(jend) = -kMET*y(fend).*y(jend) - 
(fbleach+fanlink)*kMB3MET*y(dend).*y(jend); 
dydt(kend) = -kTYR*y(fend).*y(kend) - 
(fbleach+fanlink)*kMB3TYR*y(dend).*y(kend); 
dydt(lend) = -kMEL*y(lend).*y(fend); 
dydt(mend) = kHIS*y(fend).*y(hend)+kTYR*y(fend).*y(kend) 
+kTRP*y(fend).*y(iend) + fxl*kMB3HIS*y(dend).*y(hend) + 
fanlink*kMB3TRP*y(dend).*y(iend) + fanlink*kMB3MET*y(dend).*y(jend)+ 
fanlink*kMB3TYR*y(dend).*y(kend); 
dydt(nend) = kHIS*y(fend).*y(end); 
dydt(oend) = kTRP*y(fend).*y(iend); 
dydt(pend) = kTYR*y(fend).*y(kend); 
% a = Light 
% b = MBm 
% c = MBd 
% d = MB3 
% e = O23 
% f = O21 
% g = MBdeg 
% h = HIS 
% i = TRP 
% j = MET 
% k = TYR 
% l = MEL 
% m = Xlink 
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% n = probe 1 
% o = probe 2 
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